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Abstract
Throughout evolution, mammals have co-existed with many harmless 
organisms such as saprophytic mycobacteria. These “Old Friends” have helped 
the hosts’ immune system to evolve immunoregulatory mechanisms that 
prevent inappropriate immune responses. Exposure, once a common 
occurrence has now become increasingly rare. A revised version of the hygiene 
hypothesis proposes that this reduced exposure may be a contributing factor to 
the recent increase in allergic diseases in developed countries.
In models of allergic pulmonary inflammation, treatment with M. vaccae inhibits 
airway hyperreactivity and induces allergen specific regulatory T cells (Tregs), 
which secrete IL-10 and depend upon production of IL-10 and TGF-p in vivo. 
Since Treg-induction is dependent on antigen presenting cells (APCs) such as 
CD11c+ cells, this thesis addresses the effects that M. vaccae has on CD11c+ 
APCs, in a mouse model of allergic pulmonary inflammation. M. vaccae 
treatment reduces pulmonary allergic inflammation by decreasing type-2 
responses such as eosinophilia and IL-4 expression. Rather than an increase in 
type-1 cytokines, IL-10 is elevated in the lungs, both at the protein and message 
level. Characterization of pulmonary CD11c+ APCs by ELISA, FACS and real 
time RT-PCR, shows an immunoregulatory cytokine profile with increased 
expression of IL-10, TGF-p and IFN-a. In passive transfer experiments, CD11c+ 
cells appear not play a role as regulatory cells themselves, but may be involved 
in the induction of Treg through their cytokine release. In vitro studies show 
these CD11c+ APCs are capable of inducing naive T cells to become Tregs, as 
measured by increased production of IL-10 and Foxp3 expression.
M. vaccae has been used in clinical trials of asthma and eczema, with 
encouraging results. This thesis goes some way to understanding one 
mechanism behind a potentially valuable form of immunotherapy.
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Chapter 1
Chapter 1
General Introduction
1. ALLERGY
The adaptive immune response offers specific protection against infection with 
bacteria, viruses, parasites, fungi and cancer. It has evolved to resist 
pathogens, and particularly protects against repeat infections. In certain 
circumstances, however, the immune system responds in an excessive or 
inappropriate manner to antigenic challenge. This kind of reaction is known as 
hypersensitivity. There are four types of hypersensitivity, each classified by 
their different responses (Table 1-1). Type I, or immediate, hypersensitivity is 
the most common type, and allergic reactions belong to this group [Roitt et al 
2001]. The focus of this thesis will be on the immunoregulation of allergic 
responses.
Allergy is defined as an exaggerated immune response to exposure to specific 
Ags. When an allergic response occurs immediately after contact with the Ag 
an individual is sensitized to, this is known as atopic allergy. This includes 
atopic dermatitis, allergic rhinitis and asthma. In sensitized individuals, allergy 
occurs after challenge with the allergen. Specific Ags causing an exaggerated 
response are known as allergens. Allergens are varied and may include food 
(for example peanut Ag), house dust mite (Derpl Ag) and bee venom.
1.1 Type I Hypersensitivity
Immediate hypersensitivity (Type I) is always associated with Th2-mediated 
inflammation and raised serum IgE levels. Details of the other 3 types of 
hypersensitivity have been described in Table 1-1. Th2-mediated inflammation 
results from secretion of type-2 cytokines by a number of cell types, including 
allergen activated CD4+ T cells. CD4+ T cells can be characterized by their 
particular immune properties, explained in more detail in section 2.6. Briefly, 
IFN-y and IL-2 secreting CD4+ T cells are known as Th1 cells, whilst IL-4
14
producing CD4+ T cells are termed Th2 cells. These cell types also have an 
antagonistic effect on the development of each other. Secretion of IL-4, IL-5 
and IL-13 by Th2 cells is essential for development of raised IgE levels, 
eosinophilic inflammation, mucus production and fibrosis, all of which contribute 
towards Th2-mediated inflammation.
1.1.1 IgE
IgE production is characteristic of a type-2 response, with expression of the IgE 
gene being dependent upon IL-4. Secretion of the type-2 cytokine IL-4 induces 
B cell production of IgE. The association between IgE and IL-4 has been 
investigated in a linkage analysis study involving twins. Linkage is the 
probability of two or more genes being inherited together. This study suggested 
that the IL-4 gene, on human chromosome 5q31.1, regulates IgE production in 
a non-specific manner [Marsh et al 1994]. In addition, IL-4"/_ mice have less 
serum IgE levels, compared to wild-type mice [van der Weld et al 1994, 
Morawetz et al 1996]. The production of IgE is therefore dependent on IL-4 
secretion. In addition, IFN-y secreting Th1 cells have been shown to suppress 
IgE production [Geha et al 1992], and since IFN-y is known to regulate IL-4 
secreting cells, this supports the notion that IL-4 is important for IgE production 
[Mosmann efa/1989].
Allergic individuals produce raised IgE levels in response to exposure to 
allergens. The IgE binds specifically to high affinity receptors on mast cells and 
basophils. When an allergen and two IgE Abs crosslink with the mast cell or 
basophil Fc surface receptor, this leads to degranulation and release of 
histamine and other granule contents. Allergen exposure, therefore, results in 
rapid histamine release [Gauchat et al 1993, Platts-Mills et al 2001, Marone et 
al 1997]. Histamine leads to capillary dilatation, contraction of smooth muscle, 
and increased vascular permeability. The activation of mast cells and basophils 
also leads to the gradual release of cytokines, for example IL-4. These 
cytokines further activate bystander cells, resulting in further inflammation.
Serum IgE levels are generally very low in healthy individuals (non-atopic), 
compared to the other isotypes, such as IgM and IgG. A number of factors
15
account for this. Firstly, IgE has a shorter half-life, which is less than two days. 
It is also produced in small quantities and only in response to a select group of 
foreign Ags and pathogens, such as allergens and helminths. In addition, 
circulating levels are low, because IgE is held on high affinity receptors of mast 
cells or basophils [Roitt et al 2001]. Raised levels of type-2 cytokines at the site 
of inflammation and serum IgE levels are a good indicator of allergy severity in 
all types of atopic disease.
1.1.2 Histamine
During allergic inflammation, one of the effects of exposure to an allergen is the 
release of histamine. Allergens interact with and cross-link surface IgE on the 
surface of mast cells and basophils. Once the mast cell-Ab-Ag complex is 
formed, cell-degranulation and the release of histamine occurs. Once released, 
histamine can interact with cells in local or peripheral tissues through histamine 
receptors, causing tissue damage and inflammation. Histamine exerts its 
actions by ligating with 4 specific cellular receptors located on the surface of 
cells [Simons e ta !2004].
The four histamine receptors described so far are H1, H2, H3 and H4, all belong 
to the superfamily of G-protein coupled receptors (GPCR) [Leurs et al 2001]. 
Different receptors are expressed on different cells in the body. H1 histamine 
receptors are the primary receptors involved in allergic rhinitis symptoms, and 
are found on smooth muscle cells, endothelial cells, and central nervous system 
cells, and ligation causes vasodilatation, bronchoconstriction, and smooth 
muscle activation [Reiner et al 1994]. H2 histamine receptors are located on 
parietal cells, which primarily regulate gastric acid secretion. The H3 histamine 
receptor is expressed in the central and peripheral nervous system, and is 
involved in decreased release of neurotransmitters, such as acetylcholine and 
serotonin [West et al 1990]. The exact role of H4 histamine receptors, which 
are found primarily in the thymus, small intestine, spleen, and colon, as well as 
on basophils and in the bone marrow remains unclear [Nguyen e ta !2001].
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1.1.3 Anti-histamine
An anti-histamine is a drug that serves to reduce or eliminate the effects 
mediated by histamine through its action on the histamine receptor. Only drugs 
where the main therapeutic effect is mediated by their negative modulation of 
histamine receptors are termed anti-histamines - other agents may have anti- 
histaminergic action but are not known as anti-histamines. The term anti­
histamine only refers to H1-receptor antagonists, also known as H1-anti­
histamines [Leurs et al 2002]. While H1-anti-histamines ameliorate the effects 
of histamine release, it is most effective if administered prior to the allergen- 
challenge, since it can occupy the H1 receptor and prevent histamine 
interacting with it.
Ligation of histamine with the H1 receptor has been observed to activate 
several signalling pathways, such as phosholipase D and phosholipase A2 [Hill 
eta l 1997], along with the transcription factor NF-kB [Aoki eta l 1998, Bakker et 
al 2001]. The effect of H1-anti-histamines is H1-receptor dependant, meaning 
that binding of H1-anti-histamines to the H1-receptor inhibits the action of 
histamine on these cells. The actual mechanism is still relatively unclear, but it 
is thought that H1-anti-histamines downregulate the activation of NF-kB [Bakker 
et al 2001]. NF-kB is a ubiquitous transcription factor which binds to promoter 
regions of genes which regulate the production of a number of proinflammatory 
cytokines and adhesion proteins. Anti-histamines have been shown to 
downregulate NF-kB in parallel with inhibiting production of the cytokines IL-1 p, 
IL-6, IL-8, TNF-aand GM-CSF [Arnold eta l 1999, Rihoux eta l 1999, Yoneda et 
al 1997].
An alternative to blocking the effect of histamine, is to block its release from 
mast cells. Sodium cromoglycate is able to inhibit release of histamine from 
mast cells In vitro. However its mode of action in vivo remains unknown. A 
number of related compounds that are better at inhibiting mediator release from 
mast cells in vitro have been found to be ineffective in vivo. Cromoglycate is 
available as an inhaler commonly known as “Intal”, and as a nasal spray. The 
advantage of cromoglycate is its excellent safety record.
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1.1.4 Other drugs used to treat allergy
Whereas anti-histamines are the most effective drugs against allergic reactions, 
others used to treat the symptoms include decongestants (such as 
pseudoephedrine), corticosteroids and salbutamol inhalers. Pseudoephedrine 
is a sympathomimetic amine, whose principal mechanism of action relies on its 
indirect action on the adrenergic receptor system. This is part of the 
sympathetic nervous system. The principal mechanism is to displace 
noradrenaline from storage vesicles in presynaptic neurons. The displaced 
noradrenaline is released into the neuronal synapse where it is free to activate 
the postsynapic adrenergic receptors [Abourashed et al 2003]. The result is 
vasoconstriction in the nasal mucosa, shrinking of swollen nasal mucous 
membranes, and reduction of tissue hyperaemia, oedema, and nasal 
congestion.
Salbutamol is a short-acting p2 adrenergic receptor agonist, used for the relief of 
bronchospasm during asthmatic attacks. Salbutamol is usually given by the 
inhaled route for direct effect on bronchial smooth muscle. This is usually 
achieved through a dose inhaler or nebuliser. Salbutamol is available in the UK 
under the trade name Ventolin. Salbutamol acts by binding to p2-adrenergic 
receptors in the airways. Activation of p2-receptors results in dilation of 
bronchial smooth muscle, resulting in a widening of the airway 
(bronchodilatation). Inhaled salbutamol has a rapid onset of action, providing 
relief within 5-15 minutes of administration [reviewed in Martinez Ordaz et al 
2005].
Corticosteroids are a class of steroid, which are hormones, naturally produced 
by the adrenal cortex. The target receptor for corticosteroids is the intracellular 
glucocorticoid receptor. In the steady state, inactive glucocorticoid receptors 
are located in the cytosol of the cell surrounded by multi-chaperone proteins. 
Through the steroid-binding domain, glucocorticoid receptors bind with 
corticosteroid molecules, forming a dimeric complex [Barnes et al 1997]. Upon 
binding, the corticosteroid molecule induces a conformational change in the 
receptor protein, causing the multi-chaperone proteins to dissociate. The 
activated steroid-glucocorticoid receptor complex then translocates from the
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cytosol to the nucleus of the cell where it exerts its primary anti-inflammatory 
effects. In the nucleus, the steroid-glucocorticoid receptor complex binds to 
glucocorticoid response elements (GREs), which are specific DNA sequences 
found in the promoter region of target genes, causing the cells to repress gene 
transcription of pro-inflammatory cytokines and proteins and upregulate 
production of anti-inflammatory proteins. The activated steroid-glucocorticoid 
receptor complex may also directly interact with DNA-binding transcription 
factors such as NF-kB to suppress transcription factor-mediated pro- 
inflammatory protein production [Adcock e ta l2000].
1.2 Atopic disease
Atopic diseases include atopic dermatitis, allergic rhinitis and asthma. All are 
defined as a Type I hypersensitivity and are all associated with high levels of 
IgE production. Epidemiological studies suggest that these types of allergies 
have more than doubled over the last 40 years, particularly in developed 
countries. Since this rise has happened in such a short space of evolutionary 
time, it is unlikely that change in genetic makeup is solely responsible. 
Environmental factors are likely to be involved [Arkwright et al 2001, Howarth et 
al 1998].
This increase in atopic disease was first reported by Strachan in a seminal 
manuscript published in the British Medical Journal in 1989 [Strachan et al 
1989]. There he described the prevalence of atopic disease in a national study 
concerning over 17,000 British children. He observed that the prevalence of 
allergic rhinitis was inversely correlated to the number of other children within 
the same household, particularly older ones. Similar observations were made 
with atopic dermatitis. No data on asthma, however, were reported. Strachan 
suggested that ‘unhygienic contact* with other siblings in large households 
protected against the development of atopy. In this hypothesis, termed the 
hygiene hypothesis, the combination of declining family size, increased 
standards of living and better personal hygiene is responsible for reducing the 
opportunity for cross infection between young family members, reducing 
exposure to microbes. It is this reduced exposure to microbes, which Strachan 
linked directly to an increase in clinical atopy [Strachan et al 1989].
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If Strachan’s hypothesis is correct, an association must exist between atopic 
disease and modern standards of living. Less exposure to dirt, along with an 
increased use of cleaning products and disinfectants must lead to lower 
exposure to microbes. It would therefore be of interest to determine whether 
the increase in atopic disease is due to a lack of microbial exposure. 
Geographical variation in atopic disease prevalence around the world supports 
Strachan’s hypothesis that environmental factors, such as exposure to 
infections, are partly to blame for the rise in allergic disease. An international 
study was done in the 1990s involving over 450,000 children aged between 13 
and 14 years and living in 56 countries [ISAAC et al 1998]. For example, atopic 
dermatitis varied from 0.3% of children in third world countries where exposure 
to infections is higher, such as China, India and Georgia, to 20.5% in countries 
like the UK and New Zealand. Similar trends were seen with asthma and 
allergic rhinitis, with developed countries having a higher prevalence for disease 
than developing countries [ISAAC et al 1998]. Of additional interest is the 
observation that differences in atopic disease prevalence over time can be 
observed within developed countries, with the incidence of asthmatic symptoms 
significantly increasing over a period of 20-25 years [Ninan et al 1992, Upton et 
al 2000].
The incidence of atopic disease differs between developed and developing 
countries, suggesting environmental factors play a role in disease prevalence. 
One such factor is increased use of antibiotics within developed countries, 
which might possibly have an affect on the incidence of atopic disease. For 
example, studies amongst the UK population between the years of 1946 and 
1970 observed an increase in childhood atopic dermatitis from 5% to 12% 
[Taylor et al 1984]. A study in Australia between 1981 and 1997 observed a 
rise in asthma from 13% to 39% [Downs et al 2001]. This rapid increase 
coincides with a greater use of antibiotics and disinfectants by developed 
countries, though many other factors would show similar correlations. Evidence 
is compatible with the view that environmental factors limit our exposure to 
microbial infection, and are at least partly responsible for the increased 
prevalence and incidence of atopic disease.
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1.2.1 Non-Atopic (intrinsic) asthma
Non-atopic asthma is often referred to as intrinsic asthma, and is characterized 
by inflammation that is clinically similar to allergic asthma allergy, such as 
similar pulmonary cellular infiltrate, eosinophilia and cytokine production 
[Bentley et al 1994, Ying et al 1997]. However, there is no raised IgE level in 
response to any external allergen, which is characterized by a negative skin 
prick test. It has been observed that people suffering from intrinsic asthma are 
more likely to be female, have a later onset of symptoms, have more severe 
clinical symptoms and have rhinitis associated with their asthma [Kauffmann et 
al 1995, Romanet-Manent e ta l2002]. Similar observations have been made of 
people suffering from non-atopic rhinitis and dermatitis.
As mentioned above, compared to patients with atopic asthma, the cellular 
infiltrate into the lungs of non-atopic asthmatics is similar apart from an increase 
number of MOs [Bently et al 1994]. In addition, despite the observed absence 
of IgE, patients suffering with intrinsic asthma have equivalent levels of IL-4, IL- 
5 and IL-13 in the bronchial mucosa at the mRNA and protein level [Humbert et 
al 1996, Ying et al 1997, Humbert eta l 1997, Wuthrich et al 1996]. Levels of IL- 
10 and IL-12 secreting cells are also reported to be low in the sputum of non- 
atopic patients compared to atopic asthmatics [Zeibecoglou et al 2000], which 
may explain why there is continued airway inflammation despite the absence of 
any recognised external or endogenous allergen.
1.2.2 Contact dermatitis
Several non-atopic allergic diseases, which are not dependent on Th2 or IgE 
responses, are thought to be largely attributable to Type IV Hypersensitivity, or 
delayed type Hypersensitivity (DTH). This type of Hypersensitivity occurs when 
an Ag interacts with Ag-specific lymphocytes that release inflammatory and 
toxic substances, which attract other leukocytes and results in tissue injury. 
CD8+ cytotoxic T cells and CD4+ helper T cells recognize either intracellular or 
extracellular Ag when it is presented by class I or class II MHC molecules, 
respectively. Cytotoxic T cells cause direct damage to surrounding tissue by 
releasing cytotoxic substances, such as perforin. Th1 cells secrete cytokines,
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which activate cytotoxic T cells, and recruit and activate monocytes and MOs. 
MOs function as APCs, further presenting allergen to T cells, and also release 
IL-1, which promotes the proliferation of Th1 cells. Th1 cells then release 
interferon-y and IL-2, which together regulate delayed Hypersensitivity reactions 
centred on MO activation and T cell mediated immunity [Belsito et a! 1989, 
Grabbe et aI 1998]. There are three variants of Type IV Hypersensitivity: 
Contact Hypersensitivity, tuberculin-type Hypersensitivity and granulomatous 
Hypersensitivity
1.2.3 Type IV Hypersensitivity
Contact Hypersensitivity is characterized by a reaction at the site of contact with 
the allergen (such as contact dermatitis in response to nickel or poison ivy). It is 
an epidermal response most often elicited by molecules called haptens. 
Haptens interact with host molecules to create new Ag determinants. The cell 
involved in Ag presentation at this site is the Langerhans cell, a type of DC 
present in the epidermis. The pathway from initial allergen exposure involves 
sensitization (with Langerhans cells presenting Ag to CD4+ helper T cells), 
followed by recruitment of T cells and M<I>s around blood vessels in the 
epidermis and ensuing edema. A variety of cytokines are involved in this 
process, including IL-2, IL-3, IFN-y and GM-CSF, and chemokines, such as 
RANTES and MCP-1. The reaction resolves within 48-72 hours following 
exposure [Hoefakker eta! 1995, Schwarzenberger et a! 1996].
Tuberculin Hypersensitivity was first observed when soluble Ags from 
microorganisms such as mycobacteria were administered intradermally to 
patients. In these individuals fever and hard swelling at the site of injection was 
observed after approximately 48-72 hours. This skin reaction is frequently used 
to test for recall responses to microorganisms that a person has been exposed 
to, such as for example during the Mantoux test which determines exposure to 
Mycobaterium tuberculosis [Kindler eta l 1989].
Granulomatous Hypersensitivity is characterized by persistence of intracellular 
microorganisms or other foreign Ag within MOs. Such Ags can include 
particulate matter such as talc and silica, or mycobacteria. In cases of
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Granulomatous Hypersensitivity, a granuloma is usually formed, self-containing 
the MOs. The characteristic cells found in these lesions are epitheloid cells 
(derived from activated M<I>s) and giant-cells (multi-nucleated MOs). The 
granuloma consists of a hard core of cells sometimes with a necrotic centre. 
This core is surrounded by lymphocytes with a deposition of collagen fibres, 
caused by proliferation of fibroblasts and increased collagen synthesis 
[Yamamura efa/1991, Romagnani efa/1997].
1.3 Atopic Dermatitis
1.3.1 Prevalence
As with all atopic diseases there has been an increase in atopic dermatitis over 
the last few decades. Several studies on the incidence of atopic dermatitis 
have reported increased levels in northern Europe. Interestingly, the incidence 
of atopic dermatitis in children up to the age of 7 years varied depending on the 
decade they were born. If born before 1960, the incidence was less than 3%. 
This increased to 4-8% in children born between 1960 and 1970, to 8-12% for 
those born after 1970 and is over 15% in children born in recent decades [Ninan 
et al 1992, Upton et al 2000, Nystad et al 1997, Diepgen et al 2000]. Even 
when methodological errors have been taken into account, the overall 
agreement is that there is an authentic and significant increase in the 
prevalence of atopic dermatitis over the last 40 years in developed countries 
[Diepgen etal 2000].
1.3.2 Symptoms
Atopic dermatitis, sometimes referred to as eczema, is an allergy affecting the 
skin. Symptoms include dryness and itching, which are caused by defective 
lipid barriers in the epidermis, and are often intensified by scratching. There is 
an extensive list of further symptoms, ranging from an inflamed red rash, oozing 
and crusting blisters resulting from scratching, dry and leathery skin patches, 
discolouring and thickening of the skin (known as hyperkeratonic eczema), to 
discharge or bleeding from the ears resulting from eczema in the ear canal. In 
addition, atopic dermatitis sufferers often have increased Staphylococcus
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aureus colonization of their skin. These bacteria release inflammatory 
substances which further irritate the skin. The onset of atopic dermatitis usually 
occurs in infancy, but in some cases can occur for the first time after puberty.
The extent and severity of atopic dermatitis are clinically assessed by the 
SCORAD index, which is an abbreviation of SCORing Atopic Dermatitis. This 
index was developed by the European Task Force on Atopic Dermatitis in 1993 
to allow consistent assessment of eczema severity. SCORAD is calculated by 
taking into account the area the eczema has spread, its severity and patients’ 
symptoms [Gelmetti et a /2004].
1.3.3 Controlling Symptoms
The simplest way of preventing eczema is by avoiding the allergen that triggers 
it. Unfortunately for patients, items that trigger eczema are common and can 
include woollen clothes, carpets and animal hair, chlorinated water, cosmetics 
and perfumed soaps, as well as certain foods. Skin dryness can be aggravated 
by excessive heating in the home, contributing to further skin irritation.
Colonization of the skin by Staphylococcus aureus is common in eczema 
sufferers, and can frequently be the cause of an eczema flare up. Therefore, 
treatments can include antibiotics. Systemic antibiotics, like erythromycin or 
cloxacillin are often used, and sometimes a prolonged course of antibiotics is 
required [Correale eta! 1999, Health Encyclopaedia].
The inflammatory aspect of atopic eczema is commonly treated with topical 
application of corticosteroids. These reduce the swelling, itching and redness of 
the rash. The mildest example of a corticosteroid is Hydrocortisone, whilst one 
of the strongest is Betamethasone dipropionate. Betamethasone dipropionate 
is 600 times more potent than Hydrocortisone, and as with all strong steroids 
can only be obtained by prescription. The strength of the steroid needed 
depends on the stage and location of the eczema.
The use of steroids, however, only provides symptomatic relief, since steroids 
do not target the cause of disease. In addition to only providing symptomatic
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relief they can have side effects, including thinning of the epidermis, 
tachyphylaxis (tolerance of the skin to the vascoconstrictive action of the 
steroid), allergic reactions and facial flushes. Alternative therapies include the 
use of Chinese herbs, evening primrose oil and behavioural therapy [Health 
Encyclopaedia]. Non-steroidal topical products, such as Tacrolimus, have also 
been shown to reduce skin susceptibility to irritants by providing a protective 
barrier to the skin and increasing the degree of hydration.
1.3.4 Immunology
Atopic dermatitis is characterized by inflammation of the different layers of the 
skin. This is caused by migration of eosinophils, mast cell precursors,
macrophages and lymphocytes (particularly Th2 cells) across the skin epithelia. 
These recruited cells release cytokines, for example IL-4, which increases IgE 
levels leading to degranulation of mast cells and basophils within the skin 
epidermis. Histamine, released from activated mast cells and basophils, is one 
of the major causes of atopic dermatitis symptoms following contact with an 
allergen. Histamine stimulates sensory nerves and induces itching. It also 
leads to vasodilatation, which results in reddening and facilitates inflammation 
of the skin.
1.4 Allergic Rhinitis
1.4.1 Prevalence
Allergic rhinitis is today one of the most prevalent chronic diseases affecting 
developed countries. There is no universally agreed definition of rhinitis and so 
its prevalence is difficult to assess. A number of studies have however 
demonstrated an increase in disease since the 1960s, suggesting it now affects 
between 15% and 25% of people in developed countries, such as the USA, 
Britain and Australia [Downs et al 2001, Upton et al 2000, Ninan et al 1992]. 
This is a more rapid increase than is observed in studies of asthma or atopic 
dermatitis.
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1.4.2 Symptoms
Often referred to as hay fever, rhinitis is an inflammation of the lining of the 
nose in response to an irritant or allergen. Symptoms include irritated eyes, 
nose and throat, watering eyes, nasal blockage or rhinorrhoea (running nose) 
and frequent sneezing. Wheezing may also accompany these symptoms in 
severe cases. There are two types of rhinitis, seasonal (hay fever) which 
occurs in response to pollens released at certain times of the year, for example 
tree or grass pollen, and perennial, a chronic all year round problem. This is 
usually the result of permanent, indoor allergens, like house dust mite protein or 
animal hair. The onset of allergic rhinitis usually occurs during childhood, but 
sensitisation in adulthood is becoming more common [Health Encyclopaedia].
1.4.3 Controlling symptoms
The simplest way of preventing rhinitis is by avoiding the allergen which triggers 
the symptoms. Skin prick tests can identify the allergen responsible by 
transferring a very small amount of Ag into the skin, which becomes inflamed if 
the patient is allergic. Even if the identity of the specific allergen is unknown, 
behavioural changes, such as wearing a pollen mask when mowing the grass or 
cleaning the house, may reduce exposure to the most common allergens. In 
addition, exposure can be reduced by installing an air purifier which remove 
airborne allergens or enclosing sleeping mattresses in plastic and using cotton 
or synthetic materials such as Dacron in pillows and beddings.
Although avoidance of the allergen in the most effective way to prevent allergy, 
this is often impossible. There are a number of treatments available. For 
example, flushing the nose with salt water can reduce nasal inflammation. In 
addition, it washes out thickened nasal secretions, irritants (smog, pollens, etc.), 
bacteria, and mucus crusts from the nose and sinuses to prevent nasal 
blockage. Non-prescription nasal sprays (for example Ocean spray, Ayr, Nasal) 
can be used frequently to reduce the local inflammation in the nasal passage, 
and are very convenient to obtain and use. Anti-histamines are drugs that block 
the action of histamine released during inflammation. These medications work 
best when given prior to exposure. Anti-histamines can be divided into two
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groups; sedating (for example Benadryl, ChlorTrimetron, Tavist), and non­
sedating (Claritin, Hismanal). The effectiveness of anti-histamines is hindered 
by the need of an individual to drive or use dangerous equipment if the anti­
histamines are sedating ones. In the case of non-sedating, they can have 
serious drug interactions. Nasal steroids (for example Vancenase, Beconase, 
Flonase, Nasacort, Rhinocort) also reduce allergic inflammation, and being 
effective locally they do not have the side effects that systemic steroid treatment 
has. However, sometimes their use leads to nasal bleeding. If this happens in 
children, anti-allergic drugs such as sodium cromoglycate and nedocromil 
sodium are used, which are preventative drugs. They are taken regularly to 
prevent inflammation, so decrease the need for other drugs.
1.4.4 Immunology
Like atopic dermatitis, allergic rhinitis is characterized by the infiltration of cells 
into the nasal mucosa. Superficially, the mechanisms of inflammation are 
similar in both atopic dermatitis and allergic rhinitis. Cytokines, such as IL-4, are 
released and IgE levels increased, which leads to degranulation of mast cells 
and basophils. Histamine release causes inflammation in the nasal passage, 
and stimulates sensory nerves inducing sneezing, nasal itch, vasodilatation and 
mucus production. These symptoms of histamine release in the nose are called 
rhinorrhea. Histamine also has a pro-inflammatory role through up-regulation of 
adhesion molecules such as ICAM and further release of IL-4. Lipid 
compounds known as leukotrienes are also generated by mast cells, 
eosinophils, macrophages, neutrophils and epithelial cells, and are released 
into nasal tissue. They exacerbate inflammatory responses and are also 
important later in the inflammatory reaction, causing nasal obstruction, mucus 
secretion and leading to further inflammatory cell recruitment [Health 
Encyclopaedia].
2. ASTHMA
Asthma causes morbidity and mortality throughout the developed world. It is no 
more prevalent than dermatitis or rhinitis, but its symptoms are far more severe.
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Novel treatments and therapies are constantly being sought. Asthma forms the 
focus of this thesis and this section is more detailed than that for the others.
2.1 Prevalence
Asthma has only been defined as a disease entity in its own right since the mid 
1950s, so there is little information about it prior to that time. However, since 
the 1960s, there has been a reported progressive increase in the prevalence of 
asthma in westernised societies. In the past 20 years, the prevalence of 
asthma has almost doubled, so much so that today asthma affects 
approximately 8% to 10% of the population in the United States for example. It 
is now the leading cause of hospitalisation among young children in developed 
countries such as USA and Britain [Cohn etal 2003, Arkwright et a /2003].
2.2 Asthmatic symptoms
Asthmatic symptoms are characterized by laboured breathing accompanied by 
wheezing, a sense of constriction in the chest, and often attacks of coughing or 
gasping. During an attack, the airways are severely inflamed. Tightening of 
muscles surrounding the airways (also known as bronchoconstriction) causes 
them to narrow. Goblet cells in the airways secrete mucus, which ‘plugs up’ or 
partly blocks the airways. Asthma attacks can occur very rapidly, or develop 
over several hours or even days. This is dependent upon the extent to which 
an individual is allergic to a particular Ag, and to the length of time for which 
they are exposed to it. Asthmatic symptoms may also take just as long to 
reverse after the initial asthma attack has passed. This can be explained by the 
finding that Ag presentation may be prolonged due to a small population of 
resident airway APCs that can present Ag for up to eight weeks following 
exposure [Julia et al 2002]. There are a variety of stimuli that can trigger an 
asthmatic attack. Common allergens include grass pollen, house dust mite and 
animal hair.
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2.3 Controlling asthmatic symptoms
As with other allergies, avoiding allergens is the best option to prevent 
symptoms. Eliminating other irritants from every day life, for example tobacco 
smoke and animal hair, and exercising regularly may also reduce the risk of an 
asthma attack. As most allergens are airborne avoiding them becomes difficult, 
and medical treatment is often necessary. Treatments fall into two categories, 
controlling and relieving medicines. Controlling medicines prevent the asthma 
attacks from starting, whereas relievers reverse the symptoms. Usually 
combinations of both are used to treat asthmatic patients.
Controlling medicines are usually anti-inflammatory drugs, which are taken 
regularly even without any symptoms of asthma, and prevent the likelihood of 
an attack occurring. The most effective and most commonly used anti­
inflammatory medicines are inhaled glucocorticosteroids, such as Budesonide, 
Beclomethasone and Fluticasone. Glucocorticosteroids are defined as steroids 
that regulate carbohydrate, lipid and protein metabolism. These medicines help 
to prevent severe asthma attacks if taken regularly.
Relieving medicines are bronchodilators. These are medicines that help to 
prevent attacks progressing further by quickly opening up the narrowed airways. 
They do this by relaxing the muscles surrounding the airways. Most 
bronchodilators only have a short-term effect and should not be used regularly 
as controllers. Long-acting bronchodilators, including Formoterol and 
Salmeterol, are effective when they are used with an inhaled 
glucocorticosteroid. These can be used for both the immediate relief of 
symptoms, and alongside controlling medicine to keep asthmatic symptoms 
under control.
2.4 Immunology of asthma
During an asthma attack, the airway is infiltrated with excessive numbers of 
CD4+ Th2 cells, mast cells, MOs, plasma cells and eosinophils. In the lumen of 
the lung, these cells infiltrate the airway mucosa [Cohn et al 2004]. The 
presence of so many inflammatory cells causes the airway wall to thicken 10% -
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300% compared to that of non-asthmatic patients, resulting in a reduction in 
diameter of the lumen and small airways [Homer et a /2000, Roberts et al 1997]. 
Besides inflammatory cells, other elements in the lung contribute to the 
thickening of the lumen wall. For example, mucus glands undergo hypertrophy, 
and goblet cells in the airway epithelium secrete excessive mucus. There is 
deposition of collagen (types I, III and V), fibronectin and tenascin (a protein that 
interacts with collagen) under the basement membrane in the lumen, resulting 
in thickening and hardening of the airways [Roberts et al 1997, Roche et al 
1989]. In addition myofibroblasts become hyperplastic, so small muscle mass, 
vascular permeability and airway oedema increase [Black et al 1997, Homer et 
al 2000].
Asthma is triggered when individuals come into contact with otherwise harmless 
allergens to which they are sensitized. Genetic predisposition to asthma is 
common. At least a dozen polymorphic genes associated with asthma have 
been identified, controlling mechanisms behind inflammatory responses, IgE 
and cytokine production, and AHR [Cookson et al 1999, van Eerdewegh et al 
2002, Fahy et al 2000]. For example, the ADAM33 gene belongs to a family of 
proteases, and has been identified as an asthma susceptibility gene. A genome 
screen using linkage analysis of 401 microsatellite markers in 460 Caucasian 
families was carried out. Each family had at least 2 siblings with doctor- 
diagnosed asthma. Strong linkage was seen between asthma and the region of 
chromosome 20p13. Forty genes were characterized in this region, and 
polymorphisms in the ADAM33 gene had the highest significant association with 
asthmatic symptoms [van Eerdewegh et al 2002]. Although the exact function 
of the ADAM33 protein is still unknown, a number of possible roles have been 
addressed. ADAM33 may influence remodelling of the airway, as its selective 
expression in mesenchymal cells strongly suggests that alterations in activity 
may underlie abnormalities in the function of airway smooth muscle. In 
addition, it may alter release of cytokines and growth factors. Other ADAM 
proteins have this capacity, like ADAM17, which is responsible for generating 
soluble TNF-a [Cakebread et a /2004].
Another example of a gene potentially associated with asthma is CD14. CD14 
is expressed and secreted by myeloid cells, usually monocytes and Md>s. In
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some, but not all [Sengler et al 2003], studies a polymorphism in the promoter 
region of CD 14 is associated with raised levels of IgE in peripheral blood 
[Baldini et al 1999]. In addition, during pregnancy and breast-feeding, low 
levels of secreted CD14 in the amniotic fluid and in breast milk have been linked 
with an increased risk of the child developing atopic dermatitis when born 
[Jones et al 2002].
2.5 Initiating excessive Th2 response
In healthy individuals, inhaled protein allergens induce tolerance. The 
respiratory mucosa is not completely impenetrable, and microbes and foreign 
Ags can enter the tissue. For example, some aeroallergens possess a protease 
activity that allows them to overcome the protective mucosal barrier. Therefore, 
pulmonary immune responses must be suppressed by active mechanisms. For 
example, inhaled Ag has been observed to induce immune unresponsiveness in 
naive T cells, with both Ag specific and Ag non-specific “bystander” effects 
[Wolvers et al 1994]. In addition, APCs at mucosal surfaces have the unique 
ability to secrete IL-10, promoting the development of T cells with regulatory 
properties [Iwasaki et al 1999, Stumbles et al 1998]. This leads to tolerance at 
the mucosal surface in healthy people. In the lungs of asthmatic patients, 
tolerance is not induced in response to specific allergens. Tissue resident 
APCs present these allergens to T cells, resulting in a type-2 mediated airway 
inflammation [Hewitt eta! 1995, Machado et a! 1996].
APCs are defined as cells that can present Ag to a T cell via the MHC-TCR 
complex. The most efficient presenters of Ag are the DCs, which internalise all 
Ag, process it and present it on the MHC surface molecules. Immune 
responses during asthma attacks are initiated by APCs, as they are necessary 
for allergen presentation to T cells. The importance of APCs in asthma initiation 
is supported by the observation that DCs are found in increased numbers in the 
lung biopsies of asthmatic patients [Tunon-De-Lara et al 1996]. These DCs 
also express increased levels of markers, for example MHC II, compared to the 
DCs in the lungs of non-asthmatic patients. [Tunon-De-Lara et al 1996, Moller 
et al 1996]. Tissue resident APCs pick up exogenous allergen then migrate to 
the lymphoid organs, where they present the Ag on the MHC II to CD4+ T cells.
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Once a CD4+ T cell is activated, it proliferates and secretes either type-1 or 
type-2 cytokines. The genetics of an individual may play a key role in biasing 
CD4+ T cell responses, to Th1 or Th2. In allergic individuals, CD4+ T cells are 
more commonly directed down a Th2 pathway. A number of genes have been 
closely linked with asthmatic traits. These include a cytokine cluster on 
chromosome 5q31, which contains genes for the type-2 cytokines IL-4, IL-5 and 
IL-13 [Song et al 1996, Rosenwasser et al 1997, Kawashima et al 1998]. 
Polymorphisms in these genes result in an increased incidence of asthma.
Although lymphocytes make up only a small percentage of the cells in the lung, 
CD4+ T cells are significantly increased in the airways of asthmatic patients, 
and they express activation markers such as CD25 (IL-2 receptor a chain) 
[Walker et al 1991, Corigan et al 1988]. Secretion of Th2 cytokines, such as IL- 
4, IL-5 and IL-13 by CD4+ T cells activates eosinophils, mast cells and induces 
B cell production of IgE. These further contribute to pulmonary inflammation. A 
cascade of cell activation and infiltration into the lungs then occurs, creating a 
positive feedback loop. For example, activated mast cells and NK T cells can 
further promote Th2 cell development by secretion of cytokines, such as IL-4 
and IL-13 [Zuany-Amorim eta l 1998, Akbari et al 2003b, Mosmann eta l 1989]. 
In a murine model of OVA-induced pulmonary inflammation, development of 
AHR and airway inflammation by respiratory exposure to OVA required the 
activation of pulmonary NK T cells, producing a combination of IL-4 and IL-13 
[Akbari et al 2003b]. Although CD4+ Th2 cells initiate allergic asthma, many 
activated cells contribute to airway inflammation.
The inflammatory response observed in allergic pulmonary disease is initiated 
and maintained by a number of redundant mechanisms. The pulmonary 
inflammation and increased vascular permeability results in rapid migration of 
more inflammatory cells into the airways. This promotes continued Th2 cell 
activation in the lungs. Damaged epithelial cells secrete GM-CFS, which also 
induces further DC maturation [Huh et al 2003, Celia et al 1996]. Memory 
CD4+ Th2 cells that already reside in the airways can also be activated locally 
by DCs, thereby leading to rapid induction of cytokine release and AHR [Huh et 
al 2003, Julia et al 2002, Salek-Ardakani et al 2003, Gonzalo et al 2002]. Ag
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presentation may be prolonged due to a small population of airway APC that 
can present sequestered Ag for up to eight weeks following exposure [Julia etal 
2002].
2.6 AHR
Airway hyper-responsiveness (AHR) has been identified as an important and 
defining feature of asthma. In terms of allergic asthma, AHR describes the 
increased ability of the airways to narrow after exposure to an allergen, and is 
an indication of the increased sensitivity of the airways to that allergen. The 
extent of AHR is indicated by the amount of allergen necessary to induce a 
bronchoconstrictor response, the steepness of the slope when the dose of 
allergen or agonist is plotted against the maximal response [Woolcock et al 
1984].
2.6.1 Measuring AHR in humans
In humans, the severity of AHR is generally measured by patients inhaling 
increasing concentrations of a bronchoconstrictor stimulus, such as histamine 
or methacholine, until a given level of bronchoconstriction is achieved. This 
level is usually measured as a 20% fall in the Forced Expiratory Volume in one 
second (FEVi) (PC2o) [Cockcroft eta l 1977]. Asthmatic patients generally have 
a PC20 of <8mg/ml of histamine or methacholine, whereas non-asthmatics have 
a PC20 >16mg/ml. This method of measuring AHR has been used not only to 
measure AHR in asthmatics, but also in patients suffering from airway 
obstruction due to chronic obstructive pulmonary disease (COPD) [Ramsdale et 
al 1984].
This method, however, does have a limitation in determining AHR correctly. 
There is sometimes an overlap in PC20 between asthmatic and non-asthmatic 
patients, so defining an exact level of AHR is not always possible. This is 
because there appears to be a continuous distribution of non-specific AHR in 
the general population, with asthmatic patients in one tail of this distribution. 
This makes distinguishing asthmatics from non-asthmatics difficult [Cockcroft et 
al 1983].
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2.6.2 Measuring AHR in animals
There are several procedures used to determine AHR in animals. Methods 
include in vitro measurement of intracheal smooth muscle contractility after 
electrical field stimulation [Larsen et ai 1992], in vivo measurement of lung 
resistance after i.v. injection of bronchoconstrictive agents (as described above 
in humans) [Martin et al 1988, Renz et a! 1992], and in vivo measurement of 
peak airway opening pressure [Levitt et al 1988, Hamelmann et al 1997]. Most 
experiments for measuring AHR have been carried out using murine models of 
airway inflammation, including mice, rats and guinea pigs. The use of murine 
models does present some limitations, which are discussed later.
Measurement of AHR by intracheal smooth muscle contractibility involves 
placing tracheal smooth muscle segments from allergen sensitized and 
challenged mice in an organ bath, on wire supports and attached via a gold 
chain to a FT.03 isometric force transducer. Tissues are then submerged in a 
Krebs-Henseleit solution, and each tracheal smooth muscle segment is 
equilibrated in the bath for 90 minutes at a tension of 1.5 g. A stimulus is 
applied through the tissue by means of parallel platinum electrodes. The optimal 
resting length for each tissue is established by assessing its maximal contractile 
response to the electrical field stimulation (in Hz). Recordings of resting
tensions and all contractile responses are made on a dynagraph recorder. At
the end of each experiment, the tracheal smooth muscle segment is weighed. 
All tensions were expressed as grams isometric tension per gram tracheal 
smooth muscle weight (g/g). The frequency that caused 25%, 50%, and 75% of 
the maximal contraction is calculated from linear plots of the contractile 
response versus the frequency of electrical field stimulation, and expressed as 
the ES25, ES50, and ES75 [Larsen et al 1992]. Animals sensitized and 
challenged with allergens have a reduced ES25, ES50 and ES75 compared to 
animals that are challenged but not sensitized.
Measuring lung function in vivo, using increasing concentrations of a
bronchoconstrictor stimulus, often requires animals to be anaesthetized, 
tracheotomized and ventilated. The tracheotomy tube is passed into a 
plethysmograph chamber and connected to a ventilator. A bronchoconstrictor
34
stimulus, such as histamine or methacholine, is dissolved in saline, diluted to 
different concentrations and injected individually i.p. Changes in lung pressure 
are recorded by detecting chamber pressure via a pressure transducer and flow 
is measured by electronic differentiation of the volume signal [Martin et al 1988]. 
As described above, the lower the concentration of the bronchoconstrictor 
needed to induce a 20% drop in lung function, the greater the severity of AHR.
The two methods described above for measuring AHR in animal do have 
limitations. The in vitro technique of measuring intracheal smooth muscle 
contractibility after electrical field stimulation has been shown to correlate with 
allergic airway sensitisation [Larsen et al 1992]. However, using this technique 
does not take into account the influence of other changes within the airway, 
such as mucus production. The in vivo method of measuring lung function in 
response to histamine or methacholine is limited by the fact that animals need 
to be anaesthetized and ventilated. The influence of the anaesthetic and of the 
operating procedures on lung function is unknown. In addition, this is a time 
consuming protocol [Martin etal 1988, Renz etal 1992].
These problems can be overcome by using a method, where unrestrained and 
conscious animals can be monitored. This technique is similar to the in vivo 
measurement of lung function in response to a bronchoconstrictor, except the 
pressure measurements are obtained using barometric whole-body 
plethysmography (WBP). Conscious mice are placed in the chamber of the 
whole-body plethysmograph. The pressure differences between the main 
chamber of the WBP and an empty reference box are measured. This is known 
as the known as the box pressure signal, and is caused by volume and 
resultant pressure changes in the main chamber during the respiratory cycle of 
the animal. Aerosolized methacholine is then pumped into the chamber in 
increasing concentrations and readings taken [Hamelmann et al 1997].
The changes in pressure are used to determine several aspects of the animals’ 
lung function. Inspiration and expiration are recorded, by establishing start and 
end of inspiration as where the box pressure/time curve crosses zero (see 
Figure 1-1). The time of inspiration or expiration is the time from the start of 
inspiration or expiration to the end (T j or T e ); the maximal box pressure signal in
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one breath is defined as peak inspiratory or expiratory pressure (PIP or PEP); 
relaxation time is the time of pressure decay to 36% (Tr). During 
bronchoconstriction, the main alteration in the signal occurs during early 
expiration and leads to changes in the waveform of the box pressure signal (see 
Figure 1-1) [Hamelmann efa/1997].
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Figure 1-1: Parameters measured by barometric plethysmography.
Schematic diagram of box pressure waves in inspiration (down) and expiration 
(up). Tj = inspiratory time; TE = expiratory time; PIP = peak inspiratory pressure; 
PEP = peak expiratory pressure; Tr = relaxation time.
Subtracting the Trfrom TE and dividing the whole number by Tr can determine 
the measurement Pause. This can then be multiplied by (PEP/PIP) to give the 
Enhanced Pause (Penh). Penh reflects the changes in the waveform of the 
signal pressure from both inspiration and expiration (PIP and PEP) and 
combines it with the timing of early and late expiration (pause). AHR is often 
visualised or plotted as a fold increase for each concentration of methacholine 
compared to Penh values after challenge [Hamelmann e t a l  1997, Kearley e t a l  
2005]. Although the calculations of this method are complicated, a lot of data 
can be obtained without having to terminate the animal. The protocol is also 
less time consuming and does not put unnecessary stress on the animals by 
requiring anaesthesia or tracheotomy.
36
2.6.3 Limitations of measuring AHR in animals
All the above methods of measuring AHR have been described using rodents. 
However, there are some severe limitations in using murine models to measure 
AHR. For example, murine studies may not clearly distinguish between AHR 
originating from the airways, and that due to contractile elements in the lung 
parenchyma, which is responsible for a significant component of resistance to 
airflow in the presence of airway inflammation [Nagase et al 1994]. Another 
significant deficiency is that most inflammatory models are relatively short-term 
experiments. They therefore do not exhibit many lesions in the lungs that are 
common in chronic human asthma. Also absent, are the chronic inflammation 
of the airway wall, and changes as a result of airway remodelling and fibrosis 
[Holgate e ta l2000]. Since chronic inflammation and airway remodelling are be 
related to the extent of AHR severity [Bousquet e ta l2000], the extent of murine 
AHR is not comparable to that observed in humans.
2.7 Th1/Th2 Paradigm
CD4+ T cells can be characterized by the cytokines they secrete. Cells 
producing IL-2 and IFN-y are known as Th1 cells, and those producing IL-4 as 
Th2 [Mosmann et al 1989]. These CD4+ Th cells produce cytokines, which 
differentiate naive T cells into the same T cell subtype, enhancing their own cell 
type proliferation. Each cell type also down-regulates the other. For example, 
Th1 IFN-y secretion is shown to suppress Th2 proliferation and IL-4 secretion in 
vitro [Mosmann et al 1989, Fitch et al 1993, Abbas et al 1996] and, in a 
separate study, supernatants removed from Th2 clone cultures and added to 
Th1 clone cultures inhibited IFN-y production by Th1 cells [Fiorentino et al 
1989].
Reciprocal regulation between Th1 and Th2 cells in vivo remains, however, a 
matter of debate. Whereas supporting data have so far been obtained from in 
vitro studies. A number of observations in vivo appear to contradict the 
Th1/Th2 paradigm. For example, chronic atopic dermatitis, rather than being a 
Th2-mediated disease, is associated with an increase in both Th1 and Th2 
cytokines, IFN-y and IL-4 respectively [Hamid et al 1994]. Furthermore, OVA-
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induced Th2 mediated AHR in a murine model of pulmonary inflammation failed 
to be reversed by the addition of Th1 cells. Rather, Th1 cells contributed to the 
severity of the disease [Hansen et al 1999]. In a similar study the passive 
transfer of OVA-specific Th1 cells i.v. resulted in enhancement of an originally 
Th2 mediated airway inflammation. This effect was observed regardless of 
whether the T cells were transferred before sensitisation or after airway 
inflammation was already established. The transfer of Th1 cells also resulted in 
increased recruitment of both Th1 and Th2 cells to the airways [Randolph et al
1999]. Finally, in contrast to what was predicted based on the classification of 
asthma as a type-2 disease, IFN-y has been detected in the lungs of asthmatic 
patients [Krug et al 1996].
The lack of agreement between in vitro and in vivo, data suggests a more 
complicated balance between Th1 and Th2 responses. When limited to an in 
vitro system, with controlled cell types and environment, Th1 and Th2 cells may 
easily antagonise each other’s development and expansion. However, in an in 
vivo model, responses would not be physically contained and other “bystander” 
cells would be affected by and react to changes in immune responses. 
Therefore, decreases in type-2 responses may not be due to changes in Th1 
and Th2 cell activation alone. If in vivo Th1 and Th2 cells are not regulating 
each other then some other mechanism must be involved. Allergy has been 
described as a disease of immunodysregulation, where the self-regulation 
mechanisms of the immune system are dysfunctional [Rook et al 2002]. One 
theory is that Tregs are involved in the reversal of allergic inflammation, as well 
as autoimmune disease, where their role has been firmly established [Robinson 
et al 2004, Curotto et al 2002, Wraith et al 2004]. This theory is further 
described in section 4.
2.8 Immunosuppressive cytokines
Immunosuppressive cytokines, so-called for their ability to suppress immune 
responses, play a major part in the self-regulation of the immune system. The 
best described cytokines with such abilities are IL-10 and TGF-p. Both have 
been observed to play essential roles in regulation of Th2-mediated responses 
[Ludviksson et al 2000, John et al 1998]. More recently another cytokine, IFN-
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a, has also been put forward as an immunoregulatory cytokine [Lombardi et al 
2000].
Originally IL-10 had been classified as a Th2 cytokine. It is secreted by IL-4 
producing Th2 cells and has an inhibitory effect on Th1 responses [Elliott et al
1994]. More recently IL-10 secretion by IFN-y producing Th1 cells was also 
observed [Gerosa et al 1999]. IL-10 is secreted by a variety of cells, including T 
cells, APCs and NK cells. The regulatory functions of IL-10 are discussed in 
more detail later in sections 3 and 4 [Read et al 2001, Roncarolo et al 2000]. 
IL-10'7' mice develop severe allergen-induced airway inflammation, with 
excessive IL-4, IL-5 and IFN-y production [Borish et al 1998]. Stampfli and 
colleagues have suggested that IL-10 is essential to downregulate inflammation 
in the lungs of OVA sensitized and challenged mice. Addition of IL-10 via an 
adenoviral vector alleviated airway inflammation, by inhibiting cytokine and 
chemokine production, and by downregulating CD80 and CD86, co-stimulatory 
ligands involved in T cell activation, hence preventing efficient Ag presentation 
to the T cell [Stamfali et al 1999]. A protective role for IL-10 has also been 
observed in asthmatic patients, where the use of the inhaled corticosteroid 
Budesonide, an anti-inflammatory controlling medicine for asthma, elevates IL- 
10 protein levels in the lungs [John et al 1998]. Together these observations 
suggest an important role for IL-10 amelioration of symptoms of asthma.
TGF-p is a cytokine secreted by a number of different cells types, such as T 
cells, APCs and eosinophils. TGF-p, like IL-10, has also been observed to 
regulate immune responses. TGF-P'7' mice develop a multifocal wasting 
disease, with severe multiorgan inflammation and tissue necrosis twenty days 
after birth. The inability to suppress the immune response leads to organ failure 
and rapid death [Shull 92, Prud’homme et al 2000]. TGF-p also has an 
inhibitory effect on T cells undergoing differentiation. When CD4+ T cells 
isolated from naive transgenic DO11.10 mice were treated with OVA and TGF- 
p, a significant reduction was observed in T cell proliferation, compared to CD4+ 
T cells treated with just OVA. This result occurred even when the cells were 
also treated with IL-4 and IFN-y [Ludviksson ef a/2000]. Treatment with IFN-y
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or IL-4 would have favoured Th1 or Th2 development, but the presence of TGF- 
p prevented this, suggesting an immunoregulatory role for TGF-p.
IFN-a has also been described as having immunoregulatory properties. This 
cytokine is secreted by APCs, usually in response to viral infections. Together 
with IL-10, exogenous IFN-a enables the differentiation of human T cells with 
regulatory abilities. In experiments where naive CD4+ T cells were cultured in 
the presence of exogenous IL-10 and IFN-a, the resulting T cells secreted 
elevated amounts of IL-10 and TGF-p, suggesting that the presence of IL-10 
and IFN-a induces Tregs. When these Tregs were added to co-cultured APCs 
and naive CD4+ T cells, they significantly inhibited CD4+ T cell proliferation 
[Levings et al 2001]. IFN-a also upregulates the secretion of IL-10 by DCs, 
further promoting induction of T cells with regulatory properties [Bilsborough et 
al 2003]. IFN-a has also been observed to promote survival of anergic T cells. 
Indeed, apoptosis of anergic T cells is blocked by addition of IFN-a to culture 
medium [Lombardi efa/2000].
3. Antigen Presenting Cells
APCs are a large and heterogeneous group of cells. A wide spectrum of cells 
can present Ag, but APCs consist of three main groups; DCs, MOs and B cells. 
They present Ag to T cells initiating T cell development. MHC is the molecule 
necessary for presentation of Ag to the T cell via the TCR [Bryant et al 2002]. 
The type of immune response triggered depends on the molecular context in 
which the Ag is presented. For example if an intracellular pathogen is detected, 
signalling through the MHC l-TCR activates CD8+ cytotoxic T cells, which leads 
to destruction of the cell. In contrast, extracellular foreign Ag is presented by 
the APC to the T cell by the MHC II molecule, which initiates a CD4+ Th 
response, either Th1 or Th2 depending on the cytokine environment.
APCs pick up exogenous Ag in the peripheral tissue, and degrade the Ag into 
peptides, before they migrate to the T cell rich zones of the LNs. Once in the 
LNs, APCs upregulate activation and co-stimulatory cell surface markers like 
MHC II, andCD80 and CD86. DCs alone are actually capable taking
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exogenous Ag up from outside the cell and presenting it to T cells through 
interaction with MHC I, and triggering CD8 T cell activation, normally activated 
by the MHC I pathway. This is known a cross-priming, and results in activation 
of CD8+ cytotoxic T cells that are capable of killing cells by degranulation of 
substances like granzyme B and perforin [Zinkernagel ef a/2002]. DCs are also 
the most efficient APC at presenting Ag to T cells. In addition they play vital 
roles in other aspects of the immune response, for example in cell regulation 
and peripheral tolerance.
3.1 Role of APCs in tolerance
The immune system comes into constant contact with food Ags and 
aeroallergens at mucosal surfaces. APCs at mucosal surfaces have unique 
features that stimulate the development of tolerance and may provide 
homeostatic regulation [Bilsborough et al 2003]. The generation of tolerance in 
the airways appears to be predominantly under the control of mucosal DCs, and 
may be achieved by a number of mechanisms.
One possible mechanism of tolerance may be through APC expression of co­
stimulatory molecules. DCs at mucosal surfaces have been observed to 
express low levels of MHC II and co-stimulatory molecules, such as CD80 and 
CD86 [Stober et al 1998, Janeway et al 1994]. These molecules are essential 
for naive T cell activation. The low levels of these markers expressed by 
mucosal DCs leads to reduced activation in response to harmless Ags. This 
suggests that DC expression of co-stimulatory molecules may influence 
activation of Th2 mediated inflammation.
Another possible mechanism involves APC production of immunosuppressive 
cytokines. For example, oligosaccharides derived from the helminth 
Schistosoma mansoni can induce APCs in the peritoneal cavity, which express 
low levels of proinflammatory cytokines, such as IL-12 and IFN-y, and increased 
levels of the regulatory cytokines IL-10 and TGF-p. These APC have been 
shown to mediate regulatory processes. For example, when cultured in vitro 
together with anti-CD3 and anti-CD28 stimulated narve CD4+ T cells, they also 
suppressed T cell proliferative responses [Terrazas ef a/2001]. This suggests
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that secretion of immunoregulatory cytokines by APCs may have a suppressive 
effect on T cell activation.
In addition to regulating immune responses themselves, APCs have been 
observed to induce T cells with regulatory properties. Mucosal DCs that 
produce IL-10 have been observed to promote the generation of Tregs [Iwasaki 
et al 1999, Stumbles et al 1998]. The regulatory properties of these Tregs arise 
from their secretion of immunosuppressive cytokines, such as IL-10 and TGF-p. 
These cytokines would have further suppressive effects on “bystander” cells. 
IL-10 producing DCs have been reported following respiratory exposure to 
OVA. These in turn stimulated the development of IL-10 secreting Tregs. 
Adoptive transfer of these DCs to recipient animals with allergic pulmonary 
inflammation induced Ag specific unresponsiveness [Akbari e ta l 2001, Akbari 
et al 2002]. This suggests that IL-10 secretion by Tregs could lead to immune 
tolerance, when occurring at the mucosal surface.
4. Regulatory T cells
Suppression of immune responses to self or foreign harmless Ag is known as 
tolerance. Two main kinds of tolerance exist, central and peripheral tolerance. 
Central tolerance involves negative selection of autoreactive thymocytes, 
deleting these cells by apoptosis [Kappler et al 1987]. In contrast, peripheral 
tolerance occurs once the cells have migrated away from the thymus into the 
periphery. Several mechanisms can result in peripheral tolerance, including 
suppression of cell activation [Earle et al 2005]. In this thesis, peripheral 
tolerance is concentrated on.
Tolerance to both self and environmental Ags in the periphery is important, 
particularly at mucosal surfaces. T cells exist that have the ability to suppress 
immune responses and these are known as Tregs. Recently, the term “Treg” 
has been reserved, by some authors, for constitutive CD25+, Foxp3+ regulatory 
T cells. In this thesis Treg is used for all types of regulatory T cell. Several 
types of Tregs exist, each characterized by their different cytokine secretions 
and cell surface marker expression. All Tregs do, however, have similar 
functions, and are capable of suppressing immune responses. These cells are
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probably identical to the suppressor cells studied in the late 1970’s and early 
1980s by Gershon and colleagues. However “suppressor cells” went out of 
fashion for a decade, until workers such as Weiner and colleagues at Harvard 
University rediscovered them in a model of autoimmunity. They were by Weiner 
and colleagues using MBP in an SJL mouse model to induce EAE. MBP is one 
of the components of myelin, a substance that forms part of the layer around 
the nerve axons. EAE is an animal model for multiple sclerosis, a cell mediated 
autoimmune disease that results in demyelination of axons. This group 
observed that feeding mice with EAE low doses of MBP Ag suppressed 
symptoms, by inducing a peripheral tolerance that was mediated by the 
differentiation of an Ag specific Tregs. These Tregs secreted both IL-4 and 
TGF-p [Chen et al 1994].
Tregs have since been described to secrete IL-10. Naive T cells isolated from 
the spleens of OVA-TCR transgenic DO11.10 mice were repetitively stimulated 
with OVA and IL-10. The cytokine profile of these Tregs was characterized by 
IL-10, with little IL-2 and no IL-4. This cytokine profile distinguishes this Treg 
type from Th1 or Th2 cells. When these cells were injected i.p. into a murine 
model of Th1 mediated colitis, the development of the disease was inhibited, 
demonstrating immunosuppressive properties [Groux et al 1997, Cottrez et al 
2000]. Tregs have also been described in humans. When human peripheral T 
cells were stimulated with exogenous IL-10, they also secreted the IL-10 
themselves [Groux et al 1997]. The secretion of TGF-p and IL-10 by different 
types of Tregs demonstrates that immunosuppressive cytokines are important 
in the maintenance of peripheral tolerance.
Experiments have been performed that directly demonstrate the importance of 
IL-10 and TGF-p Treg-induced peripheral tolerance. T cells have been 
engineered to secrete IL-10 and TGF-p using a retrovirus. These T cells have 
the ability to inhibit AHR and airway inflammation, when adoptively transferred 
into animals with allergic pulmonary inflammation. This suppression is reversed 
by the addition of anti-IL-10 or anti-TGF-p Ab. This suggests that these 
cytokines may have a suppressive effect of inflammatory responses [Hansen et 
al 2000, Nakao etal 2000, Oh etal 2002, Stampfli et al 1999]. Tregs have been 
hard to study, mainly due to the difficulty in culturing them in vitro. Despite
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these problems, several subtypes of T cell with regulatory properties have been 
described.
4.1 Natural CD4+CD25+ Tregs
In 1995 Sakaguchi and colleagues originally described natural Tregs as a small 
fraction, approximately 10%, of CD4+ T cells present in the periphery 
[Sakaguchi et al 1995]. They constitutively express the IL-2 receptor a chain, 
CD25, and are selected in the thymus. In addition, they have been observed to 
express a variety of cell surface markers and transcription factors, some more 
commonly associated with activated and memory T cells. These include 
CD45RBLow, CD62L, CD103, CTLA-4, GITR and Foxp3(Table 1-3) [Powrie eta l 
1993, Sakaguchi e ta l 1995, Takahashi e ta l 2000, McHugh et al 2002, Khattri 
e ta l2003]. In vitro, naturally occurring CD4+CD25+ Tregs operate in a contact 
dependent manner [Shevach et al 2002, Thornton et al 1998], although 
secretion of IL-10 has been observed [Ling et al 2004]. The mechanism of 
action adopted by naturally occurring Tregs in vivo is still unclear.
Natural CD4+CD25+ Tregs have the ability to prevent organ-specific 
autoimmunity. This was demonstrated when CD4+ T cell populations were 
depleted of CD25+ cells and transferred to recipient mice. These mice were 
shown to develop a variety of autoimmune diseases, including thyroiditis, 
gastritis and polyarthritis. Rapid reconstitution of CD4+CD25+ T cells 
prevented development of these autoimmune diseases [Sakaguchi etal 1995]. 
The importance of the thymus as the centre of origin for naturally occurring 
Tregs has been highlighted by experiments in thymectomized mice and rats 
[Asano et al 1996, Seddon et al 1999]. Mice thymectomized 3 days after birth 
spontaneously develop autoimmune diseases, like gastritis. They also have no 
detectable levels of CD25+ cells in the peripheral blood. If splenic CD25+ T 
cells isolated from healthy animals are immediately transferred into 
thymectomized mice, autoimmunity is prevented. Interestingly, mice 
thymectomized at day 7, have a decreased likelihood of developing 
autoimmunity, and no difference is seen in the number of CD25+ cells in the 
periphery. This may be due to a sufficient number of Tregs circulating in the 
periphery by day 7. This suggests that natural CD25+ T cells are important in
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the maintenance of peripheral tolerance, and that development is completed by 
day 7 [Asano et al 1996]. These data emphasise the role of natural 
CD4+CD25+ cells in peripheral tolerance.
Naturally occurring CD4+CD25+ Tregs operate by cell contact dependent 
mechanisms in vitro. Shevach and colleagues observed that CD4+CD25+ cells 
purified from the LNs of naive mice failed to proliferate after stimulation with 
either IL-2 or anti-CD3. When co-cultured together with CD4+CD25- cells, 
CD4+CD25+ cells significantly suppressed CD4+CD25- cell proliferation and IL- 
2 production, as measured by ELISA. Cytokines were believed to have no 
effect on the suppressive ability of the Tregs [Thornton et al 1998]. Indeed, 
CD4+CD25+ cells isolated from IL-4_/‘ or IL-107'mice and co-incubated with anti- 
CD3 and CD4+CD25- cells from control animals retained the ability to suppress 
proliferation of CD4+CD25- cells [Thornton et al 1998]. Cytokine mediated 
mechanisms may therefore be an unlikely mode of action of natural Tregs.
4.2 Inducible Tr1 cells
Tr1 cells are one of two inducible types of CD4+CD25+ Tregs described. 
Unlike natural CD4+CD25+ Tregs, Tr1 cells are induced in response to specific, 
non-self Ag [O’Garra et al 2004a, O’Garra et al 2004b]. Development of Tr1 
cells is still observed in thymectomized TCR transgenic after treatment with 
influenza HA peptide, suggesting that Tr1 cells are induced locally, rather than 
in the thymus [Apostolou et al 2004]. This suggests that the thymus is not 
essential for the development of Tr1 cells, and that Tregs can still be induced by 
foreign Ag in animals that lack naturally occurring Tregs. This distinguishes 
these Tr1 cells from natural CD4+CD25+ Tregs.
Tr1 cells were first described by Groux and colleagues in 1997. They showed 
that chronic activation of both human and mouse CD4+ T cells in the presence 
of IL-10 gave rise to a T cell with a low proliferative capability, and which 
secreted large amounts of IL-10, no IL-4 and low levels of IL-2. Proliferation of 
naive murine CD4+ T cells, in response to OVA presented by splenic APCs, 
was significantly reduced when Tr1 cells were present in the culture. This effect 
on proliferative responses was neutralized by the addition of anti-IL-10 and anti-
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TGF-p Abs, suggesting that both IL-10 and TGF-p are essential for the 
development and function of Tregs [Groux et al 1997]. Tr1 cells have also been 
shown to be Ag specific. For example, transfer of OVA specific Tr1 cells 
inhibited the onset of IBD in SCID mice, but only when mice had been pre-feed 
with OVA [Groux et al 1997].
Powrie and colleagues have observed similar T cells in a murine model of IBD. 
In their model, colitis was induced by transferring CD4+CD45RBH,gh T cells i.v. 
from BALB/c mice, into transgenic SCID mice. The SCID background was 
used, since it limits the number of lymphocytes naturally produced by the host 
immune system. Transfer of CD4+CD45RBHigh cells induced inflammation in 
the bowel, simulating human IBD. When CD4+CD45RBLow T cells were 
transferred, the inflammation was prevented. These cells were also observed 
to secrete IL-10 [Powrie et al 1994]. This suggests that these CD45RBLow 
Tregs are the same as Tr1 cells.
4.3 Th3 cells
Chen and colleagues originally described Th3 cells in 1994. These cells were 
induced in the MLNs by oral administration of MBP Ag, and produced high 
levels of TGF-p with varying amounts of IL-10 and IL-4. In addition they 
suppressed the development of EAE in SJL mice, orally sensitized to MBP, a 
protein component of myelin [Chen et al 1994]. MBP specific T cells, which 
secreted TGF-p, were isolated from the MLNs of these mice. These MBP 
specific T cells were also effective in suppressing the symptoms of PLP-induced 
EAE. PLP is a protein making up the myelin layer of the neurone. When 
injected i.p., PLP induces EAE in SJL mice [Chen eta l 1994]. The suppression 
of non-Ag specific EAE suggests that Th3 cells operate by cytokine mediated 
mechanisms.
4.4 Treg markers
The molecular basis for the induction of Tregs is still not clear. Several 
molecules have been implicated in the development of Tregs, including CTLA-4, 
GITR, TGF-p and IL-10. However, none of these are specific to Tregs, and are
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also expressed by other cell types. The possible mechanisms triggered by the 
cytokines IL-10 and TGF- p will be discussed in Chapter 3 and Chapter 4.
CTLA-4 and GITR are both implicated in Treg activity [Sakaguchi et al 2001, 
Shevach et al 2002, Maloy et al 2001]. GITR was originally identified as a 
marker constitutively expressed by naturally occurring CD4+CD25+ Tregs 
[McHugh et al 2002]. Blockade of GITR with a mAb (known as clone DTA-1) 
results in the blockade of CD4+CD25+ Treg function in vitro [McHugh et al
2002]. In vivo injection of DTA-1 leads to induction of autoimmune diseases, 
such as autoimmune gastritis [Shimizu et al 2002]. However, GITR has also 
been observed to be upregulated on non-regulatory CD4+ T cells. Recent 
contradictory evidence suggests that ligation of GITR actually occurs on 
activated T cells, and not on Tregs. This work suggests that ligation of GITR 
and GITR-L renders effector T cells resistant to suppression by Tregs 
[Stephens et al 2004]. This may suggest that GITR is not a reliable marker for 
T reg activity.
CTLA-4 is a negative regulator, which causes suppression of activated T cell 
signals. CTLA-4 has a high affinity for the co-stimulatory B7 ligands, CD80 and 
CD86. The activation receptor CD28, which also binds the B7 ligands, 
promotes T cell activation. Since CTLA-4 binds these ligands with 500 times 
more avidity than CD28, CTLA-4 can out compete CD28 and trigger a negative 
regulatory signal [Greenwald et al 2002]. In addition to this, CTLA-4 has been 
shown to trigger the induction of the enzyme I DO when interacting with CD80 
and CD86 on the APC. IDO depletes tryptophan and catalyses tryptophan to 
kynurenine and other metabolites, which have potent immunosuppressive 
effects on T cells. This may be another mechanism by which Tregs exert 
suppression via CTLA-4 [Grohmann et al 2002, Munn et al 2004]. However, 
both CTLA-4 and GITR are also expressed by other effector and memory CD4+ 
T cells, and are not unique to Tregs.
4.4.1 CD45
CD45 is a protein tyrosine phosphatase (PTP), expressed by most 
hematopoietic cells, except erythrocytes. The protein tyrosine phosphatases
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constitute a family of receptor-like and cytoplasmic inducing enzymes that 
catalyze the dephosphorylation of phosphostyrosine residues and are 
characterized by homologous catalytic domains [Barford et al 1994]. CD45 is 
made of a single chain type-1 transmembrane protein, which is approximately 
1100-1300 amino acids long. The extracellular domain of this protein contains 
amino acids that range from 300-500 amino acids and a long cytoplasmic tail 
with approximately 700 amino acids that contains repeats for the two 
phosphatase domains [Okumura etal 1996].
The role and function of CD45 is complex and still poorly understood. It is 
understood that CD45 is required for both B and T cell signalling. CD45 
functions to regulate Src kinases required for T and B cell receptor signal 
transduction [Kung et al 2000]. In T cells, the members of the Src family 
kinases regulated by CD45 are Lck, and Fyn and in B cells the Src family 
kinases are as Lyn and Blk. In T cells and B cells, the phosphorylation of the 
immunoreceptor tyrosine bases motifs (ITAMS) is an intracellular signal that 
alerts the cell that the lymphocyte has detected a specific Ag. When ITAMS’s 
tyrosines are phosphorylated by the receptor associated tyrosine kinases, the 
ITAMS become able to bind second family protein tyrosine phosphatase such 
as CD45 [Janeway et al 2001]. In T cells, CD45 in particular dephosphorylates 
Csk, an inhibitory protein tyrosine kinase. This activation is particularly 
important because it controls levels of tyrosine kinase activity in lymphocytes. 
In B cells, Ca2+ is transduced by the B cell receptor and this signalling is 
believed to induce the expression of CD45 [Justement et al 1991].
4.4.2 CD45 isoforms
The CD45 protein has several isoforms. Expression of the different CD45 
isoforms can be seen at different stages of cell differentiation, and 
hematopoietic cells can express more than one isoform [Virts et al 1997]. CD45 
is abundantly distributed within the cell membrane, and constitutes 
approximately 10% of all the molecules on the surface of expressing cells. The 
mammalian CD45 gene consists of 35 well characterized exons. The exons 
which determine which CD45 isoform is produced is found on the plasma 
membrane are located in the N terminus of the CD45 protein. These are exons
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4-6, although there is some evidence that exon 7 is involved in alternative 
splicing, since an isoform lacking exons 4, 5, 6 and 7 has been observed at the 
mRNA level [Chang et al 1991, Virts eta l 1998]. Although theoretically a large 
number of isoforms should exist, only a few are usually observed. These 
include CD45RO, CD45RA, CD45RB CD45RC, and CD45RABC. Each isoform 
differs in their extracellular domains because of alternative splicing of exons 4 
(CD45RA), 5 (CD45RB) and 6 (CD45RC). CD45RO results when exons 4, 5 
and 6 are all spliced out and CD45RABC when all exons are transcribed 
[Reviewed in Hermiston e ta l2003].
4.4.3 CD45 isoform function
Expression of the CD45 isoforms is tightly regulated in peripheral T cells 
[Justement et al 1991]. The different CD45 extracellular domains are 
expressed in a cell type and activation state dependent manner. This is 
conserved across species, suggesting an important function in vivo [Trowbridge 
et al 1994, Fukuhara et al 2002]. Double negative T cells and single positive 
(CD4+ or CD8+) T cells predominantly express the larger CD45 isoforms, such 
as CD45RA. In contrast, activated and memory T cells express CD45 isoforms 
encoded by mRNAs lacking most or all of the variable exons, such as CD45RO 
[Fukuhara et al 2002, reviewed in Hermiston et al 2003]. This makes CD45 a 
useful marker to distinguish between different T cell activation states, such as 
naive (CD45RA+ T cells) and memory T cells (CD45RO+ T cells).
The function of the different isoforms of CD45 is still relatively unclear. Smaller 
isoforms tend to be more prone to homodimerization, which has been shown to 
inhibit intracellular phosophotase activity [Pingel et al 1989, Stamenkovic et al 
1991]. Thus, alternation between expression of larger and smaller isoforms 
appears to affect the amount of intracellular phosphotase activity, and hence 
the efficiency of TCR signalling. T cells expressing the larger isoforms are 
therefore more likely to have high phosphatase activity and maintain the TCR in 
a state primed for Ag recognition [Pingel et al 1989]. This possible role of CD45 
in immune homeostasis or tolerance is supported by studies that correlate 
defects in CD45 splicing to susceptibility to various autoimmune diseases, such 
as multiple sclerosis [Chang efa/1991].
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4.5 Foxp3
Foxp3 is a gene for the transcription factor protein forkhead/winged-helix, or 
Scurfin, which is highly expressed in naturally occurring CD4+CD25+ Tregs 
[Hori et al 2003, Ling et al 2004]. In contrast to other markers used to identify 
Tregs, Foxp3 is not simply a marker of activation. For example, CD4+CD25- 
cells do not usually express Foxp3 message when they are stimulated. Foxp3 
is necessary for Treg development and activity [Khattri e ta l2003, Fontenot etal
2003], for example mutations in the Foxp3 gene in the mutant mouse strain 
scurfy lead to rapid development of autoimmune diseases [Khattri et al 2003, 
Brunkow e ta l2001]. In humans, the genetic disease IPEX (sometimes referred 
to as XLAAD) is due to a mutation in the human homologue of Foxp3, and 
results in onset of autoimmune diseases such as type-1 diabetes, autoimmune 
endocrinopathy and, in some cases, severe atopy [Chatila et al 2000, Bennett 
et al 2001, Wildin et al 2001, Gambineri et al 2003]. These observations have 
led to the hypothesis that this transcription factor is important for Treg 
development.
The lymphoproliferative disease seen in scurfy mice and FoxpS1' mice is similar 
to that seen in humans with IPEX, and also shares characteristics seen in 
CTLA-4 and TGF-p deficient mice [Fontenot et al 2003, Shevach et al 2002]. 
CD4+CD25+ cells isolated from FoxpS1' mice have the ability to proliferate 
themselves, and do not have the ability to suppress proliferation of other T cells, 
suggesting that they are not Tregs [Fontenot et al 2003, Khattri et al 2003]. The 
lymphoproliferative disorder observed in FoxpS1' mice is inhibited by the 
transfer of Tregs from control wild-type mice, suggesting that Foxp3 is essential 
for functional Tregs [Fontenot et al 2003].
4.6 CD8+ Tregs
In addition to CD4+ Tregs, there is also evidence that CD8+ T cells with 
regulatory abilities exist [Zhang-Hoover et al 2004, Bisikirska et al 2005, 
Bienvenu et al 2005]. For example, in a murine model of MPB-mediated EAE, 
APCs were observed to induce Ag-specific CD8+ Tregs. Transfer of these 
CD8+ Tregs to MBP immunised mice inhibited the development of EAE. This
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effect was not observed when CD4+ T cells were transferred to recipient 
mice[Faunce et al 2004]. Transfer of APC-induced CD8+ Tregs has also been 
shown to suppress pulmonary fibrosis [Zhang-Hoover et al 2004]. In MHC IF7' 
mice, CD8+CD25+ Tregs have been observed in the periphery, which express 
CTLA-4, GITR and Foxp3, and secrete IL-10. When cultured together with 
irradiated APCs, CD25- cells and anti-CD3, these CD8+CD25+ Tregs inhibited 
T cell proliferation. This was observed with both CD4+ and CD8+ naive T cells 
[Bienvenu e ta l2005]. The term Treg generally refers to CD4+CD25+Foxp3+ 
T cells, but CD8+ T cells with regulatory properties have now been observed. 
In this thesis, the term Treg refers to CD4+CD25+ T cells.
Table 1-2 Cell surface markers and cytokines expressed by CD4+ Tregs
Natural Tregs Tr1 Th3
Cell surface 
markers
CD4 +++ +++ +++
CD25 +++ +++ +
CD45RBLow + + ?
CD62L + ? ?
CD 103 + ? ?
CTLA-4 + - ++
GITR + + ?
Foxp3 ++ +/- +
Cytokines
IL-10 +/- +++ +
TGF-(5 +/- + +++
IL-4 - - +
IL-5 +
References Sakaguchi etal
Groux et al 
1997, Cottrez et
Chen et al 
1994, Fossat
1995, Powrie etal 
1993, McHugh etal 
2002, Khattri et al 
2003
al 2004 Zuany- 
Amorim etal 
2002b, 
Apostolou etal 
2004
et al 2003, 
Perez- 
Machado et al 
2003
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4.7 NK T cells
NK T cells are a unique subset of cells that express both typical NK receptors, 
including NK1.1, and T cell markers such as the TCR. Unlike NK cells, NK T 
cells develop in the thymus. In contrast to typical T cells, NK T cells respond to 
Ag presented by the MHC l-like molecule, CD1d, and express only intermediate 
levels of TCR. In addition, NK T cells are either CD4+ or CD4-CD8-. Most 
notably, NK T cells express an extremely limited T cell repertoire, since they 
bind mainly lipids, glycolipids, or highly hydrophobic peptides presented by 
CD1d molecules [Park etal 2000, Porcelli et al 1999].
Structurally, there are several subsets of NK T cell, depending on their specific 
expression of an invariant TCR chain. The most studied NK T cell in mice has a 
rearrangement of the variable region Va14 to the joining region Ja18 of the 
TCR, to form an invariant complementarity-determining region 3a (CDR3a), 
which is usually referred to as a Va14/ TCR [Lantz et al 1994, Brossay et al 
1998]. These cells preferentially co-express either V(38.2, V|37 or V(32 with 
Va14/, and are autoreactive for the MHC l-like molecule CD1d [Bendelac et al
1995]. In humans, this region is referred to as Va24-Ja15 [Spada et al 1998, 
Brossay et al 1998]. Va14/ NK T cells have unique properties compared to
other NK and NK T cell subpopulations, in that they are capable of producing 
large quantities of both IFN-y and IL-4 [Yoshimoto et al 1995, Chen et al 1997].
4.7.1 Regulation of responses by NK T cells
Increasing evidence suggests that NK T cells are essential not only for defence 
against pathogens, but also for the regulation of adaptive immune responses. 
NK T cells do this by producing specific cytokines after exposure to Ags 
[Medzhitov etal 1998]. Upon stimulation, NK T cells rapidly produce substantial 
amounts of IL-4. For example, injection of mice with both anti-CD3 mAb and 
Staphylococcal enterotoxin B induces IL-4 production from CD4+ NK1.1+ cells 
in the spleen [Yoshimoto et al 1994]. An increased production of IL-4 can be 
beneficial for certain diseases. For example, the high susceptibility of SJL/J 
mice to EAE, which is characterized by inflammation and demyelination in the
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central nervous system following immunization with myelin Ag MPB, correlates 
with a fewer number of IL-4 secreting NK T cells [Yoshimoto et al 1995].
The regulation of type-1 response by NK T cells, possibly through the secretion 
of IL-4, is highlighted by the alteration in the numbers or function of NK T cells 
in human systemic sclerosis [Sumida et al 1995], insulin-dependent diabetes 
mellitus [Wilson et al 1998], and spontaneous autoimmune diseases in mice 
[Mieza et al 1996, Baxter et al 1997, Hammond et al 1998]. In addition, mouse 
models with alterations in the level or function of NK T cells are important in 
defining the role of these cells in susceptibility or resistance to various infectious 
diseases and autoimmune disorders, such as EAE or type I diabetes [Baxter et 
al 1997, Hammond et al 1998]. Indeed, adoptive transfer of NK T cell rich 
populations to NOD mice protects against the development of disease 
conditions mediated by type-1 responses such as in diabetes. Activation of 
Va14/+ NK T cells has also bee observed to protect against type-1 mediated 
diseases [Baxter etal 1997, Hammond eta l 1998, Lehuen et al 1998].
4.7.2 NK T cells in asthma
Based on the evidence presented above, suggesting that NK T cells are 
capable of inhibiting Th1 responses by IL-4 production, the role of NK T cells in 
allergy has been investigated. NK T cell-deficient mice (Va14/'/_) do not develop 
allergen-induced AHR, a major characteristic of asthma. This is not due to an 
inability of these mice to produce effective type-2 responses, since NK T cell- 
deficient mice that are immunized s.c. at non-mucosal sites, such as footpads, 
produced normal Th2-biased responses in the draining lymph nodes. AHR can 
be induced in NK T cell-deficient mice by adoptive transfer of tetramer-purified 
NK T cells that secrete IL-4 and IL-13, from the spleens of wild type mice. In 
addition, administration of recombinant IL-13, which directly affects airway 
smooth muscle cells, to NK T-cell-deficient mice also induces AHR. Thus, it 
appears that Va14/ NK T cells are crucial in the regulation and development of 
asthma [Akbari et al 2003]. Human studies support this hypothesis. Sen et al 
were the first reported a significant increase in Va14/ NK T cells in asthmatic 
patients, measured by both mRNA and Northern and Western blotting. 
Compared to non-asthmatic volunteers, there was a significant increase in
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Va14h- NK T cells in the submucosa of patients suffering with asthma [Sen etal 
2005]. Other groups have confirmed this observation. Akbari eta l used CD1d- 
tetramers, Abs specific for NK T cells, and RT-PCR analysis for invariant TCRs, 
such as Va24, to assess the frequency and distribution of NK T cells in the 
lungs and in the circulating blood of 14 patients with asthma. Approximately 
60% of the pulmonary CD4+ cells observed in patients with asthma were not 
class II MHC-restricted CD4+ T cells but, rather, NK T cells. The NK T cells 
expressed an invariant T cell receptor and produced the type-2 cytokines IL-4 
and IL-13, but not I FN-y [Akbari e ta l2006]. These data suggest that NK T cells 
play a predominant role in the immunopathology of asthma.
5. THE HYGIENE HYPOTHSIS
Asthma has been on the increase over the last few decades, nearly doubling 
since the 1980s. In evolutionary terms, a few decades are too short an amount 
of time for rises in allergic disease to be attributed solely to mutations in human 
genetic make up. Environmental factors must therefore play a pivotal role. The 
increased incidence of allergic disease in developed countries, when compared 
to developing countries [ISAAC et al 1998], suggests that changes in living 
conditions plays a role in this increase in allergy. The observation by Strachan 
that larger families had fewer allergies [Strachan et al 1989, Strachan et al
2000] became the basis for the hygiene hypothesis (See section 1.2).
There is a positive correlation between the increase in allergies and the 
excessive use of antibiotics, and obsessive “hygiene” [Farooqi et al 1998, 
Strachan et al 1996]. Whilst disinfectant usage is an important part of healthy 
living and improved medical care, overly stringent use of cleaning products and 
disinfectants reduces all microbe contact, even the harmless ones. The 
increased use of antibiotics and vaccinations also reduces exposure to 
microorganisms.
In modern society, interactions with animals have become classified as 
“unhygienic” and a potential source of microbes. Farming communities, where 
people are in close contact with animals much of the time from an early age, are 
therefore ideal testing grounds for studying the effect of microbe exposure on
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allergy incidence. In such communities in Germany, the cowshed is part of the 
family home, usually with a connecting door in the kitchen. Studies within these 
communities showed that children who spent a lot of time in the cowshed when 
young had a lower incidence of allergy compared to other children in the 
community who were not exposed to the environment in cowsheds [Riedler etal 
2001]. Similarly a study looking at children in the same farming communities 
examined the amount of endotoxin present in the children’s mattresses, since 
endotoxin indicates bacterial presence. Again, a negative correlation was 
observed between allergy incidence and the amount of endotoxin found [Braun- 
Fahrlander et al 2002]. These studies both point to environmental factors, like 
changes in microbial contact, as a factor in the increase in allergy seen in 
recent decades.
The persuasive evidence from these epidemiological studies has given new 
impetus to the hygiene hypothesis. Over the last few years, different versions 
of the hygiene hypothesis have been formulated. The earliest versions 
suggested that a higher incidence of infection and cross infection with 
pathogens between individuals leads to a lower incidence of allergy 
[Yazdanbakhsh e ta l 2002, Strachan e ta l 1989]. A more recent interpretation 
suggests that our limited contact with harmless microorganisms, which we once 
regularly encountered, is responsible for the increase in allergies [Rook et al 
1998]. This version has developed into the “Old Friends” Hypothesis [Rook et 
a l2003, Rook e ta l2004].
6. “OLD FRIENDS”
The Old Friends hypothesis states that harmless microorganisms we have 
encountered throughout evolution have enabled our immune systems to 
develop mechanisms that prevent inappropriate responses to non-pathogens. 
Observations have been made of harmless commensal or environmental 
species being responsible for alleviating the symptoms of allergic or 
autoimmune disease. For example, germ free rats raised in sterile conditions 
are more prone to adjuvant arthritis than rats housed in standard conditions, 
where they are more likely to come into contact with non-pathogenic 
environmental microorganisms on a daily basis. Transfer of spleen cells from
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these rats to rats in sterile conditions reduces the severity of Th1 mediated 
adjuvant arthritis [Moudgil e ta l2001]. This suggests that background exposure 
to harmless microorganisms may affect the ability of the immune system to 
regulate Th1-mediated responses. Specifically studied microorganisms include 
some species of lactobacilli, helminths and mycobacteria [Ozedmir et al 2003, 
Schultz e ta l2002, Wilson efa/2003].
Studies comparing Estonian and Swedish children in the Baltic have been 
carried out, investigating the effect the presence of lactobacilli in the gut has on 
the population. Although the populations of these countries are genetically 
similar, Estonia was behind the iron curtain hence less developed than 
neighbouring Sweden. These studies showed a higher incidence of allergy in 
Sweden than in Estonia. Interestingly, children from Estonia had significantly 
higher numbers of lactobacilli in their intestinal flora. [Sepp et al 1997, 
Bjorksten etal 1999]. This negative correlation between allergy and lactobacilli 
suggests this may be an “Old Friend”, whose presence may induce tolerance 
against allergy. “Old Friends” have also been observed to have an affect on 
autoimmune disease. It has been observed that whilst colonising germ free IL- 
10'7' rats with normal pathogen-free bowel flora, leads to development of colitis, 
the subsequent introduction of Lactobacillus plantarum alleviated symptoms 
[Schultz ef a/2002].
Infection with parasitic worms is rare in developed countries today, whereas it is 
widespread in developing countries. Most infestations are low grade and 
without severe consequences for the majority of infected individuals. A lower 
prevalence of allergies is also observed in helminth-infected populations. For 
example, in South America, children infected with helminths, such as Ascaris 
lumbricoides and Trichuris trichiura, have significantly lower skin reactivity to 
house dust mite Ag, compared to children who are helminth free, [Hagel et al 
1993]. Similar findings have been recorded in children infected with 
Schistosoma haematobium and Schistosoma mansoni [Yazdanbakhsh et al
2001]. Chronic infection with helminths has been shown to be protective 
against allergic disease, with the protection being associated with the release of 
IL-10 and induction of immunoregulatory mechanisms [van der Biggelaar et al 
2000, Yazdanbakhsh e ta l2002, Kleij e ta l2002, Terrazas e ta l2001, Maizels et
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al 2003]. Th2 mediated immunity can also be regulated by environmental 
microorganisms. In experimental mouse models of airway inflammation using 
Derpl (house dust mite allergen) and OVA, chronic infection with 
Heligmosomoides polygyrus resulted in decreased eosinophilic inflammation. 
This protection was partially blocked by anti-CD25, suggesting Treg 
involvement [Wilson e ta l2004, Wilson e ta l2005].
6.1 Saprophytic Environmental Mycobacteria
Saprophytic mycobacteria are non-pathogenic and, although not part of the 
natural bacterial flora, are found abundantly in the environment. They consist of 
at least 80 species and are commonly found in soil, mud and untreated water. 
The lifestyle in developed countries has reduced exposure to such 
mycobacteria through the excessive use of concrete, and through treatment of 
water. Humans evolved as hunter-gatherers, and eventually became farmers. 
Contact with soil, and therefore saprophytic mycobacteria, was commonplace. 
Their presence in our evolutionary history is seen by the existence of CD1- 
restricted T cell subsets, which appear to only recognise mycobacterial lipids 
and glycolipids [Dutronc e ta l2002]. Moreover, these lipids have been detected 
in human lymphoid tissue, suggesting their constant and widespread presence 
in human evolution [Hanngren et al 1987]. This thesis will focus on one 
species, Mycobacterium vaccae (M. vaccae), which has been reported to have 
beneficial effects on allergic disease, supporting the “Old Friends” hypothesis.
6.2 Mycobacterium vaccae
M. vaccae is a non-pathogenic mycobacterium, first described in 1964 by 
Bonicke and Juhasz [Bonicke eta l 1964]. The strain of M. vaccae described in 
this thesis is M. vaccae R887R, which was first isolated from samples of mud 
from Lake Kyoga in Uganda in 1971. Stanford and Paul first described this 
strain in 1973 [Stanford et al 1973] and deposited it, under the Budapest 
convention, at the National Collection of Type Culture (NCTC) in London in 
1984. This particular strain of M. vaccae is acid fast (stains purple/red when 
stained by the Ziehl-Neelsen method), is a fast grower (with an optimal
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temperature of 28-33°C in aerobic conditions), and produces a bright yellow- 
orange pigment when grown in the dark.
There are only 4 known reports of M. vaccae causing disease, all in the 
Southern United States of America and all in immunosuppressed individuals. 
One patient had a cutaneous infection, and three patients had cavitary lung 
disease. All four patients responded to treatment with minocycline or 
ciprofloxacin [Hachem efa/1996], broad-spectrum antibiotics.
The potential of M. vaccae as an immunotherapy for allergic asthma has been 
suggested, both from human clinical trials [Arkwright et al 2001, Camporota et 
al 2003] and from experimental animal models [Smit et al 2003a, Smit et al 
2003b, Zuany-Amorim et al 2002a, Walker et al 2003]. Clinical trials in adults 
with grass pollen-induced asthma and rhinitis have shown that treatment with 
heat killed M. vaccae leads to fewer symptoms and less need for relief 
medication [Hopkins et al 2001]. Experiments using mouse models that 
develop AHR and pulmonary inflammation have been undertaken by several 
groups [Zuany-Amorim et al 2002a, Zuany-Amorim et al 2002b, Smit et al 
2003a]. The overwhelming evidence suggests that M. vaccae is effective at 
ameliorating type-2 mediated airway inflammation and AHR [Zuany-Amorim et 
al 2002a].
7. HYPOTHESIS
7.1 Introduction
M. vaccae, a harmless “Old Friend” which has been present throughout human 
evolution, has been shown to have an immunotherapeutic effect against allergic 
diseases in animal models [Hopfenspirger et al 2002, Hopkins et al 2002, 
Zuany-Amorim et al 2002a, Smit et al 2003a, Smit et al 2003b, Ozdemir et al 
2003]. In the case of allergic pulmonary inflammation, treatment with heat killed 
M. vaccae leads to decreased cellular infiltration into the lungs, reduced 
allergen-induced eosinophilia and an increase in IL-10 protein in the BAL fluid 
[Zuany-Amorim et al 2002a, Adams et al 2004]. IL-10 is associated with
immunoregulation, and more recently with the development and function of
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Tregs [Umetsu eta l 1999, Mason eta l 1998, Bach et a l2001]. M. vaccae has 
been shown to induce Tregs with a CD4+CD45RBLow phenotype, similar to 
Tregs described as Tr1 cells [Powrie et al 1994, Groux et al 1997]. When 
adoptively transferred to allergic mice, these CD4+CD45RBLow Tregs suppress 
pulmonary inflammation [Zuany-Amorim e ta l2002b].
Regulatory APCs have been described which play a pivotal role in regulation of 
immune responses. Some secrete IL-10 [Tormey et al 1998] and some TGF-p 
[Terrazas ef a/2001], both cytokines known to induce Tregs. IL-10 secreting 
DCs have even been shown to suppress T cell proliferation in certain conditions 
[Hawiger et al 2001, Liu et al 2002], an effect that has been proved to be 
transferable when such DCs are introduced into recipient animals sensitized 
and challenged with OVA [Akbari eta l 2002, Akbari et al 2001].
7.2 Aim of thesis
This thesis investigates several aspects of the effect of M. vaccae on pulmonary 
inflammation. First, it aims to ascertain whether a decrease in the type-2 
cytokines can be detected at the site of pathology, the BAL fluid and lung tissue. 
To determine whether a Th2 to Th1 switch occurs, type-1 responses in the 
lungs will be studied. This thesis also investigates whether immunoregulatory 
cytokines are secreted. Since Treg development is dependent on IL-10 and 
TGF-p [Zuany-Amorim et al 2002b], the source of any immunoregulatory 
cytokines is investigated. It is determined whether treatment with M. vaccae 
induces pulmonary CD11c+ APCs, which secrete immunoregulatory cytokines. 
These cells are also investigated for their cell surface marker phenotypes 
before and after M. vaccae treatment. The possible regulatory role of the 
pulmonary APCs is then investigated both In vivo and in vitro.
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7.3 Summary
In summary, the aims of this thesis are to determine:
• Whether M. vaccae treatment of allergic mice reduces type-2 cytokine 
production at the site of inflammation. If so, whether an increase in type- 
1 cytokine expression is observed (Chapter 3)
• Whether M. vaccae treatment of mice with allergic pulmonary 
inflammation induces increased expression of IL-10 and TGF-p at the 
site of inflammation (Chapter 3)
• What the possible source of any immunoregulatory cytokines may be 
(Chapter 4)
• Whether M. vaccae-induced CD11c+ cells have the ability to regulate 
immune responses, and what role they play in alleviating allergic 
symptoms (Chapter 5)
60
Table 1-1 Types of hypersensitivity
TYPE DETAILS EXAMPLE
I
Immediate hypersensitivity, 
involves production of IgE 
against foreign Ag
Allergy, like asthma
II
Caused by production of IgG or 
IgM antibodies against cell 
surface antigens. Damage is 
therefore restricted to specific 
cells types
Haemolytic disease in newborn 
babies, where the mothers IgG 
antibodies have reacted against 
the babies erythrocytes in the 
uterus
III
Occurs when there is an 
excessive build up of immune 
complexes in circulation. 
Immune complexes are formed 
every time antibody meets 
antigen and are cleared up by 
macrophages or similar cells. If 
they cannot be cleared by the 
phagocytic system, they deposit 
in tissue or organs, and cause 
damage
SLE (Systemic Lupus 
Erythematosus)
IV
Takes more than 12 hours to 
develop, and involves cell 
mediated immune reactions, 
rather than antibody reactions to 
antigens
Contact hypersensitivity, 
characterized by an eczematous 
reaction at the point of contact to 
an allergen, like nickel
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TABLE 1-3 HISTORY OF ALLERGY
Although a 21st Century epidemic, allergy is not a new disease. One of 
the earliest reports of an allergic reaction was recorded between 3640 
and 3300BC, when King Menses of Egypt died from a wasp sting. The 
documented history of allergy is summarised in Table 1-3.
YEAR EVENT DETAILS
1819 Hay fever first described
Dr John Bostock described 
“seasonal Catarrh”, that 
affected the upper 
respiratory tract. Today this 
would be called hay fever.
1873 First skin prick test
Charles Blakley performed 
the first skin prick test, by 
applying pollen through a 
break in the skin. This 
introduced the concept that 
pollen caused hay fever.
1902 Anaphylaxis first described
Charles Richet and Paul 
Portier first used the word 
“anaphylaxis” to describe the 
life threatening response 
observed to certain protein 
substances.
1906 The word “allergy” first used
Austrian Pediatrician 
Clemens von Pirquet first 
used the word 'allergy' to 
describe the strange, non­
disease related symptoms 
that some diphtheria patients 
developed when treated with 
a horse serum antitoxin. The 
word comes from the Greek 
word 'aloP, meaning, 'change 
in the original state.'
1911-1914 Immunotherapy established
Leonard Noon and John 
Freeman helped established 
the basis for immunotherapy 
or allergy shots, which 
involves injecting the allergy 
sufferer with small amounts 
of allergen. Over time, the 
body is supposed to become 
less sensitive to the allergen.
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1919 Transfer of allergy first 
described
A physician observed, 
following a blood 
transfusion, a case of 
transient asthma caused by 
allergy to horse dander. This 
was the first indication of a 
factor in blood capable of 
mediating an allergic 
reaction.
1921 Passive transfer of allergy
Prausnitz & Kustner 
performed the passive 
transfer of allergy. Both 
were allergic to different 
allergens, and by injecting 
themselves with small 
amounts of each other’s 
blood showed sensitivity to 
particular substances could 
be passed from one person 
to another through blood 
serum.
1923 The term “Atopy” first used
Coca and Cooke first used 
the term “atopy” to describe 
genetically inherited forms of 
allergy.
1937 First antihistamine drug 
synthesized
Daniel Bovet synthesized 
the first antihistamine drug.
He and his colleagues 
discovered antihistamines, in 
blocking the effects of the 
chemical histamine also 
protected against some of 
the symptoms of 
anaphylaxis.
1953 Mast cell discovered
James F. Riley and Geoffrey 
B. West discovered the mast 
cell to be the major source of 
histamine in the body.
1967 IgE discovered
Kimishige and Teruko 
Ishizaka further explained 
the allergy process by 
discovering the role of IgE 
class Abs as the principal 
mediator in the allergic 
reaction.
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Chapter 2
In this Chapter, all chemicals, equipment and supplies are ordered from the 
companies listed in Table 2-1.
Table 2-1 List of companies and addresses
COMPANY ADDRESS
Amersham Pharmacia Biotec. Uppsala, Sweden
Applied Biosystems. Warrington, GB
Becton Dickinson. Mountainview, USA
Bio-Tek Instruments Inc. East Sussex, GB
Boehringer. Bracknall, GB
Eurogentec. Romsey, GB
Gibco-BRL. Division of Invitrogen, Paisley, GB
Harlan. Oxfordshire, GB
Helena Biosciences. Sunderland, GB
Invitrogen. Paisley, GB
Millipore. Watford, GB
Miltenyi Biotec. Bergisch-Gladbach, Germany
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Molecular probes. Leiden, The Netherlands
Pharm ingen. Div. of Becton Dickinson, Mountainview, 
USA
Promega. Southampton, GB
Qiagen. Crawley, GB
R&D Systems. Oxfordshire, GB
Serotec. Oxfordshire, GB
Serva. Heidelberg, Germany
Shandon Scientific. Cheshire, GB
Sigma. Dorset, GB
SR Pharma. London, GB
Verity Software House Inc. Topsham, USA
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Chapter 2
Materials & Methods
1.1 Animals
All experiments used female BALB/c mice, 6-8 weeks old, which were 
purchased from Harlan. These were housed under standard conditions. All 
experimental protocols complied with the Home Office 1986 Animals Scientific 
Act.
1.2 Antigens and M. vaccae suspensions
OVA (chicken egg white) was obtained from Sigma (Grade V). Sterile vials of 
heat-killed suspension of M. vaccae (10mg/ml in saline) were provided by SR 
Pharma.
1.3 Injection of naVve mice with M. vaccae
Naive mice were treated on day 0 with M. vaccae s.c. (0.1 mg in 100pl saline) or 
saline alone. Mice were sacrificed at days 1, 8 and 21 by CO2 and the spleens 
removed and snap frozen in liquid nitrogen. Spleens were stored at -20°C until 
analysed by RT-PCR.
1.4 Murine model of allergic pulmonary inflammation
1.4.1 Preventive Protocol
Mice were treated s.c. with either M. vaccae (0.1 mg in 100pl saline) or with 
saline alone on day -21. All mice were sensitized i.p. on days 0 and 12 with 
OVA (10pg in 10Opil Alum; Serva) and challenged i.t. under light halothane 
anaesthesia on days 19 and 21 with either saline (negative control) or OVA
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(0.5pg in 50pl). Animals were sacrificed 24 or 48 hours later by i.p. injection of 
sodium pentobarbitone (240mg/kg) (Figure 2-1 a).
1.4.2 Therapeutic Protocol
Mice were sensitized on days 0 and 12 with OVA (10pg in 100pl Alum). On day 
21 mice were injected s.c. with either M. vaccae (0.1 mg in 100pl saline) or 
saline alone. Mice were then sensitized again on days 42 and 54. Mice were 
challenged under light halothane anaesthesia on days 61 and 63 i.t. with either 
saline (negative control) or OVA (0.5pg in 50 pi) and sacrificed 24 or 48 hours 
later by i.p. injection of sodium pentobarbitone (240mg/kg) (Figure 2-1 b). This 
protocol goes some way to mimic clinical asthma, so it is essential that the 
treatment in the therapeutic protocol is as effective as in the preventive protocol.
1.4.3 BAL fluid collection
The trachea was cannulated and the BAL fluid obtained by washing the lungs 
thrice with 0.3ml of Wash Medium (Table 2-2). Recovered BAL fluids were kept 
on ice and processed immediately when all samples were collected. The 
number of cells in the BAL fluid was determined using a Neubauer Chamber. 
Cytospins of each BAL fluid were performed. 50pl of BAL fluid was spun at 
700rpm for 5 minutes (Shandon Scientific). Slides were fixed in acetone for 2 
minutes, then stained with filter sterilised Wright Giemsa stain (Sigma) for 4 
minutes. Slides were washed in 1 x PBS once and distilled water twice for 30 
seconds before the coverslip was applied. A differential cell count was 
performed using standard morphological criteria. The remaining BAL fluid was 
frozen and kept to determine cytokine levels by ELISA.
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(a)
Days -21 0 12 19 21 23
Treatment 
M. vaccae 
or saline
Sensitisation 
OVA + Alum
Challenge 
OVA or saline
End
(b)
Days 0 12 21 42 54 61 63 65
Sensitisation T reatment Sensitisation Challenge End
OVA + Alum M. vaccae OVA + Alum OVA or saline
or saline
Figure 2-1: Allergy protocols. To determine whether treatment with M.
vaccae is able to prevent the development of symptoms associated with 
allergic pulmonary inflammation, naive mice were treated with M. vaccae and 
subsequently sensitized and challenged with OVA. This preventive protocol is 
schematically represented in (a). To determine whether treatment with M. 
vaccae is able to alleviate symptoms associated with allergic pulmonary 
inflammation, OVA sensitized mice were treated with M. vaccae and, following 
a second sensitisation, challenged with OVA. This therapeutic protocol is 
schematically represented in (b).
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2 CD11 c+ cell separation
2.1 Isolation from lung tissue
The process of cell separation from lung tissue was modified from protocols 
previously described [Gonzalez-Juarrero et al 2001]. Lungs were pooled, 
depending on treatment. Lung tissue was diced using a scalpel, and was 
digested with collagenase D (75 U/ml, Boehringer) for 1 hour at 37°C. Tissue 
was then forced through a 70-pm sieve to obtain a single cell suspension. Any 
red blood cells present were removed by hypotonic lysis (Table 2-2). After 
three washes in Wash Medium, cells were counted using a Neubauer Chamber 
and then resuspended in MACS buffer (Table 2-2) at a concentration of 2 x 
107/ml.
2.2 Isolation from spleen tissue
Spleens were pooled depending on treatment and cut up using scissors. 
Tissue was then forced through a 70-jim sieve to obtain a single cell 
suspension. Any red blood cells were removed by hypotonic lysis (Table 2-2). 
Cells were washed three times in Wash Medium, counted using a Neubauer 
Chamber and resuspended in MACS buffer (Table 2-2) at a concentration of 2 x 
107/ml.
2.3 Magnetic cell separation using MACS beads
Cells were resuspended in MACS buffer (Table 2-2) and incubated for 15 
minutes at 4°C with anti-mouse CD11c coated microbeads, clone N418 
(Miltenyi Biotec). The N418 mAb is a clone for CD11c, which has been widely 
used as a marker for DCs [Kelsall et al 1996, Marriott et al 1999, Williamson et 
al 2002]. After careful washing, 1 x 107 cells were resuspended in 500pl of 
MACS buffer, and applied onto the MACS MS+ separation column (Miltenyi 
Biotec). The column was washed three times with 500jil of MACS buffer (Table 
2-2) and the flow through collected. This fraction contained CD11c- cells. The 
column was removed from the magnet and cells
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Experim ent 
END  
Day 23 or 
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BAL Fluid
Differential 
Cell Count -  
Cytospin and 
Giesma stain
Total cell
Count
Supernatants 
for ELISA
Tissue
Snap Frozen -  
RNA analysis
Spleen
Tissue
CD11c+ cell 
Separation -  
RNA analysis, 
FACS, in vitro 
cultures
Figure 2-2: Sample Collection. Upon termination of murine allergic pulmonary 
inflammation protocol, mice were sacrificed and BAL fluid, lung tissue and spleen 
tissue were taken for further analysis. From the BAL fluid, total and differential cell 
counts were determined and supernatants kept for cytokine analysis. Lung tissue 
was frozen for RNA analysis, and CD11c+ cells were isolated from harvested lung 
and spleen tissue. CD11c+ cells were then used for RNA analysis, FACS staining 
and for setting up in vitro cultures.
71
eluted onto a second column. The cell separation was repeated and CD11c+ 
cells eluted from the second column with MACS buffer. CD11c+ cells were 
counted and used for flow cytometry, RNA extraction, in vitro cultures or 
passive transfer experiments.
In later experiments, for in vitro assays, cells extracted from the lung and spleen 
were resuspended in Growth Medium (Table 2-2) and allowed to adhere to 
plastic plates overnight at 37°C, 5% CO2. This allows MOs and debris to stick 
to the plastic and be eliminated from subsequent cell culture. Cells were then 
used for in vitro cell cultures and the supernatants kept for protein analysis.
3 Passive transfer of CD11 c+ cells
Donor animals were treated according to the preventive protocol (described in 
1.4.1, Figure 2-1) and CD11c+ cells were isolated from the lung tissue of both 
treatment groups (described in section 2). Immediately upon isolation, CD11c+ 
cells were resuspended in sterile saline (2 x 105 CD11c+ cells in 50pl). Cells 
were then transferred i.t., to recipient allergic animals on day 20, 24 hours after 
the first OVA challenge (0.5pg in 50jil). A control group, which received just 
saline (with no cell transfer), was included. All groups received a second i.t 
challenge of OVA at day 21 and were sacrificed 24 hours later (Figure 2-3). 
BAL fluid was collected as before for total cell counts.
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Donor mice
Days -21 0 12 19 21 23
A
Treatment 
M. vaccae 
or saline
Sensitisation 
OVA + Alum
Challenge 
OVA or 
saline
End
Recipient mice
Days 0 12 19
Pulmonary 
CD11c+ cells 
transferred i.t. to 
recipient mice
23
t A
Sensitisation 
OVA + Alum
Challenge 
OVA or 
saline
transfer
Challenge 
OVA or 
saline
End
Figure 2-3: Passive transfer experiment. Donor mice were treated with either M. 
vaccae or saline using the preventive protocol as described previously. CD11c+ cells 
were isolated from the lungs of donor mice and transferred to OVA sensitized recipient 
animals. Recipients were challenged with OVA a second time the following day and 
sacrificed on day 23. BAL fluid was obtained for cell counts.
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4 Protein analysis
4.1 Analysis of BAL fluid by ELISA
IL-5, IFN-y and IL-10 levels in the BAL fluid were determined using 
commercially available murine Duoset ELISA kits (R&D Systems). A human 
ELISA kit was used for murine TGF-p measurements, since no murine kit is 
commercially available and reagents were reported to be cross-reactive. 
Antibody pairs were used according to the manufacturer’s instructions. 
Cytokine recombinant proteins were used as standards and were included in 
the kit. A standard curve ranging from 4000pg/ml to 32.5pg/ml was obtained by 
serial dilution. Background levels were measured in ELISA diluent (Table 2-2). 
Since the BAL fluid was obtained using Wash Medium, a background 
measurement was done on this Wash Medium as a control for each ELISA 
(section 1.4.3). Measurements were obtained for duplicate samples. Plates 
were read on an ELISA plate reader (Bio-Tek Instruments Inc). Standard 
curves were plotted, and regression analysis was used to calculate sample 
protein concentrations/ml (using Prism 3.0 GraphPad software).
4.2 Analysis of CD11 c+ cell culture by ELISA
Supernatants from CD11c+ cells left overnight in culture were concentrated 
using a Centrifugal Filter Device, Centriprep YM-3 according to the 
manufacturer’s instructions (Millipore). Briefly, 15ml of supernatant was placed 
into the Centriprep tube and the filtrate collector was placed on top of the 
supernatant before the lid was secured. The device was centrifuged at 3000 xg 
for 95 minutes. The filtrate was then decanted off, and the device centrifuged 
for a second time, at 3000 xg for 35 minutes. The filtrate was decanted off, and 
the concentrated supernatant which was left in the collector (approximately 
900pl) was aliquoted into eppendorfs and stored at -20°C. ELISA was carried 
out using commercially available Duoset ELISA kits (R&D Systems) for IL-10 
and TGF-p as described in section 4.1, according to the manufacturer’s 
instructions.
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4.3 Analysis of in vitro culture by ELISA
IL-4, IL-5, IFN-y, IL-10 and TGF-p levels from in vitro cultures (section 7) were 
determined using commercially available Duoset ELISA kits (R&D Systems) as 
described in section 4.1, and according to the manufacturer’s instructions.
5 mRNA analysis 
5.1 RNA extraction
RNA was extracted using a commercially available kit according to the 
manufacturer’s instructions (RNeasy mini kit, Qiagen). Flash frozen lung and 
spleen tissue was homogenized using a handheld homogenizer and placed 
through an RNA-binding column. Pulmonary CD11c+ cells and in vitro culture 
cells were placed directly through a shredder column before being passed 
through an RNA binding column. Between wash steps, the RNA was DNase 
treated (Qiagen) for 15 minutes to remove any contaminating genomic DNA. 
RNA was eluted in nuclease free water.
5.2 cDNA conversion
RNA was converted into cDNA using the Omniscript kit according to the 
manufacturer’s instructions (Qiagen) with Oligo dT and RNasin (Promega). 
Briefly, 15pl RNA was added to 2pg of Oligo dT, 1x RT buffer, 5mM of each 
dNTP, 10 Units of RNasin, 4 Units of Omniscript Reverse Transcriptase and 
RNase free water and vortexed. Samples were incubated at 37°C for 1 hour, 
followed by 5 minutes at 93°C to denature the enzyme. To ensure reagents 
were not contaminated with exogenous RNA, which would give false positive 
results, a negative control (sample not containing any RNA) was included in 
every reverse transcription. cDNA was stored at -20°C before PCR 
amplification.
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5.3 Basic end point PCR
Basic end point PCR is a qualitative method, which amplifies a DNA sequence 
between two specific primers. In this thesis, it was initially used to determine 
whether designed primers were amplifying the correct sized PCR product 
(amplicon). This method of PCR was later used to create standard curves for 
each primer set, explained in section 6.2 and 6.3.
The 50|il PCR reaction consisted of 25pl of 2 x HotstarTaq Master Mix (Qiagen, 
Table 2-2), 1pl each of forward and reverse primer (10pmol/pl each; 
Eurogentec), 22pl RNase free water (Promega) and 1pJ cDNA template. 
Reactions were carried out in a Phoenix thermocycler (Helena Biosciences). 
Thermocycling conditions were as follows: 95°C for 15 minutes (to activate 
enzyme), followed by 25-35 cycles of (95°C/20 seconds, Tm°C/20 seconds, 
72°C/30 seconds).
Optimal Tm and amplicon size for each primer set can be found in Table 2-3. In 
order to avoid false positives, negative controls were included in all PCR 
experiments (sample containing no cDNA) to ensure PCR reagents were not 
contaminated with exogenous DNA. In order to confirm both presence and size 
of the PCR amplicon, PCR reactions were run on an agarose gel (Figure 2-7).
5.4 Agarose gel electrophoresis
To visualise the amplicon obtained by end point PCR, the reaction was run on 
an agarose gel with SYBR® Green I nucleic acid stain, which binds only to 
double stranded DNA. Amplicons were then visualised using the FLA3000 
scanner from Fuji film (Laser 473nm, filter Y520).
Electrophoretic grade agarose (Gibco-BLR) was dissolved in 1 x TAE (Table 2- 
2) by boiling in a microwave (1.8% final concentration). Stock solution of 
SYBR® Green I nucleic acid stain (Molecular probes) was added to the agarose 
solution at a 1:10,000 dilution. The gel was run at 120-150 constant voltage in
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an appropriate horizontal gel tank (Amersham Pharmacia Biotec) with 1 x TAE 
as a running buffer.
PCR products from end point PCR reactions were mixed with 10 x Blue Juice 
loading dye (1:10 dilution; Invitrogen) and loaded onto the 1.8% agarose gel 
along with 1pl of appropriate DNA ladder. A 50bp ladder (Gibco-BRL) was 
used to check primer function. When appropriate, a low DNA Mass Ladder 
ranging from 500ng to 6.25ng/pl (Invitrogen) was used to establish PCR 
amplicon copy number of a PCR reaction (referred to in detail in section 6.3). 
The amount of DNA in each band on the gel was calculated using the AIDA 
software and the low DNA Mass Ladder. These amplicons were then used to 
create standards, of known concentration for each specific primer set (see 
section 6.3). These standards were used to quantify samples using real-time 
PCR.
5.5 Quantitative real-time PCR
5.5.1 The theory behind real-time PCR
Real-time PCR was used as a quantitative technique. Like basic end point 
PCR, real-time PCR amplifies a DNA sequence between two specific primers 
(Figure 2-4). However, instead of having to visualise the PCR product on an 
agarose gel after amplification, real-time PCR relies on the detection of a 
fluorescent signal after each cycle by a system of lenses, filters and a camera, 
set up in the ABI7000. This signal is proportionate to the amount of PCR 
product that has been amplified.
In the ABI7000 real-time PCR machine, filters separate the light emission based 
on wavelength, which is picked up by a charge-coupled device camera capable 
of detecting these wavelengths. The quantity of starting template is established 
using a threshold cycle. The threshold cycle is defined as the number of cycles 
that have elapsed before fluorescence levels are detectable. This occurs when 
the PCR amplification is in its Exponential Phase. Therefore, the greater the 
quantity of DNA in the sample, the lower its Ct value will be (the cycle number 
at which the PCR reaction amplifies over the threshold). The ABI software
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uses the Ct values against a set of standards with known DNA concentrations 
to calculate the quantity of unknown samples, using their Ct values.
5.5.2 Real-time Vs end point PCR
Real-time PCR has several advantages over basic end point PCR. Not only is it 
less time consuming, as there is no need to run an agarose gel, but also real­
time PCR has increased sensitivity. Real time PCR can detect differences in 
DNA presence which end point PCR fails to do. This is mainly because end 
point PCR is usually analysed after the Plateau Phase has begun. PCR is 
made up of three stages; the Exponential Phase, where the product is doubling 
every cycle; the Linear Phase, when the reaction is starting to slow due to the 
consumption of the reaction components; and the Plateau Phase, when no 
more product is being amplified. This is the Phase in which most end point 
PCR products are visualised on gels. Different reactions will reach the Plateau 
Phase at different rates, depending on the amount of DNA in the sample. 
However, after a certain number of cycles, all reactions will have reached this 
phase. The time it has taken to reach the Plateau Phase cannot be determined 
from the band visualised on an agarose gel. Since all the reactions would have 
reached the Plateau Phase, the intensity of all the bands will appear the same, 
even though they reached that phase at different times, depending on the DNA 
concentration in the sample. Therefore, quantitative analysis of PCR 
amplification is inaccurate when done by end point PCR. Real-time PCR uses 
the Exponential Phase of PCR amplification to quantify DNA present in the 
reaction. A quantitative relationship exists between the amount of DNA in the 
starting reaction and the PCR cycle at any given time. Real-time PCR detects 
the accumulation of an amplicon during the reaction, measuring fluorescence 
during the Exponential Phase. This makes DNA quantification by real-time 
PCR much more sensitive and accurate than by end point PCR (Figure 2-4).
In these experiments, SYBR® Green I was used as a fluorescence signal. This 
dye non-specifically binds to double stranded DNA, and therefore will not detect 
single stranded cDNA or oligonucleotides (like primers), but only amplified PCR 
product. However, the disadvantage with using SYBR® Green I is the possibility
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of non-specific binding. Any double stranded DNA, such as primer dimers, will 
give off a fluorescent signal. To overcome these problems, after every real-time 
PCR a dissociation melting curve was carried out. A dissociation-melting curve 
is obtained from post-PCR product by ramping the PCR reaction from 60°C to 
95°C. Fluorescence is recorded after each increase in temperature. At a low 
temperature, the PCR DNA product is double stranded, so binds SYBR Green, 
which fluoresces. With increasing temperature, the DNA product denatures, 
becoming single stranded, releasing SYBR Green and the fluorescent signal 
decreases. The temperature at which this occurs is dependent on the length of 
the DNA fragment and its GC% content. The graphs are plotted as a first 
derivative, so the inflection point in the melting curve then becomes a peak. 
Single peaks indicate a single product and multiple peaks usually indicate 
multiple products. These other products can have many sources including 
primer dimers and genomic DNA contamination. The temperature at which a 
peak is observed enables the size of the PCR product to be estimated. For 
example, primer dimers will anneal together at a much lower temperature than a 
200bp amplicon. This protocol allows PCR reactions where primer dimers or 
non-specific binding contribute to the fluorescent signal to be identified (Figure 
2-5).
5.6 Real-time PCR protocol
Standard curves for real-time PCR were prepared using PCR amplicons. A 
basic end point PCR was set up as described (sections 5.3 and 5.4), using the 
primers for the gene of interest and cDNA of a sample known to express that 
gene.
PCR reactions were analysed on the ABI7000 real-time PCR machine in PCR 
microtitre plates, sealed with plastic covers and a compression pad to prevent 
any evaporation (all Applied Biosystems). Plates were set up to include a 
standard curve (section 6) for each primer set. Negative controls for both the 
PCR reaction (with no cDNA added to the PCR), and the cDNA conversion (no 
RNA added to the RT reaction - section 5.1) were also included on each plate. 
The standards acted as a positive control for each plate, as they were known to
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contain the amplicon. Samples and standards were plated in at least duplicate, 
and values averaged.
The reaction consisted of 12.5|il of SYBR® Green PCR Master Mix (containing 
1.25U of HotStarTaq DNA Polymerase in 1x Qiagen buffer containing 200pM of 
each dNTP, Tris Cl, KCI, (NH4)2S04, 1.5mM MgCI2, and SYBR® Green I and 
ROX fluorescent dyes - Qiagen) and 1pl each of the forward and reverse 
primer (Eurogentec; 10 pmol/jil). Varying amounts of nuclease free water 
(Promega) were used, depending on how much cDNA was added to the 
reaction, to make the total volume of each reaction 25jil. Variable amounts of 
cDNA sample were added to each well, depending on the expression level of 
the gene of interest. The variable amount of cDNA used was taken into account 
when calculating copy numbers. A total volume of 25pl was selected. This 
volume is preferable to 50pl since less time is required to heat the smaller 
amount of liquid to the correct temperature.
Thermocycling conditions were as follows: 95°C for 15 minutes (to activate 
enzyme), followed by 35-45 cycles of (95°C/20 seconds, Tm°C/20 seconds, 
72°C/30 seconds). A dissociation melting curve was performed at the end of 
each reaction, to ensure a single amplicon was amplified and to identify any 
fluorescence due to primer dimers. The cycle number at which each standard, 
each with a known concentration of DNA, came over the threshold (Ct value) 
was used to create a standard curve (ABI7000 software). Ct values obtained 
from samples were used to determined copy number/pl of cDNA sample by 
extrapolation using linear regression analysis.
The housekeeping gene GAPDH was used as an internal reference. A 
housekeeping gene is a gene that codes for an essential protein, expressed in 
all cells. This method of normalising a PCR product against the PCR product 
for a housekeeping gene assumes that the expression does not change, after 
treatment or between individual samples. Therefore the amount of 
housekeeping cDNA detected in a PCR reaction is an indication of the amount 
of cDNA present in the reaction. In this thesis GAPDH primers were run on 
every sample.
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Figure 2-4: The advantage of Real-time PCR. Real-time PCR measures DNA 
amplification at the Exponential Phase. This makes real-time PCR more sensitive. 
With end point PCR, the amplicon is visualised on a gel at the end of a number of 
cycles. Usually the reaction would have reached the Plateau Phase, regardless of 
how much DNA was present in the sample. For example, in this Figure five out of 
seven samples emit the same fluorescent signal at cycle 40, even though they 
obviously reached the Plateau Phase at different cycles. The amount of DNA present 
in a reaction is proportional to the cycle number that the Exponential Phase starts. 
Since the cycle when the Exponential Phase occurred cannot be determined from the 
band on a gel, the amount of DNA present in a sample cannot be determined 
accurately. All reactions, although having reached the Plateau Phase at different 
rates, will have similar band intensity when run out on an agarose gel. This can also 
be seen on a real-time PCR graph, where each plotted line (individual reactions) has a 
similar fluorescence intensity (y axis) at the Plateau Phase, even though each has a 
significantly different amplification rate in the Exponential Phase. Visualising the 
Exponential Phase makes real-time PCR a sensitive and accurate technique, since 
there is a quantitative relationship between the amount of DNA in the starting reaction 
and the fluorescent signal detected at any given PCR cycle.
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Figure 2-5: Dissociation melting Curve. SYBR® Green I is a dye which non- 
specifically binds to double stranded DNA. The disadvantage of using a fluorescent 
dye with non-specific properties is the possible incorporation of primer dimers and 
non-specific amplification into the fluorescent signal. These are identified by carrying 
out a dissociation melting curve. The post-PCR reaction is ramped from 60°C to 
95°C. A sudden decrease in the fluorescence is observed when two complementary 
DNA strands denature. The larger the DNA fragment, the higher the temperature it 
will be when the PCR product denatures. For example, primer dimers will have a 
lower denaturing temperature than a 200bp amplicon, and their presence can be 
identified.
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In Chapters 3 and 4, the PCR data were generated by creating a standard 
curve using an initial arbitrary number for the most concentrated point, and then 
serially diluting it two-fold. This allowed a linear regression equation to be 
obtained. The Ct values from each sample were then used in this linear 
regression calculation. Although not representing actual copy numbers, the 
shape of the final graph is identical using both methods.
6. Primers and DNA quantification
See Table 2-3 for primer sequences and conditions.
6.1 Primer design
Primers were designed using Primer Express software (Applied Biosystems) 
and obtained from Eurogentec. All primers were designed specifically for real­
time PCR, where a small amplicon means greater efficiency (Table 2-3). 
Primers were cDNA specific, designed to span an exon-exon boundary so that 
genomic DNA would not be amplified (Figure 2-6). This was an additional 
precaution, since all RNA extracted had already been treated with DNase to 
eliminate any genomic DNA contamination in the samples.
6.2 Standard curve for cDNA quantification using real-time PCR
To quantify all PCR reactions, standards for each primer set were made. An 
amplicon for each gene of interest was obtained from cDNA known to express 
the gene of interest. After amplification by end point PCR, 5pl of the PCR 
reaction was run on a 1.8% TAE (Table 2-2) SYBR® Green I stained gel with 1pl 
of DNA Mass Ladder (Invitrogen) (Figure 2-7 a). Each band on the ladder has a 
defined weight of DNA in ng, and is of an established bp size. A standard curve 
was plotted using the known weight from the DNA Mass Ladder (Invitrogen) and 
the fluorescence units calculated by the AIDA software (Figure 2-7 b). 
Regression analysis was used to calculate the amount of cDNA amplified in the 
PCR reaction, in jig/pl.
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Figure 2-6: cDNA specific primer design. Genomic DNA contains introns 
and exons. Exons are the “coding” parts of the DNA, which get transcribed into 
mRNA. Therefore, cDNA is only the exon sequence of DNA. Primers were 
designed to span the exon-exon boundary to ensure the primers amplified only 
cDNA obtained from mRNA. This reduces over estimations due to 
contamination with genomic DNA.
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6.3 Amplicon calculation
Once the amount of amplicon in pg/pl in the PCR reaction was established, this 
was converted to copy number/pl, by using Avogadro’s Number. The 
calculation is set out below:
NP pg/pmol x LA = WA pg/pmol
Wt lio/liI = N moles/l (Molar)
WA
N x Avogadro’s Number = Z copies/l
Z = Y copies/pl 
1 x 1 0 6
NP = average mass/mole of nucleotide pair = 660pg/pmol 
LA = length of amplicon (bp)
WA = weight of amplicon/mole (pg/pmol)
Wt = estimated weight of amplicon determined in section 6 .2  
Avogadro’s Number = 6.0221367 x 1023
The average weight of a nucleotide pair is estimated to be 660pg/pmol (NP). If 
the average weight of a nucleotide pair is multiplied by the length of the 
amplicon in bp (LA), this will give the expected weight of the amplified region in 
the PCR product in pg/mol (WA). The amount of double stranded DNA in the 
PCR reaction has already been established using linear regression in pg/pl (Wt 
- section 6.1). If this is divided by the average weight of the amplicon (WA), this 
gives moles/l (N). Multiplication of this number by Avogadro’s Number, which is 
the number of molecules in a mole, gives copies/l (Z). This can be divided by 1 
x106 to obtain copies/pl (Y).
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Figure 2-7: Creating a standard curve. A basic end point PCR was run with cDNA known 
to express the gene of interest. The amplicon was run out on an agarose TAE gel with a 
DNA Mass Ladder (a). Each band is of a known weight (in ng) and size (in bp). The 
fluorescence units for each DNA Mass Ladder band were plotted against its corresponding 
weight to create a standard curve (b). The linear regression equation from the standard curve 
was used to calculate the amount of amplicon copies in the PCR sample. The amount of 
DNA in the PCR product is used to serially dilute a standard curve of known concentrations. 
Sample 1 = GAPDH Amplicon, Sample 2 = Negative Control, Sample 3 = GAPDH Amplicon.
For example, the weight of the GAPDH amplicon shown in Figure 2-7 was 
established by linear regression as 8.161ng/pl and had a length of 192bp (Table 
2-3).
660pg/mol x 192bp = 126720pg/pmol
0.008161 gg/ixl = 6.463 x 1CT8 moles/l 
126720pg/pmol
6.463 x 10'8 moles/l x 6.0221367 x 1023 = 3.892 x 1016 copies/l
3.892 x 1 0 16 copies/l = 3.892 x 1 0 1° copies/pl 
1 x 1 0 6
6.4 Standard curve dilution
Once the copy number of each PCR product was determined in copies/pl, 
diluting the PCR product to a known concentration created a standard curve. 
The amplicon was diluted to 2 x 108 copies/pl. A serial 10 fold dilution was 
carried out, resulting in 7 dilutions: 2 x 108, 2 x 107, 2 x 106, 2 x 105, 2 x 104, 2 x 
1 0 3, 2  x 1 0 2. These standards were aliquoted and stored at -2 0 °C until use. 
These standards (0.5pl in each well) were run on every real-time PCR plate. 
Standard curves were plotted and linear regression was used to calculate copy 
number/pl for each sample with each primer set.
7. Co-culture assay
7.1 CD4 T cell separation
CD4+ T cells were obtained from naive spleen tissue using R&D Systems 
negative selection columns following the manufacturer’s instructions. Spleens
87
were processed as described in section 2 .2  to obtain a single cell suspension. 
Splenocytes were then incubated with a cocktail of mAbs for B cells, CD8 + T 
cells and monocytes. Cells were incubated at room temperature for 15 minutes, 
before being washed and applied to the CD4 subset column. Cells were left to 
bind to the column for 1 0  minutes at room temperature and then washed out 
with 1 0 ml of 1 x column buffer. Unbound CD4+ cells were eluted from the 
column in 1 x column buffer and resuspended in Growth Medium. Ab bound 
cells were retained in the column. Cell purity was determined by FACS (section 
8 ) to be >90%.
7.2 In vitro assay method 1
Two methods were used for setting up an in vitro assay. The first method did 
not always give consistent results, so a number of modifications were made. 
Method 2 was a longer protocol and involved stimulating the cells with IL-2. 
This method was adapted from a paper by MacDonald and colleagues 
[MacDonald ef a/2001].
In the first method, CD11c+ cells obtained from lung tissue were resuspended 
in 15ml Growth Medium (enough to cover the plastic surface of the flask - Table 
2 -2 ), and left to adhere overnight on plastic at 37°C, 5% C02 to minimise M3> 
contamination. CD1 1 c+ cells were then washed and resuspended at a 
concentration of 2.5 x 105 CD11c+ cells/ml in Growth Medium (Table 2-2). 
CD4+ T cells isolated from the spleens of naive mice (section 7.1) were 
resuspended in Growth Medium at a final concentration of 5 x 106 cells/ml 
(Table 2 -2 ). The in vitro assay was set up in a flat bottom 96 well plate (Gibco- 
BRL). Wells were coated with anti-CD3 (0.5jig/well, Invitrogen) and incubated 
at 37°C for 2  hours. Plates were then washed with PBS twice to remove 
unbound Ab. All wells received 5 x 105 CD4+ naive T cells in 100pl. CD11c+ 
cells were added at different CD11c+:CD4+ cell ratios; 1:100 (5 x 103 CD11c+ 
cells), 1:40 (1.25 x 104 cells) and 1:20 (2.5 x 104 cells). Total well volumes 
were made up to 200pl with Growth Medium. Control wells with 5 x 105 CD4+ T 
cells alone in Growth Medium, either stimulated with plate-bound anti-CD3 and 
stimulated with PBS, were included in a total volume of 200pl Growth Medium.
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2.5 x 104 CD11c+ cells alone in Growth Medium, stimulated with PBS, were set 
up alongside. Wells were set up in at least duplicate, and if cell numbers 
permitted, in triplicate. Cells were left in culture for 96 hours at 37°C. 
Supernatants were taken for cytokine analysis by ELISA, and cells were snap 
frozen for PCR analysis.
7.3 In vitro assay method 2
CD1 1 c+ cells obtained from lung or spleen tissue and CD4+ cells isolated from 
spleen were treated as described in section 7.2. CD4+ and CD1 1c+ cells were 
rested together in 200pl of Growth Medium for 72 hours, at the same 
CD1 1c+:CD4+ cell ratios previously described. After 72 hours, 100pl of Growth 
Medium was replaced with fresh Growth Medium containing IL-2 (50U/ml -  
Invitrogen). Cells were left for 48 hours at 37°C, 5% CO2. Cells were then 
transferred to a fresh plate pre-coated with plate bound anti-CD3 (0.5pg/well, 
incubated for 2  hours at 37°C and washed twice with PBS). Plates were left for 
48 hours at 37°C, 5% CO2 before the supernatants were taken for ELISA 
analysis and stored at -20°C (section 4.3). Cells were snap frozen for PCR 
analysis (Sections 5). This assay was based on methods previously described 
[McDonald efa/2001].
8 Flow Cytometry
Flow cytometry was carried out on the FACSCalibur™ flow cytometer (Becton 
Dickinson). Data acquired and analysed using WinList 3.0 software (Verity 
Software House Inc). The standard 488nm laser was used for up to three 
colours analysis. Forward and side scatter characteristics were used to set 
gates. When using two or three colour analysis, compensation for spectral 
overlaps was performed using single colour fluorescence-labelled beads 
(Becton Dickinson). Instrument settings were kept consistent for all repeat 
experiments.
Cells of interest (1 x 105 minimum) were resuspended in 100|il of FACS buffer 
(Table 2 -2 ). Specific Abs (Pharmingen) were added (Table 2-4) and cells were
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incubated for 30 minutes at 4°C. The appropriate isotype control was also 
added to a control tube of cells to ascertain non-specific autofluorescence. One 
sample was stained with PI to eliminate dead cell populations. After incubation, 
cells were washed to remove unbound Ab and resuspended in 300pl of FACS 
buffer. Surface expression was immediately analysed on the FACSCalibur™, 
acquiring between 5000 and 10,000 events.
Acquired FACS data was analysed using the “Subtract Histogram” feature of 
WinList 3.0 (Verity Software House Inc). This statistic uses an enhanced 
normalised subtraction (ENS) method with the Kolmogorov-Smirnov (KS) 
statistic. This method was developed in the 1930s and quantifies the difference 
between two frequency histograms with the following design characteristics: 1 ) 
no required assumptions about error distributions, 2 ) easy manual calculations, 
and 3) robust with noisy data [Overton eta l 1988, Kolmogorov et al 1993]. The 
KS statistic is a widely used nonparametric test for histogram comparison.
The KS statistic is defined as “the maximum absolute difference (Dmax) 
between two cumulative probability distributions”. A probability distribution is a 
histogram normalised with an area of one. The ENS is a means to accurately 
estimate the positive distribution in two overlapping populations, and determine 
a more accurate percentage of test histogram that is positive or the part that 
remains after subtraction [Bagwell et al 1996]. In this thesis, the control 
histogram was always subtracted from the experimental histogram. Thus, each 
resultant histogram represents the fluorescence of the positive cells and the 
part of the fluorescence from the isotype control that remains after the 
experimental histogram data are subtracted.
9 Statistical Analysis
Results are expressed as mean ± SEM unless otherwise stated. Data were 
subjected to a normality test to ensure normal distribution. All graphs are 
representative of two or more experiments. When appropriate, a one-way 
ANOVA or Student’s Mest were used to determine statistically significant 
differences between the groups. If an ANOVA was used to test for significant
90
differences, a Bonferroni post test was used to compare the mean values 
between all data sets. A p value of less than 0.05 was considered significant.
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Table 2-2 Routinely used Buffers and Tissue
Culture Media
Name Contents Obtained from
Wash Medium
RPMI Medium 
Penicillin (5% - 50U/ml) 
Streptomycin (5% - 50mg/ml)
Gibco-BRL
Invitrogen
Invitrogen
Hypotonic Lysis 
Buffer
NH4CI (0.15M) 
KHCO3 (1 0 mM) 
EDTA (0.1mM)
Sigma
Sigma
Sigma
Growth Medium
RPMI Medium 
Penicillin (5% - 50U/ml) 
Streptomycin ( 5% - 50mg/ml) 
Glutamine (1%)
Foetal Calf Serum (10%)
Gibco-BRL
Invitrogen
Invitrogen
Invitrogen
Gibco-BRL
MACS Buffer
1x PBS 
BSA (0.5%)
Gibco-BRL
Sigma
FACS Buffer
1x PBS 
BSA (1%) 
NaN3 (0.01%)
Gibco-BRL
Sigma
Sigma
1 xTAE
Tris base (40m M) 
Acetic Acid (2 0 mM) 
EDTA (1mM)
Sigma
Sigma
Sigma
HotstarTaq Master 
Mix
(available ready 
mixed)
2.5U HotstarTaq DNA 
polymerase 
MgCb (3m M)
ATP (400pM)
CTP (400}iM)
GTP (400pM)
TTP (400|iM)
Qiagen
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Table 2-3 Primer Sequences, Amplicon Length and Melting Temperature (Tm)
1 PRIMER FORWARD SEQUENCE REVERSE SEQUENCE AMPLICON
LENGTH
TM
(°C)
GAPDH 5’- CAT-TGT-GGA-AGG-GCT-CAT-G A-3’ 5’-GG A-AGG-CCA-TGC-CAG-T G A-GC-3’ 192bp 60
IL-4 5’- CGT-CCT-CAC-AGC-AAC-GGA-GA-3’ 5’- GCA-GCT-TAT-CGA-TGA-ATC-CAG-G-3’ 181 bp 60
IL-10 5’- TTT-GAA-TTC-CCT-GGG-TG A-G AA-G-3’ 5’ -  ACA-GGG-GAG-AAA-TCG-ATG-ACA -  3’ 52bp 54
TGF-p 5’- ACA-GGG-CTT-TCG-ATT-CAG-CGC-3 5’- CCC-TTG-GGC-TCG-TGG-GGT-CCT-3’ 306bp 60
IFN-ot 5’- CTC-TGT-GCT-TTC-CTG-ATG-GT-3’ 5’- AG A-G AG-GG A-GT C-T CC-T CA-TT-3’ 171 bp 60
IFN-y 5’- GGT-GAC-ATG-AAA-ATC-CTG-CAG-A -3 ’ 5’- CCT-CAA-ACT-TGG-CAA-TAC-TCA-TGA- 3’ 181 bp 59
IL-12 5’-GAC-ATC-ATC-AAA-CCA-GAC-CCG-3’ 5’- TT A-CAC-CCC-T CC-T CT-GT C-T CC-TT-3’ 182bp 59
ICOS 5’- GCT-GCC-AGA-CTA-CAG-CC-3’ 5’- CAG-GCT-GCA-TAG-TTT-CTA-G-3’ 196bp 57
ICOS-L 5’- CTT-AAG-TCC-TTC-CCG-AGT-A-3’ 5’- CCA-CCT-GAG-TTC-CTG-GG-3’ 198bp 57
Foxp3 5’- CAC-AAC-ATG-GAC-TAC-TTC-AAG-TAC- 
CAC-3’
5’- GAT-GGC-CC A-T CG-G AT - AAG-G-3’ 75bp 59
Table 2-4 Cell Surface Markers, Fluorochromes and Isotype Controls
MARKER FLUOROCHROMES ISOTYPE CONTROL
CD1 1 c FITC Rat IgGIX
CD1 1 c PE Hamster IgGIX
CD80 PE Hamster IgGIA,
CD8 6 FITC Rat lgG2 aic
l-Aa (MHC II) FITC Rat lgG2bK
CD8 a FITC Rat lgG2aK
B220 PerCP Rat lgG2aK
CD3 Cy-5 Rat lgG2bK
CD4 PE Rat lgG2aK
CD40 FITC Rat lgG2bK
F4/80 PE Rat lgG2bK
NB All Abs were from Pharmigen, except F4/80 and its isotype control, which are from Serotec
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Results 1: Effect of M. vaccae on pulmonary inflammation: 
reducing excessive type-2 response
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1 Introduction
The pathology of allergic asthma is a direct consequence of excessive type 2  
responses. Asthma is therefore associated with the secretion of high levels of 
type 2 cytokines, for instance IL-4, IL-5 and IL-13 [Bradley et al 1991, Kay 1991, 
Umetsu et al 2002]. Release of these cytokines, secreted by a number of cells 
including allergen activated CD4+ T cells, results in eosinophilia, increased 
mucus production and elevated IgE levels. These are all characteristic of 
asthma [Yamaguchi et al 1988, Whittaker eta l 2002]. This chapter investigates 
the effect of M. vaccae treatment on the type-2 response and cytokine profile of 
mice with pulmonary inflammation.
1.2 IL-4
Upon initiation of airway inflammation, IL-4 is primarily secreted by CD4+ T 
cells. IL-4 is involved in triggering type-2 responses, which results in the 
elevation of IgE levels, eosinophilia and mucus production [Snapper eta l 1988, 
Lebman et al 1989, Schleimer et al 1992, Whittaker et al 2002].
In a murine model of pulmonary inflammation, IL-4-/" mice have fewer 
eosinophils in the lung tissue and BAL fluid, when challenged with allergens in 
the airways. However, these mice still have the ability to generate and release 
eosinophils from the bone marrow [Hamelmann ef a/2000].
Although IL-4 is necessary for inducing pulmonary inflammation, one other 
important role of IL-4 is in the induction of B cell secreted IgE. IL-4 causes a 
switch from IgM to IgE Ab production [Snapper et al 1988]. IgE is a major 
contributor to pulmonary inflammation, since cross-linkage of two IgE Abs, on a 
mast cell results in degranulation and release of histamine [Kinet et al 1990, 
Umetsu e ta l2002, Fireman e ta l2003, Wynn e ta l2003]. Once activated by IL- 
4, mast cells, basophils and eosinophils also generate inflammatory cytokines 
of their own, such as IL-4, IL-5 and IL-13. These cytokines cause more cellular 
infiltration and perpetuate inflammation [Fireman et al 2003]. IL-4 is therefore 
an essential cytokine for the activation of type-2  cells, and for the development 
of Th2 mediated diseases.
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Human clinical trials using a soluble recombinant human IL-4 receptor (IL-4R; 
Nuvance; altrakincept) that blocks the function of IL-4, have been carried out. 
Patients taking inhaled corticosteroids received a single dose of either the IL-4R 
or a placebo immediately after stopping corticosteroid treatment. Compared to 
the placebo group, patients that received the IL-4R maintained stable asthma 
symptom scores despite abrupt withdrawal of corticosteroids [Borish et al 1999, 
Borish et al 2001]. This highlights the therapeutic potential of inhibiting IL-4 in 
asthma patients. However, other cytokines are involved in initiation of asthma 
symptoms, including IL-5 and IL-13.
1.3 IL-5
Upon initiation of airway inflammation, IL-5 is produced primarily by activated T 
cells, although secretion by NKs, mast cells and eosinophils is also reported 
[Tanaka et al 1994, Warren et al 1995, Okayama et al 1995]. IL-5 is essential 
for the induction of airway eosinophilia, hallmark of allergic asthma [Durham et 
al 1989].
IL-5 stimulates eosinophil expansion and differentiation [Yamaguchi eta l 1988]. 
Absence or blockade of IL-5 is reported to significantly reduce eosinophil 
numbers in experimental models. For example, injection of anti-IL-5 mAb into 
OVA sensitized mice before OVA challenge significantly reduces eosinophil 
infiltration into the lungs [Nakajima eta l 1992, Morokata eta l 1999]. In addition, 
IL-5'7' mice sensitized and challenged with OVA have significantly fewer 
eosinophils in the BAL fluid [Cho efa/2004].
Other molecules, which have a direct effect on initiating eosinophilia, include 
eotaxin and RANTES. These chemotactic chemokines are eosinophil 
attractants, and even in the absence of IL-5 can activate eosinophils [Lampinen 
et al 2004]. Eotaxin and RANTES, along with their receptor CCR3, have been 
shown to be significantly increased in the bronchial mucosa in atopic and non- 
atopic asthma patients when compared to non-asthmatic controls [Ying et al
1999]. Blockade of RANTES with mAbs resulted in inhibition of eosinophils in 
the BAL fluid of pollen allergic patients [Lampinen et al 1999]. Blockade of the
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eotaxin and RANTES receptor CCR3 with a mAb also suppressed eosinophil 
activation [Bertrand et al 2000]. Although eotaxin and RANTES are important 
for initiation of eosinophilic inflammation, IL-5 is the predominately essential 
cytokine whose secretion is induced by IL-4.
1.3.1 IL-5 therapy in animal models
IL-5 has been shown to be essential for the initiation of eosinophilia, which is a 
hallmark symptom of allergic asthma. The role of IL-5 in the induction and 
maintenance of airway inflammation has been supported by numerous animal 
models. For example, sensitisation and aeroallergen-challenge of IL57' mice 
does not induce eosinophilia, indicating a central role for IL-5 in the 
pathogenesis of allergic airways disease [Foster eta l 1996, Trifilieff e ta l2001]. 
In addition IL-57' mice have significantly less peribronchial fibrosis and less 
peribronchial smooth muscle (hyperplasia) compared with WT mice when 
challenged with OVA [Cho e ta l2004].
Such observations suggest that blocking IL-5 secretion would reduce asthmatic 
characteristics. Several methods of inhibiting IL-5 have been investigated in 
animal models. One example is the use of antisense oligonucleotides to block 
the IL-5 production at the molecular stage, by specifically binding to IL-5 or IL-5 
receptor mRNA, and causing RNase H mediated degradation. Karras et al 
demonstrated an antisense oligonucleotide that inhibited the expression of IL-5 
in vitro also significantly reduced the number of eosinophils in the BAL fluid of 
OVA sensitized and challenged mice. This correlated with reduced IL-5 protein 
levels and suppression of AHR, supporting the blocking action of the IL-5 
antisense oligonucleotide [Karras et al 2 0 0 0 ]. Similar results were shown by 
Lach-Trifilieff etal, whose group reported a significant reduction in bone marrow 
and blood eosinophilia upon treatment with an antisense oligonucleotide to the 
IL-5 receptor a unit. In addition, i.v. administration of this antisense 
oligonucleotide inhibited the development of blood and tissue eosinophilia in 
ragweed-induced allergic peritonitis [Lach-Trifilieff e ta l2001].
Encouraging results have also been observed by blocking IL-5 protein with a 
mAb. Injection of anti-IL-5 mAb into OVA sensitized mice before OVA
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challenge significantly reduces subsequent eosinophil infiltration into the lungs 
[Nakajima et al 1992, Morokata et al 1999]. In addition, treatment with an anti- 
IL-5 mAb has been shown to have a positive effect on airway remodelling. 
Blyth et al injected the anti-IL-5 mAb TRFK5 i.v 30. minutes before allergen 
challenge of sensitized mice, and observed a reduction in the amount of 
subepithelial fibrosis, along with almost total depletion of airway eosinophils 
[Blyth e ta l2000].
1.3.2 IL-5 therapy in humans
Since pre-clinical work has shown promise, a number of clinical trials have been 
conducted in human patients. SCH55700 (Schering-Plough Research Institute) 
and mepolizumab (SB-240563) (GlaxoSmithKline) were both used in a trial on 
patients with asthma [Leckie et al 2000, Flood-Page 2003, Menzies-Gow et al 
2003, Kay et al 2004]. SCH55700 is a humanized mAb derived from the rat 
anti-human IL-5, 39D10 [Zhang et al 1999], whereas mepolizumab is a 
humanized mAb derived from the murine mAb anti-human IL-5 Ab, 2B6 [Zia- 
Amirhosseini et al 1999].
Patients with severe asthma treated with SCH55700 had reduced numbers of 
eosinophils circulating in their peripheral blood. At the highest dose, SCH55700 
offered a long lasting reduction without any significant side affects. However, 
there was no significant clinical benefit, even though there was a non-significant 
trend towards improvement at day 30 in the Forced Expiratory Volume in 1 
second (FEVi) [Kips e ta l2003].
A trial in which patients suffering with mild asthma were treated with a single 
dose of mepolizumab resulted in a significant reduction in blood and sputum 
eosinophil numbers. Unfortunately, no significant changes in late asthmatic 
reaction or AHR were observed [Leckie et al 2000]. Subsequent trials using 
mepolizumab reported drastically decreased numbers of eosinophils in the bone 
marrow (70% reduction compared to placebo treated patients), BAL fluid (79%) 
and the peripheral blood (100%) 4 weeks after treatment. This decrease is 
maintained for at least 10 weeks after mepolizumab injection. In spite of this, 
there was no significant change between the placebo and treatment groups in
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clinical measures of asthma, including FEVi, AHR or peak flow readings [Flood- 
Page e ta l2003, Menzies-Gow e ta l2003].
1.4 IL-13
IL-13 is secreted primarily by T cells and binds to the IL-4 receptor [de Waal 
Malefyt etal 1993]. This cytokine plays an essential role in mucus production in 
the airways [Wills-Karp eta l 1999]. Blockade of IL-13 by soluble IL-13R inhibits 
mucus production in the lungs of OVA sensitized mice [Wills-Karp et al 1998]. 
In the complete absence of IL-13, there is no mucus secretion in the airways 
even when pulmonary inflammation is induced [Whittaker et al 2002]. In 
addition to mucus production, IL-13 is also essential in the development of 
AHR. AHR is a short term narrowing of the airways, which limits breathing. In a 
murine model of OVA-induced pulmonary inflammation, blockade of IL-13 with 
the soluble fusion protein IL-13ac-lgGFc before OVA challenge resulted in a 
complete reversal of AHR development in the lungs [Wills-Karp et al 1998]. 
However, blockade did not completely inhibit IgE levels or eosinophilic 
inflammation in the lung. This suggests that AHR is dependent on IL-13, but 
IgE production and eosinophilia are dependent upon other cytokines, such as 
previously described IL-4 and IL-5. IL-13 also plays a major role in fibrosis is 
the lungs. Fibrosis is a characteristic of chronic asthma. IL-13"7" mice infected 
with Schistosoma mansoni showed reduced liver fibrosis, compared to wild type 
mice [Kaviratne et a! 2004]. Together, all these data suggest that secretion of 
IL-4, IL-5 and IL-13 by CD4+ T cells initiate mast cell and eosinophil activation, 
and cellular recruitment into the respiratory tract.
1.5 Th1 Vs Th2
In the past it was hypothesised that pathology caused by excessive Th2 
responses may be reversed by inducing a type-1 response in the host [Surs et 
a! 1996] Cells secreting IFN-y, a Th1 cytokine, are known to cross regulate Th2 
cells, and, some researchers believed them to be ideal candidates to 
downregulate Th2-induced AHR [Mosmann et a! 1989]. In vitro assays have 
promoted these views as Th1 and Th2 cytokines have antagonistic effects on 
each other. For example when the supernatant from cultures of Th2 clones was
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added into the culture medium of Th1 clones, type-1 cytokine production was 
suppressed [Fiorentino et al 1989]. In addition, IFN-y has been observed to 
inhibit both Th2 cell proliferation and secretion of IL-4 [Fitch et al 1993]. From 
this cumulative evidence, the hypothesis that treatment aimed at inducing a 
type-1 response would be helpful in reducing the excessive Th2 response 
associated with allergic inflammation was put forward [Mosmann et al 1989].
A number of observations however were soon made which added some 
confusion. IFN-y is an abundant cytokine in lung tissue of asthmatics [Krug etal 
1996] and it is now evident that IFN-y may actually contribute to the severity of 
the disease. For example, the introduction of Th1 cells to the lungs of mice with 
allergic pulmonary inflammation actually worsens symptoms instead of 
counterbalancing the type-2 response, by aggravating airway inflammation and 
cellular infiltration [Hansen et al 1999]. It is implicit in these results that the 
Th1/Th2 paradigm, in this context, may be too simplistic a hypothesis and other 
mechanisms may be involved. Therefore, the first objective of this thesis was to 
analyse the production of type-1 and type-2 cytokines in the lungs of mice with 
allergic pulmonary inflammation, and compare them to that of mice treated with 
M. vaccae. This work would confirm published papers reporting a decrease in 
type-2 mediated eosinophilia, unaccompanied by changes in type-1 cytokine 
levels in the BAL fluid [Zuany-Amorim et al 2002a]. Despite being the site of 
inflammation the lung tissue itself has received surprisingly little attention. To 
determine if M. vaccae has an effect on the cytokine profile of treated mice, 
analysis of cytokines in the whole lung tissue was therefore undertaken, in 
parallel with type-1 and type-2 levels in the BAL fluid.
1.6 Immunoregulation
Although type-1 and type-2 cytokines antagonise each other, they generally 
have a positive effect on inducing immune responses. Other cytokines are 
essential in inhibiting the immune response. Recently, it has been suggested 
that suppressive cytokines, such as IL-10 and TGF-p, are associated with 
regulation of excessive immune responses in a number of allergic conditions, in 
autoimmune disorders and during transplant rejection [Arkwright et al 2001, 
Alansari et al 2002, Bickerstaff et al 2002, Sharif et al 2002, von Bubnoff et al
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2004]. These cytokines are also associated with the induction of Tregs, which 
are responsible for suppression of immune responses, and immunoregulation 
[Chen efa/1994, Ronocarolo e ta l2000, Read e ta l2001, Ling efa/2004].
Generally, a lack of immunoregulation during an infection can have fatal 
consequences. Death is not always caused by the infectious pathogen itself, 
but rather as a consequence of immunopathology. An immune response 
mounted against a pathogen can cause irreversible tissue damage if not 
inhibited once the pathogen has been destroyed. Suppressive cytokines, such 
as IL-10, are essential in inhibiting immune response. Several examples from 
animal models can be cited to support this. For example IL-10_/” mice have 
been observed to mount an over exuberant response when infected with the 
malaria parasite Plasmodium chabaudi chabaudi. This excessive response is 
damaging to the hosts tissue, leading to hypoglycemia, hypothermia, and loss of 
weight, when compared to IL-10 sufficient animals [Li et al 1999]. IL-10"A mice 
infected with Escherichia coli clear the bacteria significantly faster than wild type 
animals. In spite of this, the mortality rate and incidence of peritonitis in these 
mice is significantly higher. Although IL-10'7' mice can mount a vigorous 
response to the pathogen, they cannot reverse it once the infection is cleared. 
Death is a consequence of the aggressive immune response mounted 
[Sewnath et al 2001]. The exaggerated immune response observed in these 
mice, and the inability to switch this response off, illustrates that IL-10 is an 
essential regulator of the immune response.
1.7 IL-10
IL-10 has the ability to suppress both type-1 and type-2 cytokine production 
[Hoffmann et al 1999, Hoffmann et al 2000]. Single (IL-10'7') and double (IL- 
10/IL-4'7' or IL-10/IL-12'7') knock out mice were infected with Schistosoma 
mansoni and the progression of infection monitored. The IL-10'7' and double 
(IL-10/IL-4'7' or IL-10/IL-12"7') cytokine-deficient mice developed the most 
extreme infection-related tissue pathology. Interestingly, pathology in IL-10/IL- 
4'7' (Th1 polarized) differed from that observed in IL-10/IL-12'7' (Th2-polarized). 
IL-10/IL-47' mice rapidly succumbed to infection, developing fibrotic hepatic 
granulomas in response to the parasite eggs. In contrast, the IL-10/IL-12'7'
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(Th2-polarized) mice developed a slow and prolonged wasting disease that 
resulted in significant morbidity during chronic stages of infection, with much 
larger granulomas than the Th1-polarized mice. This study further offers 
evidence that IL-10 production during Schistosoma mansoni infection is not only 
important for suppressing type-1 inflammatory cytokines, but is also critical for 
the dampening of pathogenic type-2 immune responses during infection 
[Hoffmann et al 1999, Hoffmann et al 2000]. IL-10 is now considered as an 
essential cytokine in immunoregulation.
1.7.1 IL-10-like family
Cytokines have generally been placed in one of seven protein fold-based 
superfamilies, depending on their protein structure. A number of molecules are 
defined as being "a-helical", and within this grouping are at least three 
subtypes: those with short a-helices, a-helices and those with multiple repeat a- 
helices. The IL-10 family of proteins includes IL-10 and other cytokines with 
structural similarity such as IL-19 [Gallagher et al 2000], IL-20 [Blumberg et al 
2001], IL-22 [Dumoutier eta l 2000], IL-24 [Jiang et al 1995, Caudell et al 2002] 
and IL-26 [Knappe et al 2000]. Functionally, these molecules share little 
similarity. The structure common to all mature IL-10 family members is the a- 
helix. Amino acid identity of family members to IL-10 ranges from 20% (IL-19) 
to 28% (IL-20) [Fickenscher e ta l2002, Dumouter e ta l2002]. The IL-10 family 
share a combination of 5 receptors subunits: IL-10R1, IL-20R1, IL-22R, IL-10R2 
and IL-22R2. The receptors for the IL-10 family are all members of the class II 
cytokine receptor family (CRF2) [Soo etal 1999].
All functional receptors are heterodimers composed of an a or type 1 (R1) chain 
and a p or type 2 (R2) chain. At a minimum, it would appear that there are at 
least two a and two p chains involved in each signalling receptor complex 
[Kotenko e ta l2000]. Traditional nomenclature has often defined the a subunit 
as being the ligand-binding molecule and the p subunit as being the signal 
transducing subunit. For at least one member of the IL-10 family, both subunits 
can serve as ligand-binding moieties [Xie e ta l 2000, Kotenko et al 2001] and 
the a-subunit in this case generally serves as a STAT3 docking port (i.e. the 
first step in signal transduction) [Kotenko et al 2000]. Class II cytokine
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receptors are characterized by the presence of two fibronectin type III (FNIII) 
domains in their extracellular region, which are typically associated with cell 
surface adhesion molecules.
1.7.2 Function of IL-10-like family members
The functions of IL-10-like cytokines are only partially understood. IL-10 was 
first described as a Th2 cytokine in mice that inhibited IFN-y and GM-CSF 
cytokine production by Th1 cells [Moore eta l 1990, Fiorentino et al 1989]. Cells 
known to express IL-10 include CD8+ T cells [Varney eta l 1999, Daftarian eta l 
1996], CD14+ monocytes [Frankenberger et al 1996, de Saint Vis et al 1998], 
Th2 CD4+ cells [Schmidt-Weber et al 1999], Th1 CD4+ T cells [Del Prete et al 
1993], activated macrophages [Panuska et al 1995, Delgado et al 1999], NK 
cells [Mehrotra et al 1998], DCs [Iwasaki et al 1999], B cells [O'Garra et al 1990, 
Spencer et al 1997] and eosinophils [Nakajima et al 1996]. IL-10 binds to the 
IL-10R1/IL-10R2 receptors. Secreted by many cell types, IL-10 plays an 
essential role in many aspects of the immune system, including Ig class 
switching [reviewed in Stavnezer et al 1996] and as an immunoregulatory 
cytokine, responsible for inhibiting and downregulating immune responses 
[Read et al 2001, Ronocarolo et al 2000]. Although structurally similar, the 
biological activities of the rest of the IL-10-like family appear to be different from 
IL-10. In addition, the sites of expression are distinct for each cytokine. 
Whereas IL-10 is secreted by a variety of cells, the expression pattern of the 
other family members is more restricted [Fickenscher e ta l2002].
IL-19 was originally isolated from an Epstein-Barr virus-transformed human B- 
cell library [Gallagher et al 2000]. IL-19 shares approximately 20% amino acid 
identity with IL-10. More than 80% of the 50 amino acids that generate IL-10s 
dimeric structure are conserved in IL-19. Cells known to secrete IL-19 include 
monocytes and B cells [Gallagher et al 2000, Wolk et al 2002]. It is known that 
IL-19 binds the IL-22R1/IL-22R2 receptors. The function of IL-19, however, is 
still poorly understood. It has been demonstrated that treatment of monocytes 
with LPS strongly induces the production of IL-19 [Liao et al 2002]. When 
monocyte cultures are treated with IL-19, proinflammatory cytokines, such as
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IL-1 and TNF-a, are released, along with the production of reactive oxygen 
intermediates, which eventually induce apoptosis [Parrish-Novak e ta l2002].
IL-20 was initially identified in a human keratinocyte library during a 
bioinformatics search for molecules expressing a-helices. In humans, there is 
26% amino acid identity between IL-20 and IL-10, and 41% amino acid identity 
between IL-20 and IL-19 [Gallagher et al 2000, Blumberg et al 2001]. Cells 
known to produce IL-20 are monocytes [Wolk et al 2002] and keratinocytes 
[Blumberg et al 2001, Xie et al 2000]. The only suggested function for IL-20 
involves keratinocytes. Partly based on overexpression studies, it is proposed 
that IL-20 induces keratinocyte differentiation and proliferation [Blumberg et al 
2001, Xie et al 2000]. IL-20R is expressed on keratinocytes and endothelial 
cells [Blumberg et al 2001] and keratinocytes likely express the IL-20 cytokine 
[Grone ef a/2002].
IL-22 is a 179 amino acid polypeptide that contains one 33 amino acid signal 
sequence and a 146 amino acid mature region [Xie et al 2000, Dumoutier et al
2000]. The mature molecule contains three potential N-linked glycosylation 
sites plus four cysteines, only two of which are conserved in IL-10 [Fickenscher 
e ta l2002]. There is 24% amino acid identity between mature human IL-22 and 
IL-10 [Dumoutier e ta l2000]. Cells known to express IL-22 include NK cells and 
CD4+ Th1 cells [Wolk et al 2002]. The functions associated with IL-22 are still 
unclear. IL-22 induces acute phase proteins in hepatocytes (i.e. haptoglobin, 
a1-antichymotrypsin) [Dumoutier et al 2002, Dumoutier et al 2000] and may 
reduce IL-4 production by certain Th2 cells [Xie et al 2000]. In addition, 
pancreatic acinar cells, which synthesize inactive precursor forms of digestive 
enzymes, are now known to express PAP1 (pancreatitis-associated protein-1) 
and osteopontin in response to IL-22 [Lenhoff et al 1998]. These are two 
molecules that may have protective or enhancing effects during inflammation.
IL-24 was originally isolated from actively proliferating melanoma cells [Jiang et 
al 1995]. IL-24 consists of a 207 amino acid precursor, with an extended 47 
amino acid signal sequence and a 160 amino acid mature segment [Zhang etal
2000]. Within the mature segment, there are three potential N-linked 
glycosylation sites and two cysteines. Thus, it differs markedly from all other
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known IL-10 family members in the potential for disulfide-bonding [Jiang et al 
1995]. In its mature segment, it shares 20% amino acid identity with IL-10 
[Zhang et al 2000]. Cells known to express IL-24 include murine Th2 cells 
[Wang et al 2002], melanocytes [Jiang et al 1995, Soo et al 1999, Huang et al
2001], breast epithelium [Huang eta l 2001], fibroblasts (in rat) [Soo et al 1999], 
monocytes [Wang et al 2002], vascular smooth muscle [Ekmekcioglu et al
2001], NK cells [Caudell et al 2002], B cells [Caudell et al 2002] and CD4+ 
CD45RA+ (naive) T cells [Wolk et al 2002]. IL-24 was initially believed to
induce melanocyte/melanoma cell differentiation. Melanoma cells lack IL-24 
expression, while melanocytes express IL-24. In the presence of IL-24, 
melanoma cell growth was inhibited [Jiang et al 1995, Ekmekcioglu et al 2001]. 
Thus, it appeared that IL-24 might be a tumour suppressor molecule [Huang et 
al 2001, Su et al 1998]. Subsequent studies have shown that IL-24 can inhibit 
tumour growth in cells other than melanoma, such as non-small cell lung 
carcinoma, breast cancer, prostate cancer [Su et al 1998, Jiang et al 1996 
Saeki et al 2000], and that apoptosis can be induced in transformed cells 
without negatively impacting any normal cell types [Ekmekcioglu et al 2001, Su 
et al 1998, Saeki et al 2000]. IL-24 has also been shown to induce IL-6 and 
TNF-a secretion by monocytes, demonstrating an activity antagonistic to that of 
IL-10 [Caudell e ta l2002].
IL-26 is a 36 kDa homodimer that was initially identified in the supernatant of 
cultured herpesvirus-transformed T cells [Knappe et al 2000]. Its open reading 
frame encodes a 171 amino acid precursor that contains a 21 amino acid signal 
sequence and a 150 amino acid mature segment. Its mature segment shares 
25% amino acid identity with human IL-10 and retains the typical six a-helix 
pattern seen in IL-10. Remarkably, there is no mouse counterpart to IL-26 
[Dumoutier et al 2002]. Cells known to express IL-26 include CD4+ CD45RO+ 
T cells and NK cells [Wolk et a l2002 Fickenscher ef a/2002]. To date, almost 
nothing is known about IL-26 activity. It thought to play a role as an autocrine 
factor in lymphocyte transformation by HVS or in the natural y-herpesvirus 
infection, since IL-26 is over-expressed by HVS-transformed human T cells, a 
rare phenotypic differences between HVS-transformed T cells and their parental 
cells [Fickenscher e ta l2002].
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1.7.3 Type III IFNs
In addition to these structurally similar cytokines, IFN-M (IL-29), -X2 (IL-28A), 
and -X3 (IL-28B) or type III IFNs, are also part of the IL-10-like family, since they 
share the IL-10R2 subunit (which IL-10, IL-22 and IL-26 also signal through) 
[Acharya et al 2001, Conti et al 2001]. These IFNs share limited sequence 
similarity with the type-l IFNs (IFN-a and IFN-p), but like the type-l IFNs are 
expressed by human PBMCs and DCs upon infection with viruses or double 
stranded RNA [Acharya efa/2001, Conforti et al 2001]. IFN-X1, -X2, and -X3 
induce tyrosine phosphorylation of the signal transducers and activators of 
transcription (STAT) factors, which is a typical feature of the type-l IFNs [Luzio 
et al 2001, Stefano et al 2001]. Hence, although these type-ill IFNs share a 
receptor with some members of the IL-10-like family, their function appears to 
be similar to that of the type-l IFNs.
1.8 TGF-p
In addition to IL-10, TGF-p has also shown immunosuppressive characteristics 
[Ludviksson et al 00]. TGF-p'7' mice have not been extensively used in 
experimental models, as although they do not show any abnormalities at birth, 
they die within 5 weeks of birth. These mice succumb to a wasting syndrome, 
and die from multiple organ failure caused by excessive inflammation and tissue 
necrosis [Shull et al 1992]. More recent studies of TGF-p7' mice have shown 
that TGF-p supports regulatory function of peripheral Tregs. At 8-10 days old, 
TGF-p'7' animals show a significant reduction in CD4+CD25+ T cells in the 
spleen [Marie e ta l2005]. These data suggest that TGF-p may be essential for 
immunosuppression.
1.8.1 TGF-p processing and activation
The TGF-p family of cytokines consists of three closely related isoforms (TGF- 
p1—3) with a number of functions ranging from regulation of cell growth and 
differentiation, inflammatory responses and extracellular matrix (ECM) 
production. TGF-p is secreted as a latent precursor into the ECM, and activity
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is regulated by the conversion of the latent to the active form. Secretion of 
latent TGF-p prevents uncontrolled activation of the cognate receptors [Annes 
et al 2003]. The importance of TGF-p regulation is supported by the 
observation that TGF-p7' mice die within 5 weeks of birth from multiple organ 
failure caused by excessive inflammation and tissue necrosis [Shull et al 1992].
There are two types of latent precursors, the small and the large latent complex. 
The small latent complex (TGF-p-LAP) consists of a mature TGF-p dimer, 
noncovalently associated with a latency-associated protein (LAP) [Munger et al 
1998]. The large latent complex (LLC) is formed by the TGF-p-LAP, and a 
latent-TGF-p binding protein (LTBP). The LAP and LTBP are bonded together 
by disulphide linkages [Saharinen et al 1996, Gleizes et al 1996]. LTBPs 
comprise a central stack of epidermal growth factor (EGF)-like repeats and 
interspersed cysteine repeats, which binds the ECM or to TGF-p-LAP 
[Saharinen et al 2000]. These features allow LTBPs to target latent TGF-p to 
the ECM, creating localised deposits of TGF-p that can be accessed easily and 
rapidly by surrounding cells [Taipale et al 1998]. As part of the LCC, TGF-p 
cannot interact with its receptors. The LAPs function as inhibitors due to their 
noncovalent, high affinity association with mature TGF-p [Lawrence et al 1984, 
Dubois et al 1995]. The process by which latent TGF-p is activated is still 
relatively unclear. The term “TGF-p activation” refers to the release of mature 
TGF-p from the latent complex. There are several known activators of TGF-p, 
including proteases, thrombosin-1 and low pH.
1.8.2 TGF-p activators
Proteases, including plasmin, matrix metallopeptidase (MMP)-2 and MMP-9, 
have been identified as TGF-p activators in vitro. Proteases may activate TGF- 
P in several possible ways. A protease-sensitive hinge region on the LTBP may 
be a potential target for the release of the LAP [Taipale et al 1994]. In addition, 
proteases may be involved in proteolytic cleavage of LAP, to destabilise the 
LAP-TGF-p bonds, releasing active TGF-p from its latent complex [Lyons et al 
1988]. Thrombosin-1 is known to activate latent TGF-p by direct interaction 
between the matricellular protein (a non-structural extracellular matrix protein
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which is involved in adhesion) and LAP, probably by disrupting the noncovalent 
bond interactions between LAP and TGF-p [Schultz-Cherry et al 1993, Murphy- 
Ullrich et al 2000, Crawford et al 1998]. Latent TGF-p present in conditioned 
medium can also be activated by mild acid treatment (pH 4.5). It is thought that 
acid treatment denatures LAP, thereby disrupting the interaction between LAP 
and TGF-p [Lyons eta l 1988].
1.8.3 Measuring active TGF-p
The fact that TGF-p requires activation for the cytokine to effect other cells 
could explain the discrepancies often observed between measurements of 
TGF-p message and protein levels. Often an increase in TGF-p mRNA fails to 
translate in an increase at the protein level when TGF-p ELISA is carried out. 
This discrepancy suggests that TGF-p has been made, but is being held in the 
latent form as only the active form is measured by ELISA. The most common 
method used by ELISA kits for releasing TGF-p from the latent complex is by 
treating the supernatants with acid (usually HCI), which is thought to disrupt the 
bonds between LAP and the LTBP [Danielpour et al 1993, Lyons et al 1988]. 
However, measuring the amount of TGF-p after treatment with acid may not be 
accurately measuring the level of TGF-p cytokine that is active in vivo. 
Although the latent TGF-p may be present, it may not necessarily have an effect 
on cells. Measurement of active TGF-p protein following by treatment with acid 
therefore may not correlate with cytokine bioavailability.
The activation of latent TGF-p to mature TGF-p ensures that the action of TGF- 
p is tightly regulated and localised. TGF-p has been shown to be secreted by a 
number of cells, and to have many varied functions. For example, TGF-p is 
involved in remodelling of the airways during asthma and in the regulation of 
immune responses [Redington et al 1997, Chen et al 1996]. The tight control 
of TGF-p activity is therefore a necessity as release of active TGF-p could lead 
to an inappropriate reaction.
TGF-p has been shown as important for the function of Tregs [Zuany-Amorim et 
al 2002, Chen et al 2003], and is even secreted by a certain subtype, the Th3
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inducible Treg [Chen et al 1996]. Induction of Treg activity has been shown as 
advantageous for animals suffering from allergic disease, such as asthma 
[Zuany-Amorim e ta l2002, Kearley e ta l2005, Wilson efa/2005].
1.8.4 Tregs and TGF-p
Tregs have been observed to express surface membrane-bound TGF-p in both 
the latent and active form [Nakamura et al 2001, Chen et al 2002]. 
Interestingly, a population of Tregs have been shown to also express the TGF-p 
type II receptor (TGF-pRII) in addition to TGF-p [Chen et al 2003]. In addition, 
TCR interaction with the MHC on APCs upregulates the expression of active 
cell surface TGF-p and TGF-pRII. In comparison, naive CD4+CD25- T cells, 
which are negative for both TGF-p and TGF-pRII, upregulate only TGF-pRII 
after TCR stimulation [Chen et al 2003]. Engagement of CTLA-4 with CD28 on 
the surface of the Treg also results in upregulation of active TGF-p and TGF- 
pRII expression [Nakamura et al 2001]. Active TGF-p signals through the 
heretomeric complex consisting of TGF-pRI and TGF-pRII. TGF-pRI and TGF- 
pRII are serine-threonine kinases, which phosphorylate downstream signaling 
proteins upon TGF-p binding. This then propagates the signal through 
phosphorylation of cytosolic proteins, including the Smad proteins, Smad2 and 
Smad3 [Massague et al 1998]. Once activated Smad2 and Smad3 form a 
hetero-oligomeric complex and translocate to the nucleus where they can 
regulate transcription of specific genes [Roberts et al 2002]. This results in 
inhibition of proliferation and cytokine production.
The coexpression of this active TGF-p and its receptor may explain why 
CD4+CD25+ Tregs are functionally anergic and lack IL-2 expression upon TCR 
stimulation, since TGF-p has been shown to block IL-2 production [Kehrl et al 
1986, Seder et al 1998, Chen et al 2001]. This coexpression of latent and 
active TGF-p on the cell surface of certain populations of Tregs suggests that 
activation TGF-p is tightly regulated locally, at the Treg surface.
Tregs inhibit the immune response, which may also inhibit responses, which are 
necessary to eliminate pathogens [Boussiotis et al 2000, Trinchieri et al 2001,
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Gerosa et al 1999] or detect and destroy tumour cells [Liyanage et al 2002, 
Morse e ta l2002, Noma e ta l2005]. This fine balance between excessive and 
insufficient immunoregulation suggests that the regulation of Treg induction and 
function needs to be very tightly controlled and localised. In terms of Treg 
function, the regulation of mature TGF-p secretion may be essential in 
maintaining immunotolerance.
1.9 Mechanisms of immunoregulation mediated by IL-10 and TGF-p
A variety of mechanisms have been described to explain the regulatory effect 
that IL-10 and TGF-p have on both type-1 and type-2 mediated responses. For 
example, IL-10 has been shown to prevent CD28 co-stimulation. The CD28-B7 
pathway is a major co-stimulatory pathway, necessary along with the TCR-MHC 
complex for rapid activation of T cells. IL-10 has been observed to inhibit 
tyrosine phosphorylation of CD28, which is the initial step in the CD28 signal 
pathway [Moore et al 1993, Akdis et al 2001]. This would inhibit activation of 
naive T cells, resulting in diminished immune responses. Mechanisms of TGF- 
p mediated regulation include inhibition of IL-2 production [Seder et al 1998, 
Chen et al 2001] and downregulation of IL-12Rp2 expression on T cells 
[Ludviksson et al 2000]. This affects the proliferative capacity of naive T cells. 
TGF-p has also been shown to induce the production of IL-10 by APCs, thereby 
diminishing immune responses further [Maeda eta l 1995].
Another possible mechanism for which IL-10 and TGF-p may be necessary is 
the induction of Tregs. IL-10 and TGF-p have been described as essential for 
the activation and development of these cells [Zuany-Amorim et al 2002b, 
Cobbold e ta l2004, Huber e ta l2004]. These T cells have the ability to regulate 
immune cells, such as other T cells, either through cytokine-mediated 
mechanisms or via cell-contact [Groux et al 1997, Shevach et al 2002]. Indeed, 
treatment of allergic mice with M. vaccae has been observed to induce IL-10 
and TGF-p dependent Tregs. Since these immunosuppressive cytokines play 
such an important role in regulation of the immune system, one objective of this 
thesis is to analyse the production of IL-10 and TGF-p in the lungs of mice with
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pulmonary inflammation, and to compare the results to those obtained from the 
lungs of mice treated with M. vaccae.
1.10 Hypothesis
Treatment of allergic asthma with M. vaccae has been studied using a murine 
model of OVA-induced pulmonary inflammation. Treatment of mice with M. 
vaccae results in Treg induction. These Tregs are responsible for suppressing 
type-2 responses and consequently alleviating airway inflammation. These 
Tregs transfer protection against OVA specific pulmonary inflammation, when 
transferred i.v. to OVA sensitized animals. In addition, IL-10 secretion by these 
M. vaccae-induced Tregs was observed. Moreover, blockade of IL-10 and 
TGF-p in vivo with neutralising mAbs inhibited the function of these Treg, and 
as a consequence airway inflammation developed. These results suggest 
either that these M. vaccae-induced Tregs may be dependent on these 
cytokines for further development in vivo, or that they must release (or cause 
other cells to release) these cytokines in order to be suppressive [Zuany- 
Amorim e ta l2002b]. The effect of treatment with M. vaccae on IL-10 and TGF- 
p has not been studied extensively at the site of inflammation, the lungs. In this 
chapter, the type-1 and type-2 profile of the lungs is investigated to establish the 
effect M. vaccae is having.
This chapter analyses pulmonary inflammation during allergen challenge. 
Whole lung tissue and BAL fluid were investigated for cytokines essential for 
both the development and alleviation of asthma, such as IL-4, IL-5, IFN-y, IL-12, 
TGF-p and IL-10, to establish whether the mechanism behind the abrogation of 
allergic symptoms observed following M. vaccae treatment is due to a type-2 to 
type-1 switch, or whether immunoregulatory cytokines are involved.
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2 Results
2.1 Cellular infiltrate in the BAL fluid
To confirm a suitable model of pulmonary inflammation, characterized by an 
excessive type-2 response, the lung tissue from mice were investigated after 
OVA sensitisation and challenge. To determine the extent of pulmonary 
inflammation, the total number and the specific type of cells recruited in the BAL 
fluid were established. Since allergic inflammation is characterized by an 
excessive type-2 immune response, it was determined whether treatment with 
M. vaccae alters cytokine production in the lungs. The following results were 
observed when both preventive and therapeutic allergy protocols were carried 
out.
Following OVA challenge, mice previously sensitized with OVA in Alum 
presented with a dramatic increase in total cell numbers in the BAL fluid (Figure 
3-1 a). This cellular infiltrate was a result of allergen challenge, since challenge 
of OVA sensitized animals with saline alone did not result in cellular influx in the 
BAL fluid (Figure 3-1 a). However, OVA challenged animals treated with M. 
vaccae were observed to have a significantly decreased number of cells in the 
BAL fluid, compared to those mice treated with saline (Figure 3-1 a). The 
cellular infiltrate that characterizes allergic pulmonary inflammation consists for 
the most part of eosinophils, neutrophils and monocyte/M<I>s. An elevation in 
the number of these cells was observed in the BAL fluid of mice challenged with 
OVA. However, mice treated with M. vaccae had significantly lower numbers of 
eosinophils and monocyte/MC>s in their BAL fluid (Figure 3-1 b). The decrease 
in eosinophilia did not result in an increase of neutrophilia at the site of 
inflammation. These results suggest that in OVA sensitized and challenged 
mice, treatment with M. vaccae significantly reduces the severity of pulmonary 
inflammation that follows allergen challenge.
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Figure 3-1: Murine Allergic Pulmonary Inflammation Model -  Cellular infiltrate 
into the lungs. Mice were treated with M. vaccae (black bar) or saline (white bar, 
shaded bar), sensitized with OVA/Alum, and challenged with either OVA (black bar, 
white bar) or saline (shaded bar). Total cell numbers (a) and specific cell types (b) 
were quantified in the BAL fluid (n=6-8 per group, * p< 0.05 compared to negative 
control, # p<0.05 compared to saline treated animals, data expressed as mean ± 
SEM, ANOVA used to test for significant differences, with a Bonferroni post test 
which compares all data groups), eos = eosinophils, neuts = neutrophils, m/m = 
monocytes/MOs, lymph = lymphocytes
2.2 Cytokine mRNA in whole lung tissue
Since the site of inflammation is most relevant to pathology, cytokine message 
levels in whole lung tissue were analysed by real time RT-PCR. The lungs from 
mice with pulmonary inflammation were excised and RNA extracted to 
determine levels of type-1 and type-2 cytokine message. Levels of IL-4 mRNA 
in homogenised whole lung tissue were elevated significantly after the OVA 
challenge of sensitized mice (Figure 3-2 a). However, when the mice had been 
treated with M. vaccae, this level significantly decreased. Since the reduction of 
IL-4, a type-2 cytokine, could possibly be the consequence of an increase in a 
type-1 response, IFN-y and IL-12 mRNA levels were measured in whole lung 
tissue. No significant difference was found regardless of treatment in either 
cytokine profiles (Figure 3-2 b & 3-2 c). Similar results were observed using 
both the preventive and therapeutic allergy protocols. These results suggest 
that the reduced Th2 response found at the site of inflammation of mice treated 
with M. vaccae, is not caused by a switch to a type-1 cytokine environment.
2.3 Cytokine protein in the BAL fluid
To further determine whether the decrease observed in total cellular infiltration, 
eosinophilic inflammation (Figure 3-1) and IL-4 message in lung tissue (Figure 
3-2 a) following treatment with M. vaccae was associated with an increase in 
type-1 responses, levels of IFN-y in the BAL fluid were measured. Levels of IL- 
5, IL-10 and TGF-p in the BAL fluid were also determined.
Upon OVA challenge of OVA sensitized mice, levels of IFN-y, IL-5 and TGF-p in 
the BAL fluid of mice treated with M. vaccae remained unchanged, compared to 
levels observed in animals treated with saline (Figure 3-3 a & 3-3 b and 3-4 a). 
However, there was a significant increase in IL-10 protein (Fig 3- 4 b). These 
results were observed using both the preventive and the therapeutic protocols.
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Figure 3-2: Murine Allergic Pulmonary Inflammation Model -  IL-4, IFN-y and 
IL-12 expression. Mice were treated with M. vaccae (black bar) or saline (white 
bar, shaded bar), sensitized with OVA/Alum, and challenged with either OVA 
(black bar, white bar) or saline (shaded bar). IL-4 (a), IFN-y (b) and IL-12 (c) 
message in lung tissue was analysed using real time RT-PCR (n=4-6 per group, 
data expressed as mean ± SEM, * p<0.01 compared to negative control, # 
p<0.05 compared to saline treated animals, ANOVA used to test for significant 
differences, with a Bonferroni post test which compares all data groups).
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Type-1 cytokine protein data support the mRNA profile observed in whole lung 
tissue, where no changes in IFN-y or IL-12 are observed. However, no 
reduction was detected in IL-5 protein levels in the BAL fluid from mice treated 
with M. vaccae. This is inconsistent with the decrease observed in the other 
type-2 cytokine, IL-4, at the message level (Figure 3-2). Despite these 
discrepancies between protein and mRNA levels, an increase in IL-10 protein in 
the BAL fluid was observed.
2.4 Immunoregulatory cytokine mRNA in whole lung tissue
Elevated levels of IL-10 protein have been observed in the BAL fluid of mice 
treated with M. vaccae (Figure 3-4 b). Therefore, message for 
immunoregulatory cytokines IL-10 and TGF-p was analysed in whole lung. 
Upon OVA challenge, the mRNA level of IL-10 were elevated, albeit not 
significantly. However, no difference in IL-10 message was observed between 
groups of mice treated with saline or M. vaccae (Figure 3-5 b). In addition, 
neither OVA challenge nor treatment with M. vaccae appeared to have any 
effect on the mRNA expression of TGF-p in whole lung tissue (Figure 3-5 a). In 
conclusion, although IL-10 protein was observed in the BAL fluid, this was not 
accompanied by an increase in IL-10 or TGF-p mRNA in whole lung tissue.
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Figure 3-3: Effect of M. vaccae on the levels of IFN-y and IL-5 in the 
BAL fluid of allergic mice. Mice were treated with M. vaccae (black bar) or 
saline (white bar), sensitized with OVA/Alum, and challenged with OVA. 
IFN-y (a) and IL-5 (b) protein levels in the BAL fluid were analysed by ELISA 
(n=4-6 per group, data expressed as mean ± SEM, Student’s t-test used to 
test for significant differences).
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Figure 3-4: Effect of M. vaccae on the levels of TGF-p and IL-10 in the 
BAL fluid of allergic mice. Mice were treated with M. vaccae (black bar) or 
saline (white bar), sensitized with OVA/Alum, and challenged with OVA. 
TGF-p (a) and IL-10 (b) protein levels in the BAL fluid were analysed by 
ELISA (n=4-8 per group, # p<0.05 compared to saline treated animals, data 
expressed as mean ± SEM, Student’s t-test used to test for significant 
differences).
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Figure 3-5: Murine Allergic Pulmonary Inflammation Model -  TGF-p and IL- 
10 expression. Mice were treated with M. vaccae (black bar) or saline (white 
bar, shaded bar), sensitized with OVA/Alum, and challenged with either OVA 
(black bar, white bar) or saline (shaded bar). TGF-p (a) and IL-10 (b) message 
in whole lung tissue was analysed using real time RT-PCR (n=4-6 per group, 
data expressed mean ± SEM, ANOVA used to test for significant differences, 
with a Bonferroni post test which compares all data groups).
3 Discussion
The lung, as the site of inflammation, is most relevant to pathology and forms 
the focus of this chapter. Both the extent of the cellular infiltration and type-1, 
type-2 and immunoregulatory cytokine production in the lung were studied. 
Establishing cell number and cell type in the BAL fluid of mice sensitized to and 
challenged with OVA determined the extent of pulmonary inflammation. 
Cytokine production was established by carrying out an ELISA on the BAL fluid, 
and by RT-PCR on whole lung tissue. M. vaccae treatment significantly 
ameliorates pulmonary inflammation and eosinophilia, and decreases type-2 
cytokine production without inducing a type-1 response. These observations 
confirm those reported by other groups [Hopfenspirger et at 2001, Zuany- 
Amorim e ta !2002a, Smit e ta l2003a, Smit et a !2003b,]. This chapter indicates 
that M. vaccae treatment significantly ameliorates classic inflammatory 
symptoms.
3.1 M. vaccae treatment induces a decrease in type-2 responses
Results in this chapter suggest that M. vaccae treatment significantly 
ameliorates inflammatory charcateristics, such as cellular influx and eosinophilia 
in the lungs of allergic animals. This has also been observed by several other 
collaborating groups [Zuany-Amorim et al 2002a, Smit et al 2003a]. The other 
results presented in this thesis show that M. vaccae affects the IL-4 levels in the 
lung. Upon OVA challenge of sensitized mice, levels of IL-4 mRNA were 
significantly elevated in whole lung tissue. In contrast, levels of IL-4 message 
were decreased in the animals that had been treated with M. vaccae. This 
suggests that M. vaccae treatment decreases the excessive type-2 response 
associated with asthma.
To establish whether the reduction observed in IL-4 message correlated with a 
type-2 cytokine protein level, IL-5 was measured in the BAL fluid. In spite of a 
decrease in IL-4 mRNA, no difference was detected in the levels of IL-5 protein 
in the BAL fluid. M. vaccae treatment resulted in reduced eosinophilia in the 
BAL fluid and IL-4 message in the lung tissue, which are both components of
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the Th2 response. IL-5 levels were therefore expected to decrease, IL-5 being 
the type-2 cytokine primarily responsible for eosinophilic inflammation.
There are several possible explanations as to why IL-5 protein was not reduced 
in the BAL fluid. One may be the site at which this analysis was carried out. 
Although treatment with M. vaccae has been shown to reduce type-2-mediated 
pulmonary inflammation, the failure of IL-5 protein production in the BAL fluid to 
fall in parallel has been observed before, both by colleagues at SR Pharma 
[Rosa Brunet, Hunt e ta l-  unpublished observations] and a collaborating group 
[Zuany-Amorim et al 2002a]. However, a reduction in IL-5 has been observed 
in the splenocytes of mice suffering from pulmonary inflammation and treated 
with M. vaccae, compared to levels from mice treated with saline [Wang et al
1998]. This suggests that M. vaccae may not be effecting IL-5 production at the 
site of inflammation, the lungs, but may influencing effector T cell function in 
lymphoid organs, such as the spleen.
Another possibility is that treatment with M. vaccae is affecting IL-5 production 
by effector T cells and eosinophils in the lung, but other cells are triggered to 
induce IL-5 instead. For example, inducible Tregs (termed Tr1 cells) have been 
observed to secrete IL-5 in addition to IL-10 [Groux et al 1997]. When CD4+ T 
cells isolated from DO11.10 mice were culture with splenic APCs and IL-10, 
they produced high levels of both IL-10 and IL-5, with little or no IL-2 and IL-4. 
These Tr1 cells also proliferated poorly in response to Ag stimulation. Since M. 
vaccae has been shown to induce a population of IL-10 secreting Tregs [Zuany- 
Amorim et al 2002b], it may be possible that these are another source of IL-5, 
masking any reductions that do occur as a result of treatment with M. vaccae. 
This may explain the inconsistent results observed between type-2 cytokine 
protein and message levels.
M. vaccae treatment of mice with allergic pulmonary inflammation generally 
results in a decrease in Th2-mediated inflammation. One possible mechanism 
for a decrease in type-2 responses is an induction of type-1 responses, already 
shown to occur In vitro [Mosmann et al 1989, Fitch et al 1993]. If this were the 
mechanism induced by M. vaccae, an increase in type-1 cytokines in the lungs 
would be expected.
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3.2 M. vaccae does not induce an elevated type-1 response
Although a decrease was observed in the Th2 cytokine IL-4, along with the 
reduced allergen-induced eosinophilia, this was not associated with an increase 
in type-1 responses. IL-12 and IFN-y message in whole lung tissue were 
investigated, but no difference was observed between allergic mice treated with 
M. vaccae and those treated with saline. In addition, no difference was 
observed in IFN-y protein levels in the BAL fluid. Increased neutrophilia, which 
characterizes Th1 -induced inflammation, was not detected in mice treated with 
M. vaccae. This confirms previous work, which reported in a similar model that 
the beneficial effects of M. vaccae were independent of IFN-y. Upon OVA 
challenge, IFN-y levels in the BAL fluid significantly decreased, when compared 
to levels in the BAL fluid of sensitized mice challenged only with saline. 
Treatment with M. vaccae did not induce any increase in IFN-y production, 
compared to levels in the BAL fluid of animals treated with saline, as also 
observed in this chapter. In addition, transfer of splenocytes from donor mice 
treated with M. vaccae to recipient allergic mice was shown to inhibit airway 
eosinophilia. Transfer of splenocytes together with IFN-y mAb did not reverse 
this suppression [Zuany-Amorim et al 2002a]. If M. vaccae inhibited excessive 
type-2 responses by inducing a Th1 response, blocking the action of IFN-y 
would have suppressed Th1 responses and prevented the beneficial effect of 
M. vaccae. These results suggest that M. vaccae is not inducing a decrease in 
Th2-mediated inflammation by initiating a type-1 response.
3.3 M. vaccae induces regulatory cytokine IL-10 protein
Rather than affecting the Th1/Th2 balance, treatment of OVA sensitized and 
challenged mice with M. vaccae induced production of IL-10 protein in the BAL 
fluid. This increase in IL-10 protein the BAL fluid of mice treated with M. vaccae 
has been observed previously in other studies [Zuany-Amorim et al 2002a, 
Zuany-Amorim et al 2002b, Adams et al 2004]. This is important, since IL-10 
has been described to have potent anti-inflammatory and immunoregulatory 
properties [Stampfli et al 1999, Umetsu et al 1999]. For example, in a murine 
model of pulmonary inflammation, administration of IL-10 directly into the lungs, 
using an adenoviral vector, results in an abrogation of airway eosinophilia and
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decreased IL-4 and IL-5 protein in the BAL fluid of mice sensitized and 
challenged with OVA. In this model, no increase in IFN-y protein was observed 
in the BAL fluid [Stampfli et al 1999]. Since IL-10 is induced by treatment with 
M. vaccae in the absence of IFN-y, this suggests the possibility of 
immunoregulation, perhaps by Tregs [Zuany-Amorim e ta !2002b].
3.4 M. vaccae does not induce regulatory cytokine TGF-p protein
Another cytokine with potential to initiate such a regulatory response is TGF-p 
[Shull et al 1992]. TGF-p has been observed to have an inhibitory effect on T 
cell proliferation [Ludviksson et al 2000]. In addition, TGF-p is sometimes 
secreted by inducible Tregs (termed Th3 cells) [Chen et al 1994]. In this thesis, 
TGF-p levels did not differ between treatment groups when measured in the 
BAL fluid. This cytokine is secreted, amongst other cell types, by eosinophils 
and bronchial epithelial cells, stimulating fibrosis and airway remodelling 
[Redington et al 1997]. Therefore, although it is described as important for 
suppression of allergic inflammation [Nakao et al 2001] TGF-p is also involved 
in the immunopathology of the disease. This duality means that measuring 
levels in the BAL fluid may not identify the actual cell source of TGF-p. M. 
vaccae treatment may be inhibiting one cell source of TGF-p whilst showing no 
effect on another. Hence no overall difference may be seen in the BAL fluid. 
This may account for the similar levels of TGF-p protein seen in the BAL fluids 
of animals treated with saline and those treated with M. vaccae. This suggests 
that investigation of individual cell sources may be necessary before differences 
in TGF-p levels can be detected.
3.5 M. vaccae does not affect the levels of immunoregulatory cytokines 
in whole lung tissue
There is a surprising contrast between results relating to mRNA and those 
relating to proteins. Elevated IL-10 protein was detected in the BAL fluid of 
OVA sensitized and challenged mice treated with M. vaccae. However, animals 
treated with M. vaccae did not have significantly elevated levels of IL-10 mRNA 
in whole lung tissue compared to animals treated with saline. Since M. vaccae-
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induced IL-10 protein production, an increase in IL-10 mRNA at the site of 
inflammation was anticipated.
The discrepancy in the IL-10 data may be in part due to differences between the 
heterogeneity of the cell populations present in the lung tissue and those 
present in the BAL fluid. Compared to BAL fluid, lung tissue comprises a 
heterogeneous number of cell types, which may act as sources of cytokine. 
Many cells produce IL-10, not just T cells and the effect M. vaccae is having on 
IL-10 secretion of individual cell populations is so far relatively unknown. 
Hence, cytokine levels detected from all the different tissue resident cells may 
mask any differences that exist in individual cell populations. This may cause 
some of the discrepancy observed in the data between cytokine protein and 
mRNA levels. Indeed, a large difference was observed in both IL-10 and TGF-p 
mRNA levels between individual animals. The presence of IL-10 protein at the 
site of inflammation does suggest that it plays an important role in the decrease 
Th2 responses observed.
4 Conclusion
In a murine model of allergic pulmonary inflammation, treatment of mice with M. 
vaccae significantly reduced the excessive Th2 response induced by OVA 
challenge. Levels of IL-4 mRNA were reduced in the lungs, as well as cellular 
infiltration and eosinophilia in the BAL fluid. This reduction of type-2 mediated 
inflammation was not a consequence of a type-1 response in the lungs. No 
difference in IL-12 or IFN-y expression was observed in whole lung tissue of 
mice treated with M. vaccae. In addition, no increase in IFN-y protein in the 
BAL fluid was detected. Therefore M. vaccae treatment does not induce a type- 
2 to type-1 response switch. Interestingly, IL-10 protein was elevated in the 
BAL fluid, suggesting an intriguing role for M. vaccae in immunoregulation. To 
identify the possible source of IL-10, a specific cell subtype was chosen based 
on the literature, for further study and will be discussed in Chapter 4.
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Chapter 4
Chapter 4
Results 2: Pulmonary CD11c+ APCs induced by treatment 
with Jiff. vaccae: Analysis of cytokine profile and phenotype
Data in this chapter have contributed towards two posters presented at the 
British Society of Immunology meetings in Harrogate in 2002 and 2003, and 
a manuscript published in the European Journal of Immunology.
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1 Introduction
Asthma is described as a type-2 mediated disease. However, to initiate Th2 
cell activation, Ag presentation by APCs is required before any response can 
be mounted. The group of cells collectively termed APCs, generally consist 
of DCs, M<£s and B cells. They are all capable of capturing and presenting 
Ag to T cells, consequently initiating T cell activation. The important role of 
APCs in allergic asthma is indicated by the increased numbers of APCs 
which infiltrate the lungs after allergen sensitisation and challenge 
[Lambrecht et al 1999]. In addition, APCs have also been shown to play a 
regulatory role in asthma [Spiteri et al 1991, Stumbles et al 1998]. Of the 
APCs, DCs are the most efficient at processing and presenting Ag to T cells, 
and have been shown to be the APCs responsible for initiation of asthma 
[van Rijt et al 2005]. This chapter investigates the possible role M. vaccae 
plays in inducing APCs with a regulatory phenotype.
1.1 APCs initiation of asthma
APCs are essential for both the induction of allergic asthma [Holt et al 2000, 
van Rijt et al 2005] and immunoregulation [Terrazas et al 2001]. Evidence 
for initiation of asthma will be presented below, and evidence for 
immunoregulation will be described later (sections 1.2 and 1.3). Much of the 
evidence for APC initiation of asthma has been obtained using DCs, but MOs 
and B cells are also capable of presenting Ag and playing a role in allergy. In 
this chapter, APCs will only be referred to as DCs if the reference being 
discussed has characterized them as DCs. Otherwise the term APCs will be 
used to refer to all cells capable of presenting Ag to T cells.
Upon inhalation, APCs capture Ag in the peripheral lung tissue. These cells 
then migrate to the LNs where T cells are continuously circulating 
[Vermaelen et al 2001]. Migration directly to the T cell areas of the LN is a 
specialised DC function, although MOs have also been observed to transport 
Ag to the LNs [Havenith et al 1993]. Once in the LNs, APCs express high
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levels of activation and co-stimulatory molecules, such as MHC II, CD80 and 
CD86 [Roitt etal 2001]. Ag is presented to the T cell via the interaction of the 
TCR with the peptide-MHC complex, and a co-stimulatory signal, such as the 
interaction of CD28 and the CD80 or CD86 ligand [Lenschow et al 1996]. 
Without APCs, allergen would never be presented to T cells, and a type-2 
response would not be initiated.
Interaction of the TCR and MHC II receptors on APCs and T cells, in 
conjunction with CD28 and B7 ligation, leads to T cell proliferation via 
production of IL-2 from T cells. This cytokine binds to low affinity IL-2 
receptors on the T cell surface, which consist of the p and y chains. 
Interactions between the MHC ll-TCR and co-stimulatory molecules also 
result in upregulation of the IL-2 receptor a chain. Together these chains 
form a high affinity receptor [Roitt et al 2001]. This means that once 
activated, T cells can be self-propagating.
Once activated, the CD4+ T cells are influenced by cytokine production to 
develop either a Th1 or Th2 phenotype. IL-12 secreted by M<E>s and DCs 
promotes IFN-y producing Th1 cells [Hsieh eta l 1993, Macatonia et al 1995]. 
In contrast, IL-4 secretion induces Th2 development. The primary source of 
IL-4 remains an area of debate, but possibly is secreted by mast cells or 
basophils [Swain etal 1990, Seder et al 1992].
Upon activation, Th2 CD4+ T cells secrete Th2 inflammatory cytokines, such 
as IL-4 and IL-5 [Caux eta l 1994]. This cytokine release results in increased 
IgE secretion, histamine release and eosinophil activation (described in more 
detail in Chapter 3). These inflammatory symptoms are all induced by type-2 
cytokines, and allergic asthma is therefore termed a type-2 mediated 
disease. APCs are responsible for activating CD4+ T cell cytokine secretion, 
and therefore APCs are essential for initiating type-2 mediated inflammation.
Experimental animal models have shown that APCs are essential for 
inducing type-2 mediated airway inflammation. DCs in particular are
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responsible for sensitisation to inhaled Ag, are essential for initiation of 
eosinophilia and are important for the maintenance of inflammation. For 
example, when injected in the airways, FITC-conjugated OVA was observed 
to be taken up by DCs, which migrated to the DLNs and induced T cell 
proliferation of naive OVA-specific T cells [Vermaelen e ta l2001], suggesting 
DCs play a role in T cell sensitisation to OVA. In addition, eosinophilic airway 
inflammation can be initiated in naive rats by simply transferring OVA-pulsed 
BM-DCs directly into the lungs [Lambrecht et al 2000a, Lambrecht et al 
2000b]. Furthermore, depletion of airway DCs during a secondary immune 
response to OVA resulted in a decrease of cellular infiltrate into the BAL fluid, 
reduced eosinophilia and impaired Th2 cytokine secretion. These suggest 
that DCs are involved both in the initiation and maintenance of airway 
inflammation.
MOs have also been observed as important in airway inflammation. In 
sensitized mice, depletion of alveolar M3>s resulted in significantly increased 
eosinophil numbers in the BAL fluid and IgE levels in the peripheral blood, 
when compared to animals where alveolar MOs were not depleted 
[McWilliam et al 1996, Lambrecht et al 1998, Lambrecht et al 1999]. In 
conclusion, APCs in general are a potential target for therapeutic 
intervention.
1.2 Suppression of T cell proliferation by APCs
APCs have also been associated with mucosal tolerance, and play an 
important role in regulating immune responses. There are several possible 
mechanisms that both DCs and MOs can adopt to regulate the immune 
system. One is by the secretion of suppressive molecules. One example of 
such a suppressive product is NO. When secreted from alveolar MOs, NO 
suppresses the function of local DCs, keeping them in an immature Ag 
capturing mode expressing low levels of MHC II and B7 [Holt et al 2000]. 
Lower expression of activation and co-stimulatory markers results in 
decreased T cell activation. Another example is the expression of
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indoleamine 2,3 dioxygenase (IDO). IDO depletes tryptophan, and results in 
release of toxic catabolites, such as L-kynurenine and picolinic acid. These 
can lead to inhibition of T cell proliferation [Frumento et al 2002, Swanson et 
al 2003].
APCs secreting regulatory cytokines have also been observed. For instance 
two poorly characterised monoclonal antibodies, designated RFD1 and 
RFD7, that bind to “M<l>”-like cells appear to define a regulatory macrophage 
subset. RFD1 is an interdigitating cell marker, which recognises an MHC II 
associated epitope. RFD7 is a mature tissue MO cell marker, which 
recognises a predominantly cytoplasmic Ag [Allison et al 1991, Taams et al
1999]. “Suppressive” MOs have been observed as RFD1+ RFD7+ and can 
be obtained in vitro following exposure of human blood derived monocytes to 
IL-10. These cells secrete IL-10 and can suppress T cell proliferation in vitro 
when cultured with allogeneic T cells in a Mixed Lymphocyte Reaction (MLR) 
assay [Tormey et al 1998]. These observations suggest that MOs may play 
a pivotal role in APC mediated immunoregulation through secretion of 
regulatory cytokines.
Similar secretion of regulatory cytokines by other APCs has also been 
observed. APCs that mediate regulatory responses have been observed 
following injection of mice with oligosaccharides derived from schistosome, 
lacto-A/-fucopentaose III (LNFPIII) and lacto-A/-neotetraose (LNnT). These 
modified APCs secreted low levels of proinflammatory cytokines, such as IL- 
12 and IFN-y, and increased levels of the regulatory cytokines IL-10 and 
TGF-p. These APCs also suppressed T cell proliferative responses in vitro, 
when added to CD4+ T cells previously stimulated with schistosome derived 
oligosaccharide [Terrazas e ta l2001].
Secretion of regulatory cytokines by APCs plays an essential role in the 
induction of Tregs [Akbari e ta l2001, Mahnke efa/2003]. For example, DCs 
isolated from LNs of mice 24 hours after exposure to OVA produced IL-10 
and induced OVA-specific T cells to also produce IL-10. These IL-10-
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secreting T cells blocked development of AHR and eosinophilia [Akbari et al
2001]. IL-10-secreting DCs expressed high levels of co-stimulatory markers, 
such as CD80, CD86 and ICOS-L [Akbari et al 2001, Akbari et al 2002]. 
CD80 (B7.1) and CD86 (B7.2), as well as being ligands for CD28, also bind 
the receptor CTLA-4 [Greenwald e ta l2002]. CTLA-4 is found on T cells and 
engagement of CTLA-4 with CD80 or CD86 results in suppressed T cell 
proliferation. Due to its negative regulatory properties, CTLA-4 is highly, 
although not exclusively, associated with Tregs [Grohmann ef a/2002].
The ICOS-ICOS-L pathway is a co-stimulatory pathway, similar to the CD28- 
B7 pathway. Engagement between ICOS and ICOS-L results in augmented 
T cell proliferation [Coyle et al 2000]. Although blockade of this co­
stimulatory pathway has suggested that it is essential for the initiation of type- 
2 mediated airway inflammation [Gonzalo eta l 2001, Tescubia et al 2001], it 
has also been observed to be involved in DC-mediated induction of Tregs. 
The development of OVA-specific IL-10 secreting Tregs and reduction of 
airway inflammation can be inhibited by blockade of ICOS-L with neutralising 
Abs. This suggests that the induction of Tregs may be dependent on the 
ICOS-ICOS-L pathway [Akbari e ta l2002].
1.3 Immunoregulatory cytokine secretion by APCs
The cytokines IL-10, TGF-p and IFN-a, have been reported to have 
immunoregulatory properties [Umetsu eta l 1999, Levings et al 2001, Ito eta l
2001]. Treg secretion of IL-10 and TGF-p is believed to mediate T cell 
tolerance [Akbari et al 2002, Zuany-Amorim et al 2002b]. APCs have also 
been observed to secrete these cytokines. Secretion of IL-10 in particular by 
APCs has been observed to suppress immune responses both in humans 
and murine models [Tormey et al 1998, Terrezas et al 2001]. For example, 
monocytes isolated from the peripheral blood of asthmatic patients are more 
efficient at stimulating an MLR when cultured with allogeneic T cells than 
monocytes isolated from healthy people. Treatment of these monocytes from
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asthmatic patients with exogenous IL-10 inhibited this T cell proliferation 
[Tormey etal 1998].
Even though the majority of the literature published on the regulatory 
properties of IL-10 and TGF-j3 focuses on secretion by Treg [Chen et al 1994, 
Groux eta l 1997, Levings et al 2002], the development of Tregs themselves 
also appears to be dependent upon the presence of these two cytokines 
[Nakao et al 2000, Zuany-Amorim et al 2002b, Akbari et al 2002, Oh et al 
2002, Dao Nguyen et al 2004]. Hence other cell sources of these cytokines 
are involved in Treg induction and Treg function. APCs have been observed 
to secrete IL-10 and under specific conditions TGF-p [Dhadopkar et al 2001, 
Mahnke et al 2001, Lutz et al 2002, Adams et al 2004]. There is now a 
growing body of evidence that a particular subset of APCs initiates Treg 
development from non-committed T cell or memory T cells. These APCs, 
referred to as “regulatory” APCs [Smits et al 2005], are DCs which tend to 
secrete low levels of IL-12 and high levels of IL-10 [Jonuleit et al 2000, 
Gasche e ta l2000, de Heer e ta l2004].
IFN-a is another cytokine described as having immunoregulatory properties. 
This cytokine has long been considered an important mediator of the innate 
immune response, and has stimulatory effects on NK cells and M<J>s. IFN-a 
is generally secreted by APCs in response to viral infections [Colonna et al
2002]. Recombinant IFN-a has been used as a short term Hepatitis C (HCV) 
treatment for several years, with 40-60% of patients responding to this 
treatment in combination with ribavirin (a broad spectrum antiviral). There is 
an improved level of response, when compared to the response of patients 
treated with ribavirin alone [Davis et al 1997, Hoffman eta l 2005]. Evidence 
has also highlighted the ability of IFN-a to support proliferation and survival 
of specific T cell subsets [Tough et al 1996, Akbar et al 2000]. For example, 
survival of anergic T cells is inhibited by the addition of IFN-a neutralising 
mAb to the in vitro culture [Lombardi et al 2000]. A proposed mechanism of 
this suppression is the ability of IFN-a to delay entry of cells into the Gi
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phase of the cell cycle, resulting in anergy of the effected cell [Dondi et al 
2004].
In addition to maintaining anergy, exogenous IFN-a, together with IL-10 has 
also been observed to induce Tregs. Culture of CD4+ T cells with IL-10 and 
IFN-a resulted in T cells that secreted IL-10 and had a low proliferative 
capability. When co-cultured in vitro with APCs and naive T cells, these 
Tregs significantly inhibited CD4+ T cell proliferation [Levings et al 2001]. 
IFN-a also upregulates the secretion of IL-10 by DCs. IL-10 in turn promotes 
the induction of T cells with regulatory properties [Bilsborough et al 2003]. 
These data suggest that IFN-a plays a role in the maintenance of immune 
tolerance, which is mediated by APCs.
1.4 Subsets of DCs
Of all APCs, DCs are the most efficient at presenting Ag to T cells. Early 
studies identified two main DC subsets, classified mainly by their cell surface 
phenotypes [Shortman et al 2002]. Some of these subsets of DCs have 
been observed to play immunoregulatory roles at different stages of maturity. 
The “myeloid” DCs were described as CD11c+CD11b+MHC ll+CD8a- [Inaba 
et al 1993] and are derived from monocytes or myeloid precursors that retain 
the ability to generate M^ >s [Ardavin et al 2001]. “Lymphoid” DCs were 
described as CD11c+CD11b-MHC ll+CD8a+ [Ardavin et al 1993] and 
originate from lymphoid-committed precursors [Ardavin ef a/2001].
More recently a third DC subset was described in humans [Celia et al 1999, 
Jarrossay ef a/2001]. These cells initially have plasma like morphology, but 
upon activation acquired DC morphology [Liu et al 2001, Shortman et al
2002]. Termed “plasmacytoid” DCs, they were observed to be CD11c+ Gr- 
1+ B220+ and CD8a+. Whether these cells are of myeloid or lymphoid origin 
remains unclear. These pDCs have the ability to suppress the generation of 
effector T cells. Stimulation of pDCs with CpG resulted in IL-10 secretion, 
and incubation of pDCs with naive CD4+ T cells resulted in Treg induction
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[Nakano et al 2001, Martin et al 2002]. They also secrete large amounts of 
IFN-a [Celia eta l 1999, Siegal eta l 1999, Dalod etal 2002].
1.5 Phenotype of Immunoregulatory DCs
It was originally believed that Tregs could only be induced by immature DCs. 
The current hypothesis is that immature, semi-mature and mature DCs can 
all play a role in Treg development. Immature DCs induce development of 
naive T cells into Tregs by lacking expression of co-stimulatory molecules, 
such as CD80 and CD86. CD80 and CD86 have two receptors to which they 
bind, CD28 and CTLA-4. Ligation of CD80 or CD86 with CD28 induces T cell 
activation and proliferation, whilst ligation with CTLA-4 inhibits T cell 
proliferation. In addition, CTLA-4 also has a stronger binding avidity to CD80 
and CD86 compared to CD28, so it is more likely to bind these ligands. With 
less CD80 and CD86 available, the CD28 receptor is out competed by the 
other co-stimulatory receptor CTLA-4 [Jonuleit e ta l2000].
Semi-mature DCs acquire the phenotype of mature DCs, for example high 
expression of co-stimulatory molecules and the ability to migrate to the LNs. 
However these DCs lack the ability to secrete proinflammatory cytokines, 
such as IL-12. They are however, producing IL-10 hence they are capable of 
triggering Treg development [Lutz et al 2002]. Mature DCs have also been 
observed to induce tolerance by release of IL-10. These DCs express high 
levels of MHC II, CD80 and CD86, and high levels of the chemokine CCR7 
and are capable of secreting IL-12 [Gasche et al 2000, Jump et al 2002, 
Wilson et al 2003, Kobayashi et al 2004]. DCs of all levels of maturity have 
been observed to induce tolerance. In addition, whether the DCs are from 
lymphoid or myeloid origin appears to make no difference to the probability 
that they will acquire a regulatory phenotype.
Under homeostatic conditions, three subsets of DCs have been observed to 
exhibit distinct regulatory features. CD11cHl mDCs that continuously migrate 
to the LNs as immature or semi-immature DCs have been shown to drive the
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development of Ag-specific Tregs. These Tregs are specific for ubiquitous or 
self-Ag [Geissmann et al 2002, Dhodapkar et al 2002]. Other studies show 
that immature pDCs can drive the development of both IL-10 producing 
CD8+ Tregs [Gilliet et al 2002] and CD4+ Tregs [Martin et al 2002]. These 
pDCs induce tolerance to harmless inhaled Ags in the lungs and pDCs have 
been observed in murine models of pulmonary inflammation [Kadowaki et al
2000].
Although the level of maturity does not appear to be a limiting factor, cytokine 
secretion of IL-10 is a feature of all “regulatory” DCs. DCs isolated from 
mucosal sites, such as the lung and PP, and in immune privileged sites, like 
the anterior chamber of the eyes, have a unique cytokine phenotype, 
secreting low levels of IL-12 and high levels of IL-10. These DCs also drive 
Treg development [Wilbanks et al 1990, Jump et al 2002, de Heer et al 
2004]. Interestingly, mDCs found at these mucosal surfaces appear to be 
mature, expressing high levels of MHC II, CD80 and CD86 [Akbari e ta l2002, 
Kobayashi e ta l2004, Goddard efa/2004].
In the lungs of OVA-sensitized mice, pDCs have been observed to take up 
inhaled Ag. When pDCs are depleted from the lungs, enhanced eosinophilic 
inflammation is observed after OVA challenge compared to control mice, 
which had not undergone pDC depletion. This suggests that pDCs may have 
the ability to inhibit eosinophilic inflammation in response to an otherwise 
harmless Ag. Depletion of pDCs also led to increased IgE and Th2 cytokine 
production, exacerbating pulmonary inflammation. Furthermore, the 
suppressive effects pDCs have on the initiation of airway inflammation are 
transferable. Adoptive transfer of OVA-pulsed pDCs to OVA-sensitized mice 
did not induce T cell division after OVA challenge, but suppressed it [de Heer 
et al 2004]. A possible mode of action that pDCs may adopt is to induce 
Tregs. T cells stimulated with pDCs obtained from the MLN of OVA-exposed 
mice developed the ability to suppress naive T cell proliferation [de Heer eta l 
2004]. Similar observations have been made from studying pDCs isolated 
from human peripheral blood. When pDCs were cultured together with CD4+ 
T cells, they adopted an anergic state and secreted increase amounts of IL-
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10 [Kuwana et al 2001]. These data suggest that pDCs may possibly be 
involved in protection against inflammatory responses to harmless Ag, 
maybe through Treg development.
1.6 Pathogen induction of “regulatory” DCs
A role for “regulatory” DCs fits well with the revised version of the hygiene 
hypothesis. “Regulatory” DCs may be important for homeostasis at mucosal 
surfaces, but these same properties can easily be manipulated by invading 
pathogens to evade immunity. Several pathogens have been observed to 
induce “regulatory” DCs as a way of preventing immune responses. One 
mechanism adopted involves blocking the ability of the APCs to mature, 
thereby preventing T cell activation. Examples of pathogens that exploit this 
mechanism include the malarial parasite Plasmodium falciparum and HCV. 
Plasmodium falciparum infected erythrocytes have been observed to bind to 
the scavenger receptor CD26 on DCs. This binding inhibits LPS-induced 
maturation. The capacity for the DC to activate naive T cells is therefore 
inhibited [Urban et al 1999]. In patients chronically infected with HCV, 
elevated numbers of IL-10 secreting CD4+ T cells have been observed 
[MacDonald et al 2002]. In vitro studies using human DCs suggest that DC 
maturation, upregulation of co-stimulatory molecules and cytokine production 
are severely inhibited upon exposure to the HCV core protein [Dolganiuc eta l
2003]. This suggests that Plasmodium falciparum and HCV may induce 
“regulatory” APCs to evade immunity.
An alternative mechanism used by pathogens to evade immunity is through 
the manipulation of the cytokine secretion of DCs. These pathogens induce 
the production of variable quantities of IL-10, a cytokine previously described 
as instrumental for the development of Tregs. Examples of such pathogens 
include the helminth Schistosoma mansoni and the bacterium Bordetella 
pertussis. In vitro studies with human monocyte derived DCs have shown 
that Schistosoma mansoni derived lysophosphatidylserine (which is a 
glycerophospholipid involved in mast cell activation and hence histamine 
release) triggers maturation of DCs. These DCs are characterised by
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decreased secretion of IL-12, and increased production of IL-10 [van der Kleij 
et al 2002]. Bordetella pertussis, which causes whooping cough, which is 
often complicated by severe pneumonia, has been observed to induce IL-10 
secreting T cells. These T cells were isolated from the lungs of infected 
mice, and were specific for the Bordetella pertussis derived virulence factor 
filamentous haemagglutinin (FHA). FHA enhances maturation of DCs, 
inhibits DC secretion of IL-12 and induces DC production of IL-10. These 
mature DCs drive development of Tregs, which are capable of blocking Th1 
responses in secondary, unrelated infections such as Influenza A virus 
[McGuirk et al 2002]. These data suggest that pathogens avoid host 
detection by suppressing the immune system using “regulatory” DCs. It is 
also possible that pathogenic microbes mimic the mechanisms already 
adopted by non-pathogenic organisms, such as M. vaccae, to avoid 
activation of the immune system.
1.7 Hypothesis
In a murine model of OVA-induced pulmonary inflammation treatment with M. 
vaccae results in the induction of Tregs, which played a role in alleviating 
symptoms of disease. IL-10 and TGF-p have been shown as essential for 
the function of these Tregs, since blockade in vivo with mAbs prevented the 
therapeutic affect of M. vaccae. This suggests that the Tregs which M. 
vaccae induces are dependent on these cytokines for their function [Zuany- 
Amorim e ta l2002b]. An alternative source of IL-10 and TGF-p, besides from 
Tregs themselves, may therefore exist. Treg induction by DCs which secrete 
regulatory cytokines, such as IL-10 has been observed by several groups 
[Jump eta l 2002, Akbari eta l 2002, de Heer et al 2004, Jonuleit et al 2000, 
Lutz et al 2002, Gasche et al 2000]. For this reason, the effect of treatment 
with M. vaccae on pulmonary CD11c+ APCs phenotype was investigated.
CD11c is a marker that is expressed by lymphoid DCs, mDCs and pDCs 
[Metlay et al 1990]. It is also known as the integrin aX subunit, and 
combines with CD18 (integrin p2 subunit) to form the integrin p150,95 
(aXp2). Abs for CD11c are often used for isolation of DCs. In spite of this,
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the existence of cells that express both CD11c and the MO markers F4/80 or 
CD14 has been described [Ancuta et al 2000, Hogg eta l 2003]. This leaves 
doubts on the identity of a CD11c+ cell as a DC or MO. Therefore, in this 
thesis CD11c+ cells will be referred to as APCs.
This chapter investigates pulmonary CD11c+ APCs isolated from allergic 
mice, treated with or without M. vaccae, to establish whether these APCs 
have regulatory potential. Production of regulatory cytokines, such as IL-10, 
TGF-p and IFN-a by pulmonary CD11c+ APCs was measured. These cells 
were also characterized for cell surface marker expression to establish their 
phenotype.
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2 Results
2.1 Cytokine message of pulmonary CD11 c+ APCs
The role of pulmonary CD11c+ APCs in a murine model of pulmonary 
inflammation was investigated. It was determined whether treatment with M. 
vaccae induced IL-10-producing pulmonary CD11c+ APCs. CD11c+ APCs 
have previously been observed to produce IL-10 following i.n. exposure to 
OVA, and have been reported to be critical for the development of Tregs 
[Akbari et al 2001, Akbari et al 2002]. The following results were observed 
when both preventive and therapeutic allergy protocols were carried out.
To determine whether treatment with M. vaccae induced IL-10 expression in 
CD11c+ APCs, these cells were isolated from the lungs of mice with allergic 
pulmonary inflammation by positive selection with microbeads. RNA was 
extracted and the cytokine profile analysed. Cytokines IL-10, TGF-p and 
IFN-a were observed to be significantly elevated in the CD11c+ APCs 
isolated from the lungs of mice treated with M. vaccae, when compared to 
cells from animals treated with saline (Figures 4-1 a, Figure 4-1 b & Figure 4- 
1 c). This effect was not seen in the CD11c- fraction collected. These 
results suggest that M. vaccae treatment induces CD11c+ APCs to express 
elevated levels of IL-10, TGF-p and IFN-a message.
To confirm that the observed increase in mRNA is restricted to 
immunoregulatory cytokines, IL-12 and IFN-y message were also analysed. 
Expression levels of IL-12 and IFN-y were found to be unchanged after 
treatment with M. vaccae, in both the pulmonary CD11c+ and CD11c- cell 
fractions (Figure 4-2 a & Figure 4-2 b). These observations suggest that in a 
model of allergic pulmonary inflammation, treatment with M. vaccae induces 
a population of CD11c+ APCs in the lung tissue, which preferentially produce 
immunoregulatory cytokines IL-10, TGF-p and IFN-a mRNA, but not 
message levels of type-1 cytokines IL-12 and IFN-y.
141
7.5x1 O'2
XQ
CL
0  5.0x10* 
o
o
'■§ 2.5 x10'2- <o
0> cc
(a)
IL-10
BD BD
5 xIO'2*1
P - 2-1^  4 x10
®  3 x10-2-
0 o> 2x102'5
CO
S 1 xIO •2 _
CD11c+ CD11c- 
TGF-P
3x1 O'2
O 2x1 O'2
1 x10
□ Positive Control -  treatment with 
saline
Treatment 
Group - 
treatment with 
M. vaccae
CD11c+ CD11c- 
IFN-a
(c)
BD BD
CD11c+ CD11c-
Figure 4-1: Expression of IL-10, TGF-p and IFN-a message by Pulmonary CD11c+ 
and CD11c- cells. Mice were treated with M. vaccae (black bar) or saline (white bar), 
sensitized with OVA/Alum, and challenged with OVA. Cells were isolated from the lungs 
and separated into CD11c+ and CD11c- fractions. IL-10 (a), TGF-p (b) and IFN-a (c) 
message levels were analysed using real time RT-PCR (samples from each treatment 
group were pooled, n=6-8 mice per group. Data expressed as mean ± SD, BD = below 
detection, * p<0.05 compared to positive control one-tailed Student’s f-test used to 
determine significant differences).
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Figure 4-2: Expression of IFN-y and IL-12 by Pulmonary CD11c+ and 
CD11c- cells. Mice were treated with M. vaccae (black bar) or saline (white 
bar), sensitized with OVA/Alum, and challenged with OVA. Cells were isolated 
from the lung and separated into CD11c+ and CD11c- fractions. IFN-y (a) and 
IL-12 (b) message from cells was analysed using real time RT-PCR (samples 
from each treatment group were pooled, n=6-8 mice per group. Data expressed 
as mean, one-tailed Student’s f-test used to determine significant differences).
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2.2 Cytokine protein levels of pulmonary CD11c+ APCs
To confirm that the increase observed in the levels of cytokine mRNA is 
translated into increased protein levels, ELISA measurements for IL-10 and 
TGF-p were done. CD11c+ cells isolated from the lungs of mice with 
pulmonary inflammation were left to incubate overnight in Growth Medium at 
37°C, 5% C02. Supernatants were then collected and concentrated as 
described in Chapter 2. Protein analysis revealed elevated IL-10 and TGF-p 
levels in the supernatants from the cultures containing CD11c+ cells isolated 
from mice treated with M. vaccae, when compared to levels in the 
supernatant of cultures of CD11c+ cells isolated from animals treated with 
saline (Figure 4-3 a & Figure 4-3 b). In summary, both protein and message 
data suggest that CD11c+ APC cells isolated from the lungs of mice with 
allergic pulmonary inflammation secrete elevated levels of IL-10 and TGF-p 
protein following treatment with M. vaccae.
2.3 Effect of M. vaccae on the ICOS-ICOS-L pathway in naive mice
Several research groups have investigated the role of the ICOS-ICOS-L 
pathway in the initiation of allergic asthma. For example, blockade of the 
ICOS-ICOS-L pathway has been observed to ameliorate pulmonary 
inflammation [Gonzalo et al 2001, Tesciuba et al 2001, Akbari et al 2002]. 
These data suggest that ICOS may play a role in the initiation of allergic 
inflammation. The potential role of ICOS in allergic inflammation led to the 
investigation of the effect of M. vaccae treatment on the ICOS-ICOS-L 
pathway.
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Figure 4-3: Production of IL-10 and TGF-p Protein by Pulmonary CD11c+ 
cells. Mice were treated with M. vaccae (black bar) or saline (white bar), 
sensitized with OVA/Alum, and challenged with OVA. CD11c+ cells were 
isolated from the lungs, pooled and cultured overnight. IL-10 (a) and TGF-p (b) 
protein production was analysed using ELISA (samples from each treatment 
group were pooled, n=6-8 per group, data expressed as mean ± SD, * p<0.05 
compared to negative control one-tailed Student’s f-test used to determine 
significant differences).
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To determine whether M. vaccae treatment did indeed influence the 
expression of ICOS or ICOS-L, preliminary experiments were carried out 
using naive mice. Naive BALB/c mice were injected s.c. with either M. 
vaccae or saline. Animals were sacrificed on days 0 (before treatment), and 
days 1, 8 and 21 after treatment, when the spleens were harvested. RNA 
was extracted from the homogenised tissue and real time RT-PCR analysis 
of ICOS and ICOS-L expression carried out on the samples.
Following M. vaccae treatment, ICOS expression in the spleen of naive mice 
was observed to increase on day 1, albeit not significantly. By day 21 it had 
decreased, to below the level expressed by untreated animals (Figure 4-4 b). 
When Student’s t-test was used to test significance between Day 0 and Day 
21, there was a significant difference (p<0.05). However, a Student’s t-test 
can only be used if there are two groups to compare. In this time course, 
there were four different time points, so an ANOVA was used. This reduction 
was not significant (p=0.372) when tested by one-way ANOVA, but since the 
Student’s t-test showed a significant difference between day 0 and day 21, 
this suggested M. vaccae may have a possible effect on ICOS expression, 
especially since the ICOS expression in the spleens of animals treated with 
saline did not alter over time (Figure 4-4 a). No significant differences were 
observed in the expression of ICOS-L, neither over time nor between 
treatment groups (Figure 4-5 a & Figure 4-5 b). In summary, although 
treatment of naive mice with M. vaccae had no effect on the expression of 
ICOS-L in whole spleen tissue, a small decrease in ICOS expression was 
observed 3 weeks after treatment, albeit not a significant one. These initial 
observations were encouraging enough to warrant analysis of the expression 
in the lung tissue of animals with allergic pulmonary inflammation.
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Figure 4-4: Time Course Experiment. Naive mice, injected s.c. with either 
saline (a) or M. vaccae (b) on day 0, were sacrificed on days 1, 8 and 21. ICOS 
message in spleen tissue was then analysed using real-time RT-PCR (n=4 per 
group, data expressed a mean ± SEM, ANOVA used to test for significant 
differences).
Saline treated Naive mice
2.5x10-°1n
2.0x10 '01
r  3 r  i.5xio-°1
1,0x10'01
5 .0 x 1 0 02
0.0x1 O’00
d)
>
ro
o
k .
-j x
00 Q 
O
o  ^  -  o
2.5x1 O'01 t
2 .0 x 1 0 '° 1-
1.5x10-°1-
1.0x10'01-
Day after treatment 
M.vaccae treated Naive mice
(b)
cDO
E
<
5.0x1 Q-°2-
0 .0 x 1 0 °°-
I M S Sg 1
■ H P
1 8 
Day after treatment
Figure 4-5: Time Course Experiment. Naive mice, injected s.c. with either saline 
(a) or M. vaccae (b) on day 0, were sacrificed on days 1, 8 and 21. ICOS-L 
message in spleen tissue was then analysed using real-time RT-PCR (n=4 per 
group, data expressed a mean ± SEM, ANOVA used to test for significant 
differences).
148
2.4 Effect of M. vaccae on the ICOS-ICOS-L pathway in mice with 
pulmonary inflammation
Since results from M. vaccae treatment of naive mice on ICOS expression 
were intriguing (Figure 4-6 a), expression of ICOS and ICOS-L in the lung 
tissue of mice with allergic pulmonary inflammation was examined. The 
ICOS-ICOS-L pathway is important for the development of type-2 responses 
[McAdam 2000, Sharpe 2002]. Since blockade of ICOS has been observed 
to improve allergic pulmonary inflammation [Gonzalo ef a/2001, Tesciuba et 
al 2001, Akbari et al 2002], treatment of mice with allergic pulmonary 
inflammation with M. vaccae was expected to reduce the levels of ICOS and 
ICOS-L expressed in the lung.
Upon challenge with OVA, ICOS expression in the whole lung tissue of mice 
sensitized to OVA significantly increased (p=0.0103). However, no 
significant difference was observed between mice treated with M. vaccae and 
animals treated with saline (Figure 4-6 a). ICOS-L expression in whole lung 
tissue did not change after OVA challenge. Treatment with M. vaccae also 
had no effect on ICOS-L expression. When tested by one-way ANOVA, 
changes in ICOS-L expression were not significant (p=0.1015) (Figure 4-6 b). 
In conclusion, OVA challenge of sensitized mice significantly elevates ICOS 
expression, but treatment with M. vaccae did not affect ICOS expression. In 
addition, the expression of ICOS-L mRNA in whole lung tissue was not 
significantly altered by treatment with M. vaccae.
2.5 Effect of M. vaccae treatment on ICOS-L expression of pulmonary 
CD11c+ APCs
Although no significant differences were seen in ICOS or ICOS-L expression 
in whole spleen tissue, it was still deemed worthwhile to look at the 
expression of ICOS and ICOS-L in the pulmonary CD11c+ APCs, since the 
induction of Tregs has been shown to be dependent upon the ICOS-ICOS-L 
pathway [Akbari et al 2001, Akbari et al 2002]. The effect that M. vaccae
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Figure 4-6: Expression of ICOS and ICOS-L in the Lung Tissue of a Murine 
Model of Allergic Pulmonary Inflammation. Mice were treated with nothing 
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data expressed as mean ± SEM, ANOVA used to test for significant differences, 
with a Bonferroni post test which compares all data groups).
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treatment had on ICOS-L expression by these pulmonary APCs was 
investigated. Initially, levels of ICOS-L mRNA were elevated. However, no 
difference was detected between the ICOS-L mRNA extracted from the cells 
of both treatment groups in subsequent experiments. No significant changes 
were observed in the expression of ICOS-L by the pulmonary CD11c+ APCs 
isolated from the lungs of animals treated with M. vaccae.
2.6 Phenotype of CD11 c+ APCs
As previously mentioned, the term APCs covers a relatively large group of 
cells with the ability to present Ag to T cells. CD11c is a marker universally 
used for DC isolation, but has been detected also on MOs [Ancuta et a /2000, 
Hogg et al 2003]. Therefore, to further characterise these pulmonary APCs, 
isolated CD11c+ cells were stained for a selection of cell surface markers 
and analysed using FACS. Staining for CD3, B220 and F4/80 confirmed 
limited T cell, B cell or MO contamination. MHC II (l-Ad), CD80 and CD86 
were detected on cells isolated from the lungs of both the animals treated 
with M. vaccae and saline, although no significant difference was seen 
between them (Figure 4-7). Surprisingly CD40 staining appeared to be 
negative when analysed. In addition, CD8-a was also undetected on the 
CD11c+ APCs (data not shown). In conclusion, the pulmonary CD11c+ 
APCs isolated stained negative for CD3, B220 and F4/80, which suggests 
they are DCs. Analysis of activation and co-stimulatory markers suggests 
that there is no significant difference between CD11c+ APCs isolated from 
the lungs of mice treated with M. vaccae and those isolated from the lungs of 
animals treated with saline.
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Figure 4-7: Examples of MHC II, CD80 and C86 positive staining. Pulmonary 
CD11c+ cells stained positive for MHC II, CD80 and CD86 from allergic mice 
treated with M. vaccae. Saline treated animals showed similar staining. Staining 
for MHC II ranged from between 44-50%, CD80 between 21-52% and CD86 
between 34-40%. All data was analysed using WinList.
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3 Discussion
APCs have the ability to influence T cell development, and are essential for 
activating T cells [Hawiger et al 2001, Terazzas et al 2001]. IL-10 producing 
APCs, which can influence Treg development and function, have been 
described in the literature [Tormey et al 1998, Akbari et al 2001, Swanson et 
al 2003]. Akbari and colleagues have shown that the adoptive transfer of 
these CD11c+ APCs induces unresponsiveness in recipient animals [Akbari 
et al 2001]. To determine whether M. vaccae-induced CD11c+ APCs with a 
“regulatory” phenotype, cytokine expression of pulmonary CD11c+ APCs 
from mice treated with M. vaccae was investigated by RT-PCR and ELISA.
3.1 M. vaccae induces APCs with an immunoregulatory cytokine 
profile
In Chapter 3, elevated IL-10 protein was detected in the BAL fluid of mice 
treated with M, vaccae [Adams et al 2004], which suggested a possible role 
for M. vaccae in immunoregulation. This hypothesis is supported by data 
collected by collaborators, who have observed IL-10 secreting Tregs induced 
by M. vaccae treatment. Moreover, these Tregs actually require the 
presence of IL-10 and TGF-p for function. Indeed, the ability of the IL-10 
secreting Tregs, induced by M. vaccae treatment, to alleviate pulmonary 
inflammatory symptoms was blocked by in vivo administration of anti-IL-10 
and anti-TGF-p mAbs [Zuany-Amorim 2002b]. This suggests there may be 
an alternative source of IL-10 and TGF-p besides from Tregs. APCs were 
chosen for study, since a review of the literature suggested that APCs with 
regulatory properties existed.
Previous studies have shown that following i.n. exposure to OVA, CD11c+ 
APCs express high levels of IL-10 mRNA. The presence of IL-10 influences 
T cell development, as Ag specific CD4+ T cells cultured in vitro in the 
presence of these CD11c+ cells acquire a Treg phenotype. Further work has 
also showed that adoptive transfer of IL-10 producing CD11c+ cells induces
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unresponsiveness to OVA sensitization and challenge in recipient mice. 
Thus, there is convincing evidence to suggest that CD11c+ APCs play a 
critical role in the regulation of the immune responses in the lungs [Akbari et 
al 2002, Swanson et al 2003]. For these reasons, CD11c+ APCs were 
focussed on for further investigation and results from this chapter suggest 
that M. vaccae induces pulmonary CD11c+ APCs that secrete both the 
cytokines IL-10 and TGF-p, as well as IFN-a.
IL-10, TGF-p and IFN-a have all been reported by many to play a significant 
role in the differentiation and effector function of Tregs [Levings et al 2001, 
Read et al 2001, Akbari et al 2001, Akbari et al 2002, Levings et al 2002, 
Zuany-Amorim et al 2002b]. However, the mechanisms by which they affect 
T cells are still largely unclear. It is likely that these cytokines have work in 
conjunction with each other. For example, TGF-p and IL-10 have been 
described as modulators of one another. TGF-p has been observed to 
influence both production and function of IL-10. A single i.n. dose of a 
plasmid encoding active TGF-pi (pCMV-TGF-pi) prevented the 
development of Th1 mediated experimental colitis induced by the 
haptenating reagent, 2, 4, 6-trinitrobenzene sulfonic acid (TNBS). This 
treatment led to the expression of TGF-p 1 mRNA in the intestinal lamina 
propria and spleen, as well as the appearance of TGF-pt- producing T cells 
and MOs in these tissues. Enhancement of IL-10 production was also 
observed in these cells. If pCMV-TGF-p1 was co-administrated with anti-IL- 
10, IL-10 production was inhibited and the suppression of IL-12 reversed. 
This suggests that TGF-p promotes IL-10 production, which suppresses IL- 
12 secretion and hence inhibits development of colitis [Kitani e ta !2000].
IL-10 has also been shown to modulate TGF-p production. Addition of IL-10 
in vitro enhanced CD4+ T cell production of TGF-p in response to stimulation 
by anti-CD3, anti-CD28 and IL-2 [Seder et al 1998]. In the presence of TGF- 
p and IL-2, T cells have been reported to become non proliferative after 
activation, and acquire the ability to suppress the responses of other T cells 
[Levings ef a/2002, Steinbrink et a l2002, Ludviksson efa/2000].
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IFN-a also has immunoregulatory properties. It has been observed to 
upregulate IL-10 production by DCs [Levings et al 2001, Ito et al 2001, 
Stordeur eta! 2002, Bilsborough et a /2003] and prevent anergic T cell death 
[Lombardi et al 2000]. Together, all these cytokines derived from APCs may 
be acting in synergy to promote Treg development, which are responsible for 
inhibition of pulmonary inflammation. Therefore, the presence of these 
cytokines in protein and message form is an important observation and 
suggests a role for these M. vaccae-induced CD11c+ APCs in 
immunoregulation.
3.2 M. vaccae does not affect type-1 cytokine profile of CD11c+ APCs
Although IFN-y is usually thought to be produced mainly by T cells, APCs 
secretion of IFN-y has been described in the literature [Le Page et al 2000, 
Fukao et al 2000]. For this reason, expression of IFN-y message by 
pulmonary CD11c+ APCs was investigated alongside IL-12, which initiates T 
cell production of IFN-y production and hence a Th1 response [Alzona et al 
1995]. The increases observed in the immunoregulatory cytokines IL-10, 
TGF-p and IFN-a from in CD11c+ APCs following M. vaccae treatment was 
not mirrored by an increase in the proinflammatory cytokines L-12 and IFN-y. 
These data further support the earlier observations in Chapter 3, that M. 
vaccae does not induce a type-1 response.
3.3 Treatment with M. vaccae affects the ICOS-ICOS-L pathway in 
naive mice
In this chapter, M. vaccae is reported to induce CD11c+ APCs, which secrete 
immunoregulatory cytokines. The ICOS-ICOS-L pathway has been 
described as important in the induction of Tregs [Akbari et al 2002] so the 
effect that M. vaccae has on ICOS and ICOS-L expression became an area 
of interest. No difference was seen in the ICOS-L expression after M. vaccae 
treatment. A large number of cells express ICOS-L, such as DCs, B cells 
and T cells [Ling et al 2000], particularly in the spleen where numerous
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heterogeneous populations of cells reside. This would make differences 
difficult to detect when looking at whole tissue, since M. vaccae may affect 
the activation of individual cell types differently. Any difference in ICOS-L 
expression present in any one population may be masked by the expression 
of ICOS-L by other cells. Treatment with M. vaccae may affect ICOS-L 
expression on one cell subtype differently from another. In contrast, ICOS 
expression is almost uniquely limited to activated T cells [Hutloff et al 1999]. 
Although the groups treated with M. vaccae had slightly less ICOS-L mRNA 
in the spleen on days 1, 8 and 21 compared to day 0, but this general 
decrease is also observed in the group treated with saline. This may be an 
artefact of the injection, for example LPS on the animals’ coat being injected 
along with the saline or M. vaccae.
3.4 Treatment with M. vaccae does not affect the expression of ICOS 
or ICOS-L in the lungs of mice with pulmonary inflammation
The decision to analyse ICOS and ICOS-L expression in the lung tissue of 
allergic animals was taken because of published data, suggesting that ICOS 
and ICOS-L are important for the induction of Tregs [Akbari et al 2002]. It 
was difficult to predict whether expression of ICOS and ICOS-L would 
increase or decrease after treatment with M. vaccae, because of conflicting 
published reports. Blockade of ICOS in murine models of pulmonary 
inflammation inhibits airway eosinophilia [Gonzalo et al 2001, Tesciuba et al 
2001], suggesting treatment with M. vaccae should decrease ICOS 
expression. On the other hand, blockade of ICOS-L was shown to inhibit 
development and function of Tregs [Akbari et al 2002], which suggests 
treatment with M. vaccae should increase expression of ICOS and ICOS-L. 
In this thesis no significant difference in ICOS expression was observed 
between mice treated with saline and animals treated with M. vaccae.
Along with being important for Treg induction, ICOS is also involved in 
initiating Th2 responses [Coyle et al 2000]. Data in this thesis supports this 
observation. Upon OVA challenge of sensitized mice, ICOS expression 
significantly increased. This was expected, since ICOS is upregulated after
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naive T cell activation by the CD28-B7 co-stimulatory pathway [Hutloff et al 
1999, Mueller et al 2000, Chambers et al 2001]. Several other groups have 
observed the importance of the ICOS-ICOS-L pathway in the onset of allergic 
airway inflammation. Blockade of ICOS at various stages of sensitisation 
and challenge with both OVA and Schistosoma mansoni egg Ag, inhibits 
airway inflammation and eosinophilia [Gonzalo et al 2001, Tesciuba et al
2001]. In view of these data, it would be expected that ICOS and ICOS-L 
expression should decrease in the lung tissue, since both blockade of ICOS 
and treatment with M. vaccae result in ameliorated inflammatory symptoms.
The finding of no difference in ICOS or ICOS-L expression in whole lung 
tissue may be explained by the fact that whole tissue was used to analyse 
ICOS and ICOS-L expression. Expression of ICOS by effector T cells and 
Tregs could be detected altogether. The same could have happened with 
ICOS-L expression by different APC subsets. Any changes in expression on 
particular cell subsets could be masked by the changes in expression by 
other cells. Separation of different T cell types, or APC subsets, may be 
required to observe any differences. M. vaccae may be affecting ICOS 
expression by Tregs, which may not be picked up in whole tissue. This was 
the reason for investigating the expression of ICOS-L in the pulmonary 
CD11c+ APCs isolated from mice with allergic pulmonary inflammation.
3.5 Treatment with M. vaccae does not affect ICOS-L expression in 
pulmonary CD11c+ APCs
In this thesis, treatment with M. vaccae was found to enhance IL-10, TGF-p 
and IFN-a expression by pulmonary APCs. Therefore, the expression of 
ICOS-L in the same APCs was expected to increase similarly. Surprisingly, 
the expression levels of ICOS-L on CD11c+ APCs did not differ between the 
cells isolated from the lungs of mice treated with M. vaccae and those from 
mice treated with saline. This result may be due to a technical limitation. 
The observation of an increased ICOS-L expression in the first experiment 
could have been due to a contaminating population, such as B cells, which 
also express ICOS-L. ICOS is known to be important in T cell-B cell
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interactions [McAdam et al 2000]. In vivo, blockade of ICOS results in 
deficient T-cell-dependent B-cell responses. Germinal centre formation is 
impaired and Ig class switching is defective, including production of IgE 
[Tafuri efa/2001, McAdam efa/2001].
B cell contamination remains a possibility, as these particular samples were 
not checked by FACS staining for CD11c+ purity or B cell contamination. All 
subsequent CD11c+ samples were B220-, suggesting no B cell 
contamination. Treatment with M. vaccae may have effected the ICOS-L 
expression of the B cells, which may have been contaminating the CD11c 
cell separation from the first experiment, and not have effected the 
expression on CD11c+ APCs. The differences picked up in the first 
experiment could therefore have been coming from a contaminating 
population, which was not present in subsequent experiments. IL-4 has been 
shown to play a major role in downregulating B cell expression of ICOS-L. 
Treatment of B cells with IL-4, when in culture together with CD4+ T cells, 
resulted in rapid reduction in ICOS-L expression by the B cells [Liang et al 
02]. It is a possibility that since M. vaccae is reducing IL-4 production in the 
lungs, downregulation of B cell ICOS-L expression is not occurring. 
Therefore, animals treated with M. vaccae, which have less IL-4 in the lungs, 
would have B cells which express more ICOS-L, when compared to animals 
treated with saline, which have elevated IL-4 levels in the lungs.
An increase in ICOS-L expression on the pulmonary CD11c+ cells was 
anticipated, since T cell tolerance by DCs is dependent on the ICOS-ICOS-L 
pathway. Blocking ICOS-L abrogated the inhibitory capacity of DCs [Akbari 
et al 2002]. This may be explained by the fact that these cells were isolated 
from the lungs and not from a lymphoid organ. APCs may need to migrate to 
the LNs before maturation occurs. Expression of ICOS has been observed 
to upregulate 24-48 hours after activation. Expression of ICOS and ICOS-L 
is also abundant in places like the spleen, tonsils and thymus. Since these 
are all lymphoid organs, this suggests that migration of APCs to the LNs may 
be necessary before these APCs are capable of influencing T cell 
development. It may therefore have been more appropriate to test for ICOS-
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L expression on APCs isolated from one of the LNs [Coyle et al 2004]. The 
timing of the experiment may also explain why no difference was observed. 
A longer period between final challenge and cell isolation may be needed 
before differences between treatment groups can be identified.
3.6 Phenotype of CD11 c+ APCs
The pulmonary CD11c+ cells isolated from mice with pulmonary inflammation 
in this thesis were further characterized by FACS analysis. Pulmonary 
CD11c+ cells were stained for a variety of cell surface markers, to establish 
firstly if any contaminating populations existed. All CD11c+ cell fractions 
stained negative for lymphocyte markers CD3 and B220. This eliminated 
both T cells and B cells populations from the CD11c+ cell fractions. CD3 and 
B220 were both detected in the CD11c- cell fractions obtained from the 
separation. These data suggest that the positive selection process did not 
non-specifically bind any T cell or B cell populations, hence the CD11c+ cells 
subsequently used in all further experiment were not significantly 
contaminated with lymphocyte populations which may have affected results.
Although contamination of the CD11c+ cells with lymphocyte populations 
was limited, the actual classification of these cells was still unclear. CD11c 
was used to isolate these cells, which is a commonly used marker for DCs 
isolation. The existence of cells that express both CD11c and F4/80 or 
CD14, which are common M<E> markers have also been described [Ancuta et 
al 2000, Hogg et al 2003]. To try and establish if these CD11c+ cells isolated 
from the lungs of mice with pulmonary inflammation were indeed DCs, they 
were also stained for F4/80. F4/80 was not detected on the CD11c+ cells 
from either the mice treated with M. vaccae or the ones treated with saline. 
This result suggests that the contamination of the CD11c+ cells with M<J>s 
was limited. However, there is some confusion as to whether alveolar M<I>s 
express F4/80. Some groups have observed that alveolar MOs do not 
express F4/80 [Tedjo e ta !2003], whilst other groups have observed that they
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do [Maus et al 2001]. It would therefore have been useful to stain CD11c+ 
cells with another M0> marker, such as CD14.
Three main types of DC exist, lymphoid DCs, mDCs and pDCs. The pDC 
subset is generally associated with immunoregulation [Martin et al 2002, 
Lambrecht e ta !2005] and has been shown to secrete large amounts of IFN- 
a [Celia et al 1999, Dalod et al 2002]. Since IFN-a mRNA was observed in 
M. vaccae-induced pulmonary APCs, CD11c+ cells were stained with CD8a, 
which along with B220 have been described as pDC markers [Nakano et al
2001]. CD8a was not detected on the CD11c+ cells isolated from the lungs 
of allergic mice. The lack of CD8a suggests that these DCs are not 
plasmacytoid, although there is evidence for a subset of pDCs that are 
CD8a- [de Heer et al 2004]. Incidently, the cells also stained negative for 
B220, another marker expressed by some pDCs [Nikolic et al 2002, 
Bilsborough et al 2003, Okada et al 2003]. This is surprising as the 
properties of M. vaccae-induced CD11c+ cells mirror those of pDCs, which 
have been shown to provide protection against inflammatory responses to 
harmless inhaled Ags [Colonna et a! 2002, Lambrecht et al 2003]. More 
staining needs to be done, possibly Gr-1 and CD11b to establish that the 
CD11c+ cells are not pDCs.
The difference in cytokine profile between CD11c+ cells isolated from the 
lungs of mice treated with saline versus mice treated with M. vaccae 
suggests that M. vaccae is inducing a population of “regulatory” DCs. 
Therefore, the differences in cell surface marker expression were 
investigated. Although these CD11c+ APCs were probably DCs, their state 
of maturity was not known. The co-stimulatory markers MHC II, CD80, CD86 
and CD40 were chosen since their expression was enhanced on the IL-10 
secreting DCs described by Akbari et al as tolerogenic DCs [Akbari et al 
2001, Akbari e ta l 2002]. CD11c+ cells isolated from both the saline and M. 
vaccae treatment groups stained positive for MHC II (l-Ad), CD80 and CD86. 
This was expected, since these molecules are upregulated after cell 
activation [Mahanonda et al 2002, Sahoo et al 2002, Cheng et al 2003].
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However, no significant differences in CD11c+ expression levels were 
detected between the two groups.
The surprising observation was the lack of CD40 staining detected on the 
CD11c+ cells isolated from mice treated with either saline or M. vaccae. This 
was unexpected since the CD40-CD40-L pathway is involved in T cell 
activation by DCs. CD40 has been observed to upregulate upon OVA 
challenge [Vermaelen et al 2003]. Also, when DCs are exposed to M. 
tuberculosis, another member of the mycobacterial genus, CD40 expression 
increases [Gonzalez-Juarrero et al 2001]. It may be possible that M. vaccae 
activates APCs through a different pathway to the CD40 pathway. CD40 
signalling is associated with IL-4 production [Flynn et al 1998]. Since IL-4 
has been shown to decrease in the lungs of mice treated with M. vaccae, it is 
possible that another co-stimulatory pathway is activated and the CD40 
pathway is not involved. However, this does not explain the lack of CD40 on 
CD11c+ APCs isolated from mice treated with saline, where IL-4 is in 
abundance.
Another possibility is that these observations are due to technical problems. 
During characterization of pulmonary CD11c+ APCs by FACS, extremely 
high autofluorescence of the cells was detected. Gating specific populations 
did not significantly alter this. Autofluorescence of APCs has been observed 
before and often hampers attempts to characterize APCs, since they emit 
within the wavelengths of the two most commonly used flurochromes, FITC 
and PE. This significantly interferes with the detection of weakly expressed 
cell surface markers [Keping et al 2000]. It is possible that this occurred with 
CD40 and CD8a staining, which in this thesis were not detected on the 
pulmonary CD11c+ APCs isolated from the allergic mice. CD40 is unlikely to 
be completely unexpressed by all APCs in the lungs, so it is possible that 
CD40 and, maybe CD8a, was weakly expressed, and was indistinguishable 
from the APCs autofluorescence.
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One method that may help reduce this autofluorescence, is the treatment of 
cells with crystal violet. Crystal violet quenches both cell surface and 
intracellular fluorescence. The problem with this method is that the crystal 
violet alters the FSC/SSC, but does decrease background noise by up to 
80%. Detection of low level Ab staining is possible after treatment with 
crystal violet [Keping et al 2000]. Any further FACS staining of pulmonary 
APCs should use the crystal violet method to maximize cell surface marker 
staining.
4 Conclusion
This chapter describes the finding of M. vaccae-induced pulmonary CD11c+ 
APCs, expressing increased levels of both IL-10 and TGF-p mRNA and 
protein. In addition, elevated IFN-a message, another cytokine described to 
have immunoregulatory potential, was detected. Pulmonary CD11c+ cells 
from mice treated with either saline or M. vaccae showed no significant 
differences in cell surface marker expression of MHC II, CD80 or CD86. The 
effect of M. vaccae on the ICOS-ICOS-L pathway was also addressed albeit 
without significant findings. CD11c+ cells may play a pivotal role in 
immunoregulation of responses in the lung, and may be a potential target of 
M. vaccae. Therefore, these cells were further investigated in the next 
chapter to establish what immunoregulatory role they played in a mouse 
model of allergic pulmonary inflammation.
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Chapter 5
Chapter 5
Results 3: Immunoregulatory role of M. vaccae-induced
pulmonary CD11c+ cells
1 Introduction
APCs, in particular DCs, have been shown to play a regulatory role in asthma 
[Spiteri et al 1991, Stumbles et al 1998]. This thesis proposes that pulmonary 
CD11c+ APCs, that secrete IL-10, TGF-p and IFN-a, can be isolated from the 
lungs of mice with allergic inflammation that have been treated with M. vaccae. 
The mechanism by which these APCs induce tolerance is unclear. It is not yet 
determined whether the M. vaccae-induced CD11c+ cells are “suppressor” 
APCs in their own right, or whether they induce suppressive responses via 
other cells. This chapter examines two of the possible mechanisms that 
CD11c+ APCs have been observed to adopt to inhibit inflammatory responses 
in the lungs.
1.1 Mechanisms of action adopted by “regulatory” APCs
There are several mechanisms, which “regulatory” APCs are involved in, and 
which result in inhibition of immune responses. One such mechanism is the 
failure of APCs to fully mature in response to certain foreign, non-pathogenic 
Ags. It has been observed that upon exposure to these Ags, such as OVA, T 
cell proliferation In vivo is initiated in the MLNs [Lambrecht e ta l 2000, Hammad 
e ta !2003]. Despite the activation of effector T cells, the functional outcome for 
the immune response is tolerance [Lambrecht e ta l2000]. This may explain the 
failure of harmless Ags to fully activate airway DCs, leading to immature or 
semi-mature DCs, which induce an abortive T cell response. The T cells fail to 
become effector cells and undergo apoptosis [Gett e ta l2003]. This hypothesis 
is supported by the observation that stimulation of T cells with immature DCs 
results in T cell death [Brimnes et al 2003]. Immature APCs express low levels 
of MHC II, CD80 and CD86, so activation of T cells will not occur and apoptosis 
would occur. This is known as deletion tolerance.
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APCs can also inhibit immune responses by secreting proteins that have a 
suppressive effect. These are termed “suppressor” APCs. For example, a 
subset of DCs which express IDO has recently been described both in human 
peripheral blood and mouse spleen [Munn et al 2002, Mellor et al 2003, 
Wakkach e ta l2003]. It has been suggested that APCs express active IDO can 
inhibit T cell proliferation by depleting tryptophan. This enzymatic reaction, 
which results in an accumulation of toxic catabolites, such as L-kynurenine and 
picolinic acid [Frumento et al 2002, Swanson et al 2003]. APC expression of 
IDO has been shown to upregulate after exposure to IL-10 [Munn e ta l2002] or 
by CTLA-4-B7 interactions [Grohmann et al 2002]. Inhibition of immune 
responses, initiated by “suppressor” APCs and T cell deletion, may operate in 
conjunction with APC induction of Tregs, to maintain homeostasis in the 
periphery and at mucosal surfaces.
1.2 Induction of Tregs by APCs
An alternative hypothesis to “suppressor” APCs is that of APCs induction of 
Tregs. These Tregs are responsible for the suppression of immune responses. 
APCs are known to influence T cell development, and the induction of Tregs by 
APCs has been reported [Hawiger et al 2001, Liu et al 2002]. For example, 
following respiratory exposure to OVA, lung DCs have been shown to produce 
IL-10. IL-10 has been appears essential, since blockade of IL-10 with mAbs 
inhibits Treg development. Adoptive transfer of these DCs to recipient allergic 
mice induced Ag-specific unresponsiveness [Akbari et al 2002]. Both mDCs 
and pDCs have been observed to induce Tregs [Martin et al 2002, Geissmann 
e ta l2002]. For example, murine CD8a+B220+ pDCs isolated from the thymus, 
spleen or LNs, have the ability to induce Treg differentiation from OVA-specific 
transgenic T cells. When these pDCs were co-cultured together with OVA- 
specific transgenic T cells, and stimulated with IL-2 and OVA, no T cell 
proliferation was observed [Martin et al 2002]. Both mDCs and pDCs, tend to 
secrete low levels of IL-12 and high levels of IL-10 [Jonuleit e ta l2000, Gasche 
et al 2000, de Heer et al 2004]. Along with IL-10, TGF-p has also been 
observed as essential for the development of Tregs. TGF-p7' mice have 
significantly reduced numbers of CD4+CD25+ Tregs in their peripheral blood,
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compared to TGF-p competent mice [Marie et al 2005]. In addition, blockade of 
TGF-p with a neutralising mAb inhibited the function of Tregs induced by M. 
vaccae [Zuany-Amorim et al 2002b]. These data highlight the possible 
importance of IL-10 and TGF-p in the induction of tolerance by Tregs.
1.3 Contact dependent mechanisms of Tregs
The exact mechanisms adopted by Tregs to suppress immune responses are 
unclear. In vitro studies suggest that naturally occurring CD4+CD25+ Tregs 
operate via a contact dependent manner [Thornton et al 1998, Shevach et al
2002]. Possible receptors involved in contact dependent tolerance could 
include CTLA-4 and GITR. CTLA-4 is a negative co-stimulatory receptor, which 
inhibits proliferation of activated T cells. Although CTLA-4 shares ligation of the 
B7 ligands with CD28, it binds them with 500 times more avidity [Munn et al
2002]. This suggests it may out compete CD28 ligation, resulting in an 
inhibitory T cell signal. GITR is a positive co-stimulatory receptor, which ligates 
with GITR-L. Ligation results in T cell proliferation [Tone e ta l2003]. Although 
the activation of the GITR pathway results in proliferation of T cells, studies 
have still associated it with Tregs function. For example, blockade of GITR with 
a mAb inhibits CD4+CD25+ Treg function in vitro [McHugh et al 2002]. In vivo 
injection of GITR mAb leads to induction of autoimmune diseases, such as 
autoimmune gastritis [Shimizu et al 2002]. More recent literature however 
suggests that GITR expression is upregulated on non-regulatory CD4+CD25+ T 
cells, and ligation renders them resistant to suppression by Tregs [Stephens et 
al 2004]. Hence the role of GITR, along with contact dependent mechanisms, is 
still unclear.
1.4 Cytokine dependent mechanisms of Tregs
It has been suggested that naturally occurring Tregs operate by contact 
dependant mechanisms. In contrast, Tregs induced by foreign Ag have been 
observed to secrete IL-10 and TGF-p, and act in a cytokine mediated manner 
[Chen et al 1994, Groux et al 1997, Cottrez et al 2004]. These cytokines are 
responsible for initiating mechanisms that lead to inhibition of immune 
responses and maintaining peripheral tolerance at mucosal surfaces.
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IL-10 has been shown to be essential in inhibiting local immune responses, 
since addition of IL-10 into the lungs by viral vector reversed OVA induced 
localised eosinophilic inflammation in the lungs [Stampfli et al 1999]. The actual 
mechanisms activated by IL-10 are still unclear. One such mechanism, the 
role of IL-10 in Ig class switching, has however long been understood. IL-4 
influences B cells to secrete IgE, which leads to mast cell and basophil 
activation and histamine release, resulting in inflammation. The presence of IL- 
10 influences B cells to secrete lgG4, rather than IgE. lgG4 is an Ig found 
abundantly in the serum of healthy volunteers, and does not cause mast cells or 
basophils to release histamine [Banchereau eta l 1994]. It has been shown that 
IL-10 secreted by inducible Tr1 cells plays a role in Ig class switching 
[Satoguina et al 2005]. Culturing IL-10 secreting Tr1 cells and B cells together 
with tetanus toxoid, anti-CD3 and anti-CD28 resulted in enhance levels of lgG4 
production, which was dependent upon the presence of the Tr1 cells. This 
suggests that Ig class switching may be one mechanism by which IL-10 
secreting Tregs inhibit airway inflammation.
TGF-p, although not exclusively secreted by Tregs, has been shown as 
essential in Treg development and activity [Maloy et al 2001, Shevach et al 
2002]. TGF-p also has an inhibitory effect on T cells undergoing differentiation. 
CD4+ T cells isolated from naive transgenic DO11.10 mice and treated with 
OVA and TGF-p proliferated poorly, when compared to CD4+ T cells treated 
OVA alone [Ludviksson 00]. TGF-p has also been observed to influence the 
development of Foxp3+ T cells. Foxp3 is a transcription factor, which has been 
described as “unique” to Tregs.
1.5 Foxp3
Foxp3 is a recently described marker, which has been shown to be expressed 
only by Tregs. The Foxp3 gene codes for the transcription factor protein 
Scurfin, which is expressed in naturally occurring CD4+CD25+ Tregs and is 
essential for Treg development and activity [Hori et al 2003, Khattri et al 2003, 
Fontenot et al 2003, Ling et al 2004]. This is highlighted by mutations in the 
Foxp3 gene. Transgenic mice, which have a disrupted Foxp3 gene, are known
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as scurfy. Mutations in the Foxp3 gene lead to development of autoimmune 
diseases, such as type-1 diabetes [Brunkow et al 2001, Khattri et al 2003]. In 
addition, whereas normally Tregs proliferate poorly, but have the ability to 
suppress proliferation of other T cells. CD4+CD25+ cells isolated from Foxp3- 
/- mice are able to proliferate themselves, and do not suppress the proliferation 
of effector T cells. This suggests that they do not have regulatory properties 
[Fontenot et al 2003, Khattri et al 2003]. The lymphoproliterative disorder 
observed in FoxpJ1' mice is inhibited by transfer of CD4+CD25+ Tregs from 
healthy Foxp3+/+ mice, suggesting that Foxp3 is essential for functional Tregs. 
In contrast, FoxpS1' mice injected with CD4+CD25- T cells from healthy animals 
went on to develop clinical and pathological symptoms of the 
lymphoproliferative autoimmune disease [Fontenot et al 2003]. This suggest 
that only CD4+CD25+Foxp3+ T cells have the ability to suppress the onset of 
the autoimmune diseases observed in mice lacking Foxp3 expression.
TGF-p has been shown to be essential for the development of Foxp3+ Tregs in 
a murine model of diabetes. Peng and colleagues showed that, in a NOD/SCID 
murine model of diabetes, pulsing the islets in the pancreas with TGF-p during 
the priming phase of the disease inhibits the onset of diabetes by promoting the 
expansion of CD4+CD25+Foxp3+ T cell populations. This protection can also 
be transferred to recipient NOD/SCID mice by cell transfer [Peng et al 2004]. 
The importance of TGF-p in the maintenance of Foxp3 expression and 
regulatory function of peripheral CD4+CD25+ Tregs has been shown using 
TGF-p7' mice. Cells isolated from TGF-p'A mice were used to investigate the 
effect of absence of TGF-p in vitro. Purified splenic CD4+ T cells from TGF-p'/_ 
mice were activated with anti-CD3 and anti-CD28 in the presence or absence of 
TGF-p in vitro. Foxp3 expression was elevated in the CD4+ T cells treated with 
TGF-p. TGF-p also lead to the differentiation of CD4+CD25+ Tregs from 
peripheral CD4+CD25- T cells in vitro [Chen et al 2003, Fantini et al 2004, 
Marie et al 2005]. These results suggest that, in addition to playing a role in 
Treg function, TGF-p also stimulates Treg differentiation. The presence of the 
cytokines IL-10 and TGF-p, along with elevated Foxp3 expression would be 
suggestive of Treg development.
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1.6 Hypothesis
M. vaccae-induced pulmonary CD11c+ APCs have been shown in this thesis to 
express immunoregulatory cytokine message and protein (Chapter 4). This 
thesis proposes that CD11c+ APCs may play a pivotal role in the induction of 
Treg development. M. vaccae has already been observed to induce Tregs. As 
well as producing IL-10, the function of these Tregs was reported to be IL-10 
and TGF-p dependent [Zuany-Amorim et al 2002b]. The pulmonary CD11c+ 
APCs described herein may therefore be good candidate source of IL-10 and 
TGF-p, and may play a role in Treg induction.
This chapter attempts to further characterize the role played by M. vaccae- 
induced CD11c+ APCs. To establish whether or not the protective effect of M. 
vaccae could be transferred via the CD11c+ APCs, these cells were passively 
transferred to recipient allergic mice. In addition, to determine if these cells had 
Treg inducing abilities, an in vitro assay was set up by co-culturing CD11c+ 
cells with naive CD4+ T cells. Immunoregulatory cytokines and Treg markers 
were investigated to establish whether these CD11c+ cells are capable of 
influencing Treg function.
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2 Results
2.1 Cellular infiltration of the BAL fluid in donor mice
Two possible mechanisms for immunoregulation mediated by M. vaccae- 
induced pulmonary CD11c+ APCs were investigated. The first being that the 
cytokine production from the APCs directly causes downregulation of Th2 cell 
effector function. The second is that CD11c+ APCs induce Tregs, which are 
responsible for downregulating the immune response.
To determine whether the pulmonary CD11c+ cells had regulatory function per 
se, a passive transfer experiment was carried out. CD11c+ cells isolated from 
the lungs of M. vaccae or saline treated mice (donors), were transferred i.t. to 
untreated mice with allergic pulmonary inflammation (recipients). Donor mice 
were treated with M. vaccae or saline on day -21, and underwent a preventive 
allergy protocol (Figure 2-1). Animals were sacrificed on day 23 and the 
number of cells infiltrating the BAL fluid was determined to confirm the OVA 
challenge had induced airway inflammation, and to determine whether the M. 
vaccae treatment had suppressed inflammation.
In the BAL fluid of donor mice, a significant decrease was observed in the 
number of cells recovered from mice treated with M. vaccae when compared to 
animals treated with saline (Figure 5-1). In summary, treatment of donor mice 
with M. vaccae significantly alleviated airway inflammation, when compared to 
the cellular infiltrate in the BAL fluid of mice treated with saline. This finding 
suggests that the donor allergy protocol worked. The CD11c+ cells isolated 
from the lungs of these animals were subsequently transferred to mice with 
pulmonary inflammation.
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Figure 5-1: Pulmonary inflammation of donor mice. Donor animals were 
subjected to a preventive allergy protocol. Mice were treated with M. 
vaccae (black bar) or saline (white bar), sensitised with OVA/Alum, and 
challenged with OVA. Upon sacrifice, the BAL fluid was obtained to 
determine cellular infiltrate. Pulmonary CD11c+ cells from the lungs of 
these animals were then used in a passive transfer experiment. (n=6-8 per 
group, # p<0.05 compared to animals treated with saline, data expressed as 
mean ± SEM, one tailed student f-test used to test for significant 
differences^
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2.2 Cellular infiltration in the BAL fluid of recipient mice upon CD11c+ 
cell transfer
To determine whether pulmonary CD11c+ cells from mice treated with M. 
vaccae had regulatory abilities per se, CD11c+ cells isolated from the lungs of 
the donor mice treated with saline or M. vaccae were transferred i.t. to recipient 
animals with allergic pulmonary inflammation (Figure 2-3). As an additional 
control, a group of mice received an i.t. injection of saline alone. After injection 
of CD11c+ cells directly into the lungs, mice were challenged i.t. with OVA and 
sacrificed on day 23. Cellular counts from the BAL fluid were then obtained to 
determine whether the affect seen after treatment with M. vaccae could be 
transferred by pulmonary CD11c+ APCs (Figure 5-2).
After CD11c+ cell transfer and OVA challenge, no significant difference in the 
number of cells obtained from the BAL fluid was observed in mice injected with 
CD11c+ cells from animals treated with M. vaccae (Figure 5-2), when compared 
the cell number in the BAL fluid of animals injected with either saline alone or 
with CD11c+ cells from animals treated with saline. This lack of effect was not 
due to a failure of M. vaccae to reduce inflammation in donor mice, since 
cellular infiltrate was significantly decreased in the BAL fluid of these mice 
(Figure 5-1).
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Figure 5-2: Passive Transfer Experiment. Pulmonary CD11c+ cells were 
isolated from M. vaccae (black bar) and saline-treated (white bar) donor allergic 
mice (cells pooled, n=6-8 per group). 2 x 105 CD11c+ were transferred to 
recipient mice with allergic pulmonary inflammation. A recipient group, which 
underwent the allergy protocol but had only saline transferred was also included 
(shaded bar). Cellular influx in the BAL fluid was determined (n=4 per group, 
data expressed as mean ± SEM, ANOVA used to determine significant 
differences).
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2.3 Purity of CD4+ and CD11 c+ cell isolations
Since injection of M. vaccae-induced CD11c+ APCs into the lungs of recipient 
mice with pulmonary allergic inflammation did not transfer the protective effect 
of M. vaccae (Figure 5-2), alternative mode of action was investigated. To 
determine whether the APCs have the ability to induce development of Tregs, 
an in vitro assay was set up, with pulmonary CD11c+ cells and naive splenic 
CD4+ T cells, an aliquot of the CD4+ and CD11c+ separated cells were stained 
and analysed by FACS to establish purity. CD4+ cells had a purity of >90% 
(Figure 5-3 a & Figure 5-3 b), and the CD11c+ cells had a purity of >70% 
(Figure 5-4). This leads to the possibility that results obtained from the in vitro 
assay may be a consequence of contaminating APC or B cell populations in the 
T cell fraction. However, FACS staining of the CD4 separated fraction 
suggested that they were not contaminated with B220+ B cells. Although only 
of 70% purity, the CD11c+ cells stained negative for B220 and CD3, suggesting 
that lymphocyte contamination was limited.
2.4 In vitro assay optimisation
Optimisation of APC.T cell ratio in vitro was necessary to determine the most 
efficient Effector to Stimulator ratio, to give optimal cytokine levels. Preliminary 
experiments were carried out using three different CD11c+:CD4+ ratios, 1:100, 
1:40, 1:20. Cultures set up with the ratio of 1 CD11c+ cell to every 100 CD4+ T 
cells produced minimal levels of cytokines, such as IL-4 and IL-10 (Figure 5-5 a 
&Figure 5-5 b). The 1:40 and 1:20 CD11c+:CD4+ T cell ratio appeared to give 
higher levels of cytokines than the 1:100 CD11c+:CD4+ T cell ratio. Availability 
of pulmonary CD11c+ APCs was a limiting factor of these experiments, so the 
1:40 APC:T cell ratio was used in all further experiments, since this ratio gave 
higher levels of cytokines compared to the 1:100 but fewer cells are required to 
set up an in vitro assay than when using the 1:20 ratio. All wells received a set 
number of CD4+ T cells, 5 x 105, and the numbers of CD11c+ APCs were 
varied accordingly, in a final volume of 200jil.
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Figure 5-3: CD4+ splenocytes staining. CD4+ T cells isolated from the spleens 
of naive mice by negative selection are shown by both the forward/side scatter (a) 
and by CD4+ staining (b) to be a heterogeneous population, above 90% positive. 
Contaminating cells consisted of a small number of CD8+ cells (<5%) but no B 
cells (B220-). Cells were used in an in vitro culture with CD11c+ cells. WinList 
was used to analyse the data.
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Figure 5-4: Pulmonary CD11c+ cell staining. CD11c+ cells separated from 
the lungs of allergic mice by positive selection were shown by FACS staining to 
be above 70%. All cells were CD3- and B220-, eliminating lymphocyte 
contamination. WinList was used to analyse the data.
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Figure 5-5: Optimisation of in vitro culture. Pulmonary CD11c+ cells were isolated 
from allergic mice treated with M. vaccae (black bar) or saline (white bar). These cells 
were co-cultured with naive CD4+ T cells at a ratio of 1:100, 1:40 and 1:20 CD11c+:CD4+ 
cells. T cells were also cultured alone with anti-CD3 and IL-2 (checked bar). CD11c+ 
cells were culture alone in Growth Medium (without anti-CD3 and IL-2). Levels of IL-4 (a) 
and IL-10 (b) protein were measured in the culture supernatants. The 1:40 ratio gave a 
high cytokine release whilst using less cell numbers than the 1:20 ratio (CD11c+ cells from 
each treatment group were pooled, n=6-8 per group, data expressed mean ± SD).
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Initially pulmonary CD11c+ cells were cultured together for 96 hours with naive 
CD4+ T cells isolated from the spleen in plates pre-coated with anti-CD3. 
However, this protocol failed to induce any consistent profiles in either cytokine 
production or Foxp3 expression. It is possible this may not have been a long 
enough period of time to observe the effect of APCs on T cell development. To 
improve on the original protocol, the literature was reviewed to investigate 
potential amendments. A second protocol, based on one described by 
McDonald and colleagues, was developed. This protocol rested the CD11c+ 
and CD4+ cells together for 72 hours before stimulating them first with IL-2 and 
then with plate bound anti-CD3 [MacDonald ef a/2001]. This protocol lasted a 
total of 7 days rather than the 4 days of the original protocol. After 7 days, the 
supernatants from the cultures were taken for analysis by ELISA, and the cells 
were flash frozen for RNA analysis.
To determine the type of T cell response being induced by the pulmonary 
CD11c+ APCs, IFN-y, IL-4 and IL-5 levels in the in vitro culture supernatants 
were determined by ELISA. Levels of the Th1 cytokine IFN-y were below 
detection, but high levels of IL-4 and IL-5 protein were detected, suggesting the 
CD11c+ APCs from allergic mice were primed to induce a Th2 response. 
Interestingly, no significant differences were detected between cultures 
containing pulmonary CD11c+ cells from mice treated with saline and those 
from mice treated with M. vaccae (Figure 5-6 a & Figure 5-6 b).
2.5 In vitro assay immunoregulatory cytokine mRNA production
Since there was no difference in the levels of type-2 cytokine in the 
supernatants regardless of treatment, IL-10 and TGF-p mRNA levels in the 
culture cells were also measured. RNA was extracted from the culture cells and 
RT-PCR analysis carried out. Significantly elevated levels of IL-10 and TGF-p 
mRNA were observed in the cell cultures containing the pulmonary CD11c+
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I□ Positive Control - CD11c+ cells from mice treated with saline
Treatment Group -  CD11c+ cells from mice treated with M. 
vaccae
Negative Control -  T cells cultured 
alone
Negative Control -  CD11c+ cells 
cultured alone
Figure 5-6: In vitro assay Th2 cytokines. Pulmonary CD11c+ cells were isolated from 
allergic mice treated with M. vaccae (black bar) or saline (white bar). These were co­
cultured with naive CD4+ T cells at a ratio of 1:40 CD11c+:CD4+ T cells. T cells were also 
cultured alone with anti-CD3 and IL-2 (checked bar). CD11c+ cells were culture alone in 
Growth Medium (without anti-CD3 and IL-2). IL-4 (a) and IL-5 (b) protein measurements 
were determined from the culture supernatants (CD11c+ cells from each treatment group 
were pooled, n=6-8 mice per group, data expressed mean ± SD, Students f-test used to 
test significant differences).
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□ Positive Control - CD11c+ cells from mice treated with saline
Treatment Group -  CD11c+ cells from mice treated with M. 
vaccae
Negative Control -  T cells cultured 
alone
Negative Control -  CD11c+ cells 
cultured alone
Figure 5-7: In vitro assay message. Pulmonary CD11c+ cells were isolated 
from allergic mice treated with M. vaccae (black bar) or saline (white bar). These 
were co-cultured with naive CD4+ T cells. T cells were also cultured alone with 
anti-CD3 and IL-2 (checked bar). CD11c+ cells were culture alone in Growth 
Medium (without anti-CD3 and IL-2). IL-10 (a) and TGF-p (b) mRNA levels were 
determined from the cells in each culture (CD11c+ cells from each treatment 
group were pooled, n=6-8 mice per group, data expressed as mean ± SD, * 
p<0.05 compared to positive control, Students Mest was used to test for 
significant differences. This experiment was carried out at least three times).
182
cells from allergic mice treated with M. vaccae (Figure 5-7 a and Figure 5-7 b).
When an APC internalises and processes Ag, it usually migrates to the LNs 
before it presents the Ag on its MHC receptor. The lung is not a lymphoid 
organ, and this may affect the ability of CD11c+ cells isolated from this organ to 
induce Tregs. For this reason, the same experiment was also carried out using 
CD11c+ cells isolated from the spleens of mice with allergic pulmonary 
inflammation, treated with M. vaccae or saline. Significantly elevated levels of 
IL-10 and TGF-p mRNA were also observed when CD11c+ cells from the 
spleen of allergic mice treated with M. vaccae were co-cultured with naive 
CD4+ T cells (Figure 5-8 a and 5-8 b).
2.6 In vitro assay immunoregulatory cytokine production
To establish whether the increase in IL-10 and TGF-p mRNA observed is also 
observed at the protein level, the supernatants from the in vitro cultures were 
analysed by ELISA. Despite no difference being seen in the levels of Th1 or 
Th2 cytokines, an elevated amount of IL-10 protein was found in the 
supernatants from the wells, which contained cells from animals treated with M. 
vaccae (Figure 5-9). TGF-p levels were below detection. This increase in IL-10 
was also observed in the supernatants from the wells that contained splenic 
CD11c+ cells from mice treated with M. vaccae (Figure 5-10). Interestingly, 
less IL-10 was secreted from the cultures containing CD11c+ cells isolated from 
the spleen, compared to those containing pulmonary CD11c+ APCs. In 
summary, co-culture of CD11c+ APCs from allergic mice treated with M. vaccae 
with naive CD4+ T cells showed an increase in IL-10 protein production. The 
IL-10 was not secreted from the T cells cultured alone, nor was detected in 
CD11c+ cells cultured alone in medium.
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Positive Control - CD11c+ cells from mice treated with
■ Treatment Group -  CD11c+ cells from mice treated with M. vaccae
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Figure 5-8: In vitro assay message. CD11c+ cells were isolated from the 
spleen of allergic mice treated with M. vaccae (black bar) or saline (white bar). 
These were co-cultured with naive CD4+ T cells. T cells were also cultured 
alone with anti CD3 and IL-2 (checked bar). CD11c+ cells were culture alone in 
Growth Medium (without anti-CD3 and IL-2). CD11c+ cells were culture alone in 
Growth Medium (without anti-CD3 and IL-2). IL-10 (a) and TGF-p (b) mRNA 
levels were determined from the cells in each culture (CD11c+ cells from each 
treatment group were pooled, n=6-8 mice per group, data expressed as mean ± 
SD, * p<0.05 compared to positive control, Students f-test was used to test for 
significant differences. This experiment was carried out twice).
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Figure 5-9: In vitro assay IL-10 protein. Pulmonary CD11c+ cells were isolated 
from allergic mice treated with M. vaccae (black bar) or saline (white bar). These 
cells were co-cultured with naive CD4+ T cells. CD4+ T cells were also cultured 
alone with anti-CD3 and IL-2 (checked bar). CD11c+ cells were culture alone in 
Growth Medium (without anti-CD3 and IL-2). IL-10 protein measurements were 
determined from the culture supernatants (CD11c+ cells from each group were 
pooled, n=6-8 mice per group, data expressed mean ± SD, * p<0.05 compared to 
positive control, Students Mest was used to test for significant differences).
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□ Positive Control - CD11c+ cells from mice treated with saline
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Figure 5-10: In vitro assay IL-10 protein. Splenic CD11c+ cells were isolated 
from allergic mice treated with M. vaccae (black bar) or saline (white bar). These 
cells were co-cultured with naive CD4+ T cells at a ratio of 1:40 CD11c+:CD4+ 
cells. T cells were also cultured alone with anti-CD3 and IL-2 (checked bar). 
CD11c+ cells were culture alone in Growth Medium (without anti-CD3 and IL-2). 
IL-10 protein measurements were determined from the culture supernatants 
(CD11c+ cells from each treatment group were pooled, n=6-8 mice per group, data 
expressed mean ± SD, * p<0.05 compared to positive control, Students f-test was 
used to test for significant differences).
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2.7 In vitro assay Foxp3 mRNA expression
Data obtained from the experiments outlined so far failed to identify which cell 
types were secreting IL-10, the T cells or the APCs. Expression levels of 
Foxp3, a specific marker for the development of Tregs, were investigated to 
determine whether M. vaccae-induced CD11c+ cells were inducing Tregs. 
Foxp3 mRNA levels in the cells containing pulmonary CD11c+ cells from mice 
treated with M. vaccae were increased compared to levels from the cells from 
mice treated with saline, albeit not significantly (Figure 5-11 a).
The increase of Foxp3 expression was not significant in the cultures containing 
pulmonary CD11c+ APCs from mice treated with M. vaccae. The same in vitro 
assay was set up using splenic CD11c+ cells isolated from the spleen of allergic 
mice. Elevated levels of Foxp3 message was detected in the cells containing 
splenic CD11c+ APCs from mice treated with M. vaccae (Figure 5-11 b). In this 
case, Foxp3 expression was more pronounced than in the assays containing 
pulmonary CD11c+ APCs. In summary, when cultured together with naive 
CD4+ T cells, CD11c+ isolated from both the lung and spleen induce elevated 
expression of Foxp3 mRNA from the cells in culture. This suggests that co­
culture of naive T cells with M. vaccae-induced CD11c+ APCs from the spleen, 
and possibly the lung, may activate a regulatory like T cell.
188
*5 75000-
</>0)
to
X
s eV. ^
8.0
(J)a>'5.o
o
50000-
25000-
Foxp3
1:40 1:40
BD
T cells 
alone
*5 30000-
(/>0
1  O
,„° X  20000 
g o
</>
<D
Q.Oo
10000-
Foxp3
1:40 1:40
BD
T cells 
alone
BD
CD11c+ 
cells alone
BD
CD11c+ 
cells alone
189
□ Positive Control - CD11c+ cells from mice treated with saline
■ Treatment Group -  CD11 c+ cells from mice treated with M. vaccae
|jgj Negative Control -  T cells cultured
cultured alone
Figure 5-11: In vitro assay message. CD11c+ cells were isolated from the lung 
(a) or spleen (b) of allergic mice treated with M. vaccae (black bar) or saline (white 
bar). These were co-cultured with naive CD4+ T cells. T cells were also cultured 
alone with anti-CD3 and IL-2 (checked bar). CD11c+ cells were culture alone in 
Growth Medium (without anti-CD3 and IL-2). Foxp3 mRNA levels were 
determined from the culture cells (CD11c+ cells from each group were pooled, 
n=6-8 mice per group, data expressed as mean ± SD, * p<0.05 compared to 
positive control, Students f-test was used to test for significant differences. This 
experiment was carried out at least three times).
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3 Discussion
This chapter attempts to address the immunoregulatory role played by M. 
vaccae-induced CD11c+ APCs. The two possible hypotheses explored are; a) 
that the APCs act as regulatory cells themselves, and are “Suppressor APCs” 
[Rook et a /2004], or b) that they are involved in inducing Tregs, which then act 
as suppressor cells [Hawiger et al 2001, Lui et al 2002]. A passive transfer 
experiment was carried out, isolating pulmonary CD11c+ APCs from of mice 
treated with M. vaccae or saline, and injected to the lungs of mice with allergic 
pulmonary inflammation. The extent of inflammatory symptoms was 
determined to establish if these CD11c+ APCs were regulatory themselves. In 
addition, pulmonary and APCs were also cultured with naive T cells and the 
cytokine release was analysing by ELISA and RT-PCR to determine if these 
APCs may be capable of inducing Tregs.
3.1 Transfer of CD11c+ APCs from mice treated with M. vaccae does 
not transfer protection
Results from this chapter suggest that the pulmonary CD11c+ APCs isolated 
from mice with pulmonary inflammation treated with M. vaccae may not be 
“regulatory” APCs per se. A passive transfer experiment was carried out by 
injecting the pulmonary CD11c+ cells from allergic mice treated with either M. 
vaccae or saline, directly into the lungs of allergic mice. It has been previously 
shown that IL-10 secreting cells, both T cells and APCs, can inhibit OVA- 
induced airway inflammation in a murine model [Akbari et al 2001, Zuany- 
Amorim et al 2002b, Akbari ef a/2002]. These IL-10 secreting APCs may have 
the potential to inhibit inflammatory symptoms. In this thesis, no difference was 
observed in the number of cells in the BAL fluid between the recipient mice that 
received pulmonary CD11c+ APCs derived from mice treated with M. vaccae, 
the control groups (no cells injected) and the group injected with cells derived 
from allergic mice treated with saline. The animals that received an i.t. injection 
of pulmonary CD11c+ cells actually appeared to have an elevated number of 
cells in the BAL fluid. This may be due to the CD11c+ cells transferred into the 
lungs. These CD11c+ cells may have exacerbated inflammation and attracted 
other cells to the lungs.
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From analysing the BAL fluid of donor mice, it was shown that treatment of the 
donor group with M. vaccae was successful in reducing pulmonary 
inflammation. This suggests that, the failure of the transfer experiment, where 
CD11c+ APCs were transferred from the lungs of mice treated with M. vaccae 
into the lungs recipient animals, was not because the M. vaccae treatment did 
not improve inflammation in the donor animals.
There are several possible explanations as to why CD11c+ cells failed to 
transfer the therapeutic effect of M. vaccae. The experimental design may have 
been at fault. CD11c+ cell numbers obtained in each experiment were a 
limiting factor. For this reason, 2 x 105 CD11c+ cells were injected per recipient 
mouse. This may not have been enough cells, since when carrying out passive 
transfer experiments other groups have transferred between 1 x 106 and 5 x 106 
APCs [Lambrecht et al 2000, Akbari et al 2001 ]. However, very few cells were 
actually obtained from the lungs of 8 mice. If there were so few pulmonary 
CD11c+ APCs in vivo, it would be expected that few cells would be needed to 
have a suppressive effect, if indeed these APCs are capable of suppressing 
immune responses.
The route of delivery of these cells may also have an effect on suppressive 
ability of the APCs. These CD11c+ cells were injected i.t. into recipient mice. 
One other group has injected IL-10-secreting APCs i.v., which transferred 
suppression of inflammation to recipient mice [Akbari et al 2001]. However, 
another group has induced sensitisation to OVA by transferring OVA-pulsed 
DCs i.t. [Lambrecht e ta !2000]. This was why this route was selected.
The timing of the experiment may also have played a role in the transfer 
experiment. Mice were sacrificed 3 days after passive transfer of CD11 c+ cells. 
This may not have been enough time for the pulmonary CD11c+ cells to exert 
any “bystander” effects on the local cell population. However, the CD11c+ 
APCs were already secreting IL-10, TGF-p and IFN-a when transferred into the 
allergic recipient animals. It would be assumed that the “bystander” effect of the 
secreted cytokines would be rapid, since inflammatory responses can cause 
irreversible tissue damage quickly if not kept under control. It is therefore 
unlikely that 3 days was too short a time.
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Another possible reason for the failure of the experiment may be that the source 
of the CD11c+ cells. When other groups have carried out similar transfer 
experiments, the APCs were isolated from lymphoid organs, such as the 
spleen, PPs or MLN [Akbari e ta !2001, Akbari e ta !2002, Chambers e ta l2004]. 
APCs may need to migrate to these lymphoid organs to receive instructions 
before developing into “regulatory” APCs.
A final possible explanation as to why passive transfer of pulmonary CD11c+ 
cells did not result in reduced pulmonary inflammation is that these cells are 
simply not regulating immune responses themselves, and instead act by 
inducing regulatory cells. Injection of the CD11c- fraction from animals treated 
with M. vaccae into allergic recipients resulted in a small reduction in cellular 
influx, albeit not a significant one (data not shown). This may be due to T cells 
contained in the CD11c- cell fraction. An improvement in pulmonary 
inflammation has been observed when IL-10 secreting Tregs isolated from the 
LNs of allergic mice treated with M. vaccae are transferred into recipient allergic 
mice [Zuany-Amorim et al 2002b]. Any Tregs already in the lungs of mice 
treated with M. vaccae could be expected to be in the CD11c- cell fraction. 
Transfer of these cells, even in small numbers, could possibly reduce cellular 
infiltration. Therefore, it may be a possible hypothesis that these pulmonary 
CD11c+ cells are inducing Tregs.
3.2 CD11 c+ APCs induce a Th2 response
Pulmonary CD11c+ cells were co-cultured with splenic CD4+ T cells from naive 
mice, to determine if the CD11c+ APCs were capable of inducing T cells with 
regulatory characteristics. The CD11c+ cells induced a Th2 response, initiating 
IL-4 and IL-5 secretion. A decrease in IL-4 and IL-5 production was expected 
from the cultures containing CD11c+ cells from mice treated with M. vaccae, 
since M. vaccae treatment has been shown to decrease type-2 responses 
[Zuany-Amorim et al 2002a, Adams et al 2004]. It may be possible that more 
time is needed for any Tregs to inhibit type-2 cytokine production by activated T 
cells in the culture.
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3.3 M. vaccae-induced CD11c+ APCs may be inducing T cells with 
regulatory like properties
IL-10 protein was increased in the supernatants of the cultures containing APCs 
from allergic mice treated with M. vaccae. TGF-p in the culture supernatants 
was below detection, although this is not surprising since elevated TGF-p was 
not observed in the BAL fluid of mice treated with M. vaccae (Chapter 3). 
Incidentally, these results were accompanied by an increase in both IL-10 and 
TGF-p mRNA from the wells containing CD11c+ cells from mice treated with M. 
vaccae. The inconsistencies in the TGF-p results may be due to the fact that 
Tregs are not producing TGF-p, and simply need it for development. Any TGF- 
p being secreted by the CD11c+ cells may have been used up by Tregs, hence 
none would be detected in the supernatants. Alternatively, it may be due to the 
fact that TGF-p is post-transcriptionally regulated [Chang et al 2002], so that 
TGF-p mRNA may have been transcribed but the TGF-p protein not translated.
From these experiments, the source of, IL-10 and TGF-p message remains 
unclear. Neither naive CD4+ T cells nor CD11c+ APCs cultured alone in just 
Growth Medium, produced any IL-10 protein. Unfortunately, the CD11c+ cells 
alone were not cultured with IL-2 and anti-CD3. This should have been done, 
so that conditions were kept consistent and the effect of anti-CD3 and IL-2 on 
these APCs was known. IL-2 and anti-CD3 should have a minimal effect on 
CD11c+ APCs alone, since CD3 is part of the TCR signalling complex involved 
in activating T cells, and IL-2 is responsible for T cell activation and proliferation. 
However, without these controls the effect of IL-2 and anti-CD3 on CD11c+ 
APCs is not known. The only way to determine the exact source of the 
cytokines is to separate the T cells and the CD11c+ cells at the end of the in 
vitro assay, possibly using CD11c and CD4 magnetic microbeads. To 
determine the source of IL-10 and TGF-p, either intracellular staining or RT- 
PCR could be carried out on the individual cell populations. Technically, this 
would be a difficult experiment to do, since cell numbers were very limited, and 
amounts of RNA extracted from the individual cell populations would be 
minimal.
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3.4 Foxp3 expression is induced in naive T cells by M. vaccae-induced 
CD11c+ APCs
Since the source of IL-10 and TGF-p was unclear, the levels of Foxp3 mRNA in 
the culture cells was determined, since Foxp3 should only be expressed by T 
cells. Foxp3 is a transcription factor protein, which has been observed as 
defective in autoimmune diseases [Bennett et al 2001, Khattri et al 2003, 
Gambineri et al 2003]. Recently it has been described as a marker for Tregs, 
since it is highly expressed by naturally occurring CD4+CD25+ Tregs [Hori etaI 
2003, Read et al 2003, Ling et al 2004]. Since CD4+CD25- do not express 
Foxp3 once they have been activated, it was suggested that Foxp3 was not 
simply a marker of T cell activation, but a marker unique to Tregs [Fontenot etal
2003]. However this is now an area of conflict, since stimulation of human 
CD4+CD25- effector T cells with PHA enhances Foxp3 expression [Morgan et 
a l2005]. However, to date this has not been observed in mice.
In this thesis, Foxp3 mRNA levels were observed to be increased in the wells 
containing pulmonary CD11c+ APCs from mice treated with M. vaccae, albeit 
not significantly. Foxp3 message is not be expressed by the APCs, and is 
unique to Tregs. An increase of Foxp3 would suggest possible Treg 
development. However, not all Tregs have been observed to express Foxp3 
and several different Treg subtypes have been described, each with a 
distinctive phenotype [Vieira ef a/2004].
Naturally occurring CD4+CD25+ Tregs have been reported to express both 
Foxp3 and secrete IL-10. They constitutively express the IL-2 receptor a chain, 
CD25, and play a critical role in the prevention of autoimmunity and allograft 
rejection [Sakaguchi et al 1995, Salomon et al 2000]. They are naturally 
produced in the thymus and make up approximately 10% of all CD4+ T cells 
[Sakaguchi et al 1995, Salomon et al 2000, Stephens et al 2001]. However, it 
has been suggested that naturally occurring CD4+CD25+ Tregs are specific 
only for autoantigens expressed by the thymus. Naturally occurring 
CD4+CD25+ Tregs are important for inducing tolerance against self-Ag 
[Anderson et al 2000, Salomon et al 2000]. In contrast, Tr1 is a type of Tregs 
shown to be specific for Ags derived from, for example, bacteria and pathogens
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[Cong et al 2002, Satoguina et al 2002]. Tr1 cells are induced by repetitive 
stimulation in the presence of IL-10, in both mice and humans. These cells 
produced high levels of IL-10, low levels of IL-2 and no IL-4 and have been 
shown to inhibit the onset of colitis in SCID mice [Groux et al 1997]. However, 
these cells have been reported to lack Foxp3 expression [Vieira et al Jl 2004]. 
This may be a reason as to why the increase in Foxp3 mRNA is not significant 
in the CD4+ cells from the cultures containing CD11c+ cells derived from mice 
treated with M. vaccae. Another possible explanation for the unconvincing 
increase observed in Foxp3 expression may be because these cells were 
isolated from the lungs. When presenting Ag to T cells, APCs first migrate to 
the lymphoid organs. It may be possible that “regulatory” APCs need to migrate 
to lymphoid tissue before being able to affect T cell development and function. 
To test this theory, CD11c+ APCs were isolated from the spleens of allergic 
mice and the same assay carried out.
3.5 IL-10, TGF-p and Foxp3 expression induced in naVve T cells by 
CD11c+ APCs from the spleen of mice treated with M. vaccae
To establish whether APCs from a lymphoid organ had a similar effect on 
inducing Tregs, CD11c+ cells were isolated from the spleen of allergic mice and 
co-cultured with naive CD4+ T cells. Increases in IL-10 protein and message, 
and TGF-p message were observed. This result was similar to that reported 
when pulmonary CD11c+ APCs were co-cultured with naive T cells. The 
expression of Foxp3 was however significantly elevated in the cells containing 
CD11c+ spleen cells isolated from mice treated with M. vaccae, compared to 
those containing CD11c+ APCs from animals treated with saline. These data 
may suggest that CD11c+ APCs isolated from mice treated with M. vaccae 
have the capability to induce Tregs, but they may first need to have migrated to 
a lymphoid organ.
3.6 CD11 c+ cell purity
The purity of the CD11c+ cell separations, when stained with CD11c+ Ab and 
analysed by FACS, was not always very high (>70%). This means that the cells 
could have contained additional cell types, such as lymphocytes.
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Contamination could have had an affect on the results obtained from the in vitro 
assay, since cytokine secretion could have come from an unknown 
contaminating cell source. The CD11c+ fractions did however stain negative for 
CD3 and B220, suggesting minimal lymphocyte presence. In addition, the 
CD11c+ cells were incubated overnight in plastic flasks, before being used in 
the in vitro assay. This would have removed the majority of MOs, which would 
have adhered to the plastic. The reason for such a low purity is therefore 
unclear.
There are several possible explanations. As discussed in Chapter 4, the natural 
autofluorescence of APCs is very high, covering a wide spectrum. It is 
therefore possible that the CD11c+ cells are purer than the FACS analysis is 
detecting. Some of the staining, particularly staining of cells with weaker CD11c 
signals, may be masked by the populations’ own autofluorescence. Another 
possibility is that the CD11c Ab to which the magnetic MACS microbead is 
attached is the same clone as used by BDPharmigen for FACS stains. If this 
were the case, treatment of the pulmonary cells with the microbeads would 
sequester all the CD11c+ surface Ag specific for that clone. Further treatment 
with a FITC or PE conjugated Ab would be unsuccessful, since all cell the 
surface Ag would be blocked. However, microbeads are meant to drop off after 
approximately 6 hours, and these CD11c separated APCs were cultured 
overnight. It is therefore unlikely that the FACS Ab did not bind to the cell 
surface CD11c.
As discussed previously, CD11c alone is not an ideal marker for DC isolation. It 
is expressed not only by DCs, but also by M<I>s and NK cells [Ancuta e ta !2000, 
Hogg eta l 2003, Lima etai 2002]. A more appropriate method for isolating DCs 
from organs such as pulmonary tissue would be to sort them using the 
FACSCalibur. Different DC subsets could be separated this way using 3 DC 
specific markers. For example, CD11 c+CD11 b+CD8a+ pDCs could be isolated 
by staining with each Ab on a different fluorochrome. This would involve 
staining the cells with flurochrome conjugated Abs, and setting the gates on the 
CellQuest program to sort cells which appeared positive at all 3 wavelengths. 
However, the FACSCalibur is not designed for such complicated, high quality 
sorting. A more sophisticated cell sorter exists, known as the MoFlo (made by
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BD). The MoFlo is capable of four way sorting, using four different flurochrome 
conjugated Abs, giving purities of >95%. However, this piece of equipment was 
not available during the performance of this thesis, so other methods of DC 
separation had to be used.
4 Conclusion
This chapter analyses the possible role of M. vaccae-induced CD11c+ APCs in 
the lung. When they are isolated from the lungs, they do not transfer the 
protective effect of M. vaccae to other animals with allergic pulmonary 
inflammation. When cultured in vitro, elevated IL-10 detected in the 
supernatants and in the cells from the cultures suggests that pulmonary 
CD11c+ APCs derived from allergic mice treated with M. vaccae may have the 
ability to influence T cell development when cultured together with naive T cells. 
More work is required to determine the exact source of IL-10 and TGF-p in 
these cultures, since both CD11c+ APCs and T cells from allergic animals 
treated with M. vaccae have been shown to produce these cytokines. Although 
more work is needed, these data provide some tantalising preliminary data to 
suggest CD11c+ APCs isolated from allergic mice treated with M. vaccae may 
have the ability to induce Tregs.
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Chapter 6
Chapter 6: General Discussion
1.1 Introduction
The last three chapters have described the preventive and therapeutic effect of 
treatment with M. vaccae on the symptoms of allergic pulmonary inflammation in a 
murine model. Treatment with M. vaccae alleviated symptoms by reducing 
eosinophilia and IL-4 production. Treatment with M. vaccae was also shown to 
induce secretion of IL-10 and TGF-p, and increased expression of IFN-a, by 
pulmonary CD11c+ APCs. Culture of these CD11c+ APCs with naive T cells 
resulted in increased IL-10 levels in the culture supernatants, and elevated 
expression of Foxp3. This suggests that CD11c+ APCs derived from mice treated 
with M. vaccae may have the ability to induce T cells with a regulatory phenotype. 
The main focus of this discussion will be on the role of M. vaccae in 
immunoregulation, and how it may interact with the immune system to induce 
tolerance to allergens.
1.2 M. vaccae
Although M. vaccae was first described in 1965 [Bonicke et al 1965], the strain 
used as treatment in this thesis, M. vaccae R887R, was described later in 1973 
and was isolated from mud samples obtained from the Lango district of central 
Uganda [Stanford eta! 1973]. M. vaccae has been used as an immunotherapy for 
several different diseases, including cancer [Baran et al 2004], leprosy [Katoch et 
al 1996] and tuberculosis [Stanford et al 2004]. This thesis has focussed on the 
use of M. vaccae as an immunotherapy for allergy, in particular asthma.
1.2.1 Effect on type-2 responses
Several groups have investigated the effect treatment with M. vaccae has on the
symptoms of asthma, both in murine models and in human clinical trials. Treating
allergic mice with M. vaccae results in a decrease in eosinophils numbers in the
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BAL fluid [Hopfenspirger et al 2002, Zuany-Amorim et al 2002a, Smit et al 2003], 
which suggests a reduction in inflammation. This decrease in eosinophilia was 
therefore an important outcome measurement in this thesis, and was expected and 
observed every time mice with pulmonary inflammation were treated with M. 
vaccae (Chapter 3). Eosinophilic inflammation is a result of an excessive type-2 
response. If eosinophilia decreased, it would be expected that a decrease in other 
type-2 cytokines would be observed.
Research on the treatment with M. vaccae has shown conflicting results in regards 
to its effects on Th2 cytokine levels such as IL-4 and IL-5 in the BAL fluid. One 
group observed no difference between IL-4 and IL-5 levels from mice treated with 
saline and mice treated with M. vaccae [Zuany-Amorim e ta !2002a]. Other groups 
have however observed reductions in either IL-4 levels [Smit et a! 2003] or IL-5 
[Hopfenspirger et al 2002, Smit et al 2003] in the BAL fluid of mice treated with M. 
vaccae. Until now alterations to the cytokine milieu in the lung tissue itself, which 
is the actual site of inflammation, has never been investigated. This thesis is the 
first to report a decrease in IL-4 expression in the lung, which was not associated 
with an increase in type-1 cytokines IFN-y and IL-12. This suggests that the 
observed decrease in type-2 responses in not due to the development of a type-1 
response.
1.2.2 Effect on immunoregulation
Treatment with M. vaccae has been observed to induce elevated levels of IL-10 in 
the BAL fluid, both in this thesis (Chapter 3) and by collaborators [Zuany-Amorim et 
al 2002a]. This suggests the development of immunoregulatory mechanisms, 
since the decrease in local type-2 responses is not due to an antagonistic increase 
in a type-1 response. Both IL-10 and TGF-p are involved in regulating the immune 
response, although the exact mode of action induced by these cytokines remains 
unclear. IL-10, for example, has been observed to play a major role in Ig class 
switching, influencing B cells to produce lgG4 rather than IgE [Banchereau et al 
1994]. A reduction of IgE would reduce inflammation, since less mast cells and
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basophils would be activated to degranulate. On the other hand, TGF-p has been 
shown to inhibit IL-2 production, which would affect the proliferation capability of 
naive T cells [Seder et al 1999]. M. vaccae is likely to trigger a combination of 
different mechanisms concerning both IL-10 and TGF-p, and possibly other 
cytokines, which contribute to the suppression of type-2 inflammatory responses.
One additional mechanism by which IL-10 and TGF-p influence immunoregulation 
is though the differentiation and function of Tregs. Indeed, treatment with M. 
vaccae has been shown to induce CD4+CD45RBLow Tregs. Transfer of these 
sorted Tregs isolated from the spleens of mice treated with M. vaccae into 
sensitized recipient mice significantly reduced the OVA-induced eosinophilic 
inflammation. In contrast, transfer of CD4+CD45RBHlQh T cells from animals 
treated with saline had no suppressive effect [Zuany-Amorim et al 2002b]. This 
suggests that the Tregs induced by treatment with M. vaccae may be responsible 
for alleviation of allergic symptoms [Zuany-Amorim e ta !2002b, Adams e ta !2004]. 
In this thesis, the increase observed in IL-10 protein levels in the BAL fluid of mice 
treated with M. vaccae (Chapter 3), may be consistent with Treg activity.
The source of IL-10 detected in the BAL fluid of mice treated with M. vaccae is still 
unclear. Although M. vaccae-induced Tregs were observed to secrete IL-10, the 
suppressive effect on pulmonary inflammation is inhibited by anti-IL-10 and anti- 
TGF-p neutralising Abs [Zuany-Amorim et al 2002b]. The function of these Tregs 
must be dependent on these cytokines. In addition to the function, the 
development of Tregs has also been shown to require IL-10 and TGF-p [ref]. If the 
presence of IL-10 and TGF-p is necessary for Treg development and function, then 
there must be an initial source of these cytokines. Tregs cannot be the only major 
source of IL-10 and TGF-p, as these cytokines are required for their initial 
development. This primary source of IL-10 and TGF-p remains elusive, but 
examples of “regulatory” APCs which are capable of inducing Tregs have been 
observed. For example, tolerogenic DCs isolated from the LNs of mice exposed to 
OVA secrete IL-10. In addition, when cultured with naive T cells, these DCs 
induced OVA-specific T cells in vitro, which also secreted IL-10. These IL-10-
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secreting T cells blocked AHR development and eosinophilia when transferred to 
allergic recipient animals [Akbari e ta !2001].
In this thesis, CD11c+ APCs isolated from the lungs of mice with pulmonary 
inflammation treated with M. vaccae were observed to produce increased levels of 
IL-10 and TGF-p protein, compared to CD11c+ APCs isolated from the lungs of 
animals treated with saline. In addition, increased levels of IFN-a mRNA were 
observed in the CD11c+ APCs from the lungs of mice treated with M. vaccae. IFN- 
a has been observed to upregulate IL-10 production by DCs [Bilsborough et al
2003]. This suggests that secretion of IFN-a by APCs may contribute to the 
inhibition of inflammatory responses, through Treg development. From these data, 
it would appear that M. vaccae has the ability to regulate immune responses. 
There are a number of other microbial organisms with similar characteristics that 
will be discussed in the next sections.
1.3 Microorganisms and immunoreguiation
All microorganisms, whether pathogenic and harmless, influence the immune 
system. Typically, bacterial infection induces a type-1 response, whereas infection 
with helminths induces a type-2 response. Mycobacteria in particular are known 
for their strong induction of Th1 responses upon infection [Rook et al 1998, Manca 
et al 2001]. Linder certain conditions, however, microorganisms can induce 
immunoreguiation in the host. Examples will be discussed in the next sections.
1.3.1 Induction of immunoreguiation by Lactobacilli
The “Old Friends” hypothesis suggests that harmless microorganisms which have 
been encountered by humans throughout evolution have influenced the immune 
system, so that excessive immune responses are not mounted against non- 
pathogenic Ags. The constant presence of lactobacilli in the natural intestinal flora 
leads to their inclusion as an “Old Friend”. As the increased use of antibiotics 
coincides with an increase in the prevalence of allergy [Taylor eta! 1984, Downs et
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al 2001] it may be inferred that the destruction of lactobacilli also correlates with a 
rise in prevalence of allergy, since the increased use of antibiotics in modern 
medicine has led to lowered bacteria populations, including lactobacilli, in the gut. 
Evidence that the correlation exists comes from the association of lower incidence 
of allergy with the presence of large amounts of lactobacilli in the intestinal flora 
[Sepp et al 1997, Bjorksten et al 1999]. These indirect evidences have led to the 
hypothesis that the presence of lactobacilli may induce tolerance against allergy 
[Reviewed in Rook et a /2004].
Direct evidence of a correlation between lactobacilli and tolerance against to is 
available. The ingestion of Lactobacillus rhamnosus by children with atopic 
dermatitis does result in a rise in IL-10 levels both in the patients’ serum, and by 
their stimulated PMBCs [Pessi et al 2000]. The source of this IL-10 may be 
inducible Tregs, since Lactobacillus reuteri and Lactobacillus casei primed DCs 
have been shown to induce an IL-10-secreting Treg, when they are cultured with 
naive T cells. These Tregs were also capable of inhibiting proliferation of 
stimulated T cells, an effect that was suppressed by addition of anti-IL-10 
neutralising Ab [Smitts ef a/2005].
There is an evolutionary advantage to developing immunoreguiation to harmless 
Ags, such as lactobacilli and M. vaccae. An excessive reaction of the immune 
system can cause tissue damage and may under certain conditions be fatal. It is 
therefore likely that the host immune system has developed mechanisms by which 
tolerance is induced upon recognition of, for example, lactobacilli-specific Ag. One 
such mechanisms include the induction of Tregs and the secretion of 
immunosuppressive cytokines.
1.3.2 Induction of immunoreguiation by helminths
Infection with parasitic helminths typically induces a type-2 response from the host, 
with the production of cytokines IL-4, IL-5 and IL-13, increased serum IgE levels 
and the activation and degranulation of mast cells, eosinophils and basophils 
[Maizels e ta !2004]. Since allergy is also a result of excessive Th2 responses, the
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expectation is for infection with helminths to exacerbate allergic symptoms. 
However, in tropical countries where helminth infection is commonplace, allergies 
are rare [Wilson et al 2004]. One study compared the rate of infection with 
Schistosoma haematobium with positive skin tests to house dust mite in school 
children from The Gambia. It was observed that fewer Schistosoma haematobium 
infected children gave a positive skin test result compared to those children who 
were parasite free [van der Biggelaar et al 2004]. In a murine model, infection of 
OVA or Derpl-sensitized mice with the nematode Heligmosomoides polygyrus or 
Litomosoides sigmodontis resulted in a significant decrease in eosinophilia in the 
BAL fluid and epithelial goblet cell proliferation in the lungs [Maizels et al 2004, 
Wilson efa/2005].
Following murine infection with helminths, the host develops type-2 responses, 
with high levels of IL-4, IL-5 and IL-13. This response reaches its peak 
approximately 8 weeks after infection, and then starts to gradually decline. By 
week 16, the type-2 response has significantly downmodulated, but does not 
completely cease. Significantly, the decrease of a type-2 response is 
accompanied by an increase in IL-10 production [King et al 1993, Yazdanbakhsh et 
al 2002, Cooper et al 2001]. Indications of the involvement of Tregs in helminth 
infection have been highlighted by studies with Schistosoma mansoni. 
CD4+CD25+ T cells which secrete IL-10 and express Foxp3, have been isolated 
from the LNs of Schistosoma mansoni infected mice. When cultured in vitro with 
CD4+CD25- cells, these cells inhibit proliferation of naive T cells [McKee et al
2004]. Similarly, IL-10 secreting CD4+CD25+ T cells have been isolated from egg- 
induced granulomas in the liver. Again, these T cells have the ability to inhibit in 
vitro proliferation of naive T cells [Hesse et al 2004]. Induction of Tregs has also 
been observed during experimental infection with the filarial nematode, 
Litomosoides sigmodontis. CD4+CD25+ T cells isolated from the thoracic cavity, 
the site of infection, expressed high levels of CTLA-4, GITR and Foxp3, all markers 
associated with Treg activity [Taylor et al 2005]. These studies suggest that Tregs 
are induced during helminth infection.
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1.3.3 Induction of immunoreguiation by Bordetella pertussis
Respiratory infection with the Gram-negative bacterium Bordetella pertussis, which 
causes whooping cough, induces a Th1 response [Mills et al 1993, Ryan et al 
1997, Ivanoff et al 1997]. Bordetella pertussis produces a number of virulence 
factors which aid the survival of the bacterium in the respiratory tract by mediating 
adherence to the epithelium [Bromberg et al 1991, Steed et al 1992]. One such 
virulence factor is filamentous haemagglutinin (FHA). FHA has been observed to 
inhibit IL-12 production by M<t>s and the development of Th1 responses by the host 
[McGuirk eta! 2000a, McGuirk et a! 2000b]. Incubation of DCs with FHA induced a 
significant production of IL-10. These DCs were shown to direct the generation of 
Tregs in the lungs of mice infected with Bordetella pertussis. The DC-induced 
Tregs secreted high amounts of IL-10, and perhaps surprisingly IL-5. These Tregs 
were able to suppress a Th1 response to an unrelated Ag, influenza virus 
hemagglutinin [McGuirk et al 2005]. Bordetella pertussis is a highly pathogenic 
microbe, which induces this mechanism of tolerance to prolong its survival in the 
host.
1.3.4 Evolution
Data suggest that both pathogens and harmless microorganisms have evolved
regulatory mechanisms to avoid detection by the host immune system, and to
control immune-mediated pathology. The need of regulating immune responses is
critical for host survival. For example, IL-107' mice infected with the malaria
parasite, Plasmodium chabaudi chabaudi mount a vigorous immune response
which cannot be suppressed even once the pathogen is cleared. Mice die from
irreversible tissue damage [Li et al 1999]. Hence morbidity is a direct consequence
of the host immune response, rather than of the pathogen. In the case of M.
vaccae, a non-pathogenic organism which only survives briefly in the host, the
exposed host would waste energy and potentially incur immune mediated
pathology if it were to mount an immune response. Hence, by taking specific cues
from M. vaccae, the host may regulate the immune response and prevent immune-
mediated pathology by developing IL-10-secreting Tregs. Once induced these
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immunoregulatory mechanisms can be useful under other conditions where 
developing an immune response would be harmful. It is possible that pathogens 
may have evolved to mimic this mechanism adopted by harmless, non-pathogenic 
microorganisms, such as M. vaccae. This is an example of the evolutionary arms 
race between the immune system and pathogenic organisms. Pathogens are 
constantly evolving new ways of preventing elimination from the host. In turn, this 
is a major selective force for the immune system to evolve new and improved ways 
of detecting and clearing potentially dangerous infections.
1.4 M. vaccae and the hygiene hypothesis
M. vaccae is a harmless pathogen, which has been described as an “Old Friend” 
[Rook et al 2004], and incorporated into the revised version of the hygiene 
hypothesis [Rook et al 1998]. M. vaccae has several unique characteristics which 
make it an interesting immunomodulator. It is a ubiquitous, saprophytic organism, 
found abundantly in the environment, in the soil and untreated water. The fact that 
exposure to M. vaccae was once a common occurrence warrants its inclusion as 
an “Old Friend”. The existence of a subset of CD 1-restricted T cells lends further 
supporting evidence to the exposure of saprophytic mycobacteria throughout 
human evolution. These appear to recognize only mycobacterial lipids and 
glycolipids [Dutronc et al 2002]. Mycobacterial lipids have also been detected in 
healthy human lymphoid tissue, such as the tonsils [Hanngren et al 1987]. 
Whereas in the past exposure to M. vaccae would have been a common 
occurrence, in modern living conditions limited exposure may have resulted in 
immunodysregulation. The lack of immunoregulatory signals may have lead to the 
observed increased in the development of inappropriate immune responses to 
common allergens, to self and to gut content.
One of the most unique characteristics of M. vaccae is that it retains its 
immunotherapeutic properties even after it has been heat-killed. The paper by 
Hopfenspirger and Agrawal is the only study to look at the effect of live M. vaccae 
on mice with allergic pulmonary inflammation, and showed similar results to those 
presented in this thesis, which addressed treatment with heat-killed M. vaccae. A
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significant reduction in total cell numbers in the BAL fluid was observed, along with 
reduced eosinophil numbers [Hopfenspirger e ta !2002].
Similar studies using BCG as a treatment for allergic pulmonary inflammation have 
been attempted. BCG is an attenuated strain of M. bovis, which is used as a 
vaccine to prevent TB, with a protective efficacy that ranges from 0-80% in different 
locations [Colditz et al 1994]. Similarly to treatment with M. vaccae, in a murine 
model of OVA-induced pulmonary inflammation, treatment BCG i.n. was shown to 
be affective in inhibiting airway eosinophilia and IL-4 and IL-5 in the BAL fluid and 
MLN respectively [Major et al 2002]. In humans, according to a single study, 
vaccination of asthmatic children with BCG results in improvement of symptoms. 
In addition, it was claimed that revaccination of the same children resulted in 
further improvement of lung function [Choi et al 2002]. This observation needs to 
be confirmed, because epidemiological studies do not find decrease in atopic 
symptoms in BCG-vaccinated compared to non-vaccinated children [Aim et al 
1998].
Unlike M. vaccae, data suggest that BCG reduces symptoms of allergic disease by 
inducing a type-1 response, which may antagonise the type-2 response associated 
with asthma. In a murine model of allergic pulmonary inflammation, treatment with 
BCG significantly inhibits eosinophil numbers, IL-4 production in the BAL fluid and 
IgE levels in the peripheral blood [Major et al 2002]. In addition, a shift towards a 
type-1 response was observed in the peripheral blood of asthmatic children treated 
with BCG. The ratio of IFN-yto IL-4 protein in the supernatants of PBMC cultures 
increased [Choi et al 2002], suggesting that BCG vaccination was inducing an 
increase in the Th1 cytokine, IFN-y. In spite of this, evidence of a Th1 switch 
following treatment with BCG remains controversial, as other research groups have 
not successfully replicated these data.
1.4.1 Th1 responses
The use of M. vaccae as a Th1 stimulator has been investigated. In the case of
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cancer, Th1 responses promote cytotoxic immunity, and hence cell destruction. 
Indeed, Th1 mediated immunity has been shown to be impaired in patients 
suffering from many types of cancer, including prostate, colon and renal cancer 
[Elsasser-Beile et al 1998, Heriot et al 2000]. The treatment of several types of 
cancer with M. vaccae has been attempted, including prostate cancer, melanoma 
and lung cancer [Hrouda et al 1998, Maraveyas et al 1999, O’Brien et al 2000]. It 
was hypothesized that M. vaccae was rich in heat shock proteins largely 
homologous with those of cancer cells [Ferrarini eta! 1992], hence would initiate a 
Th1 response that may directly attack the tumour cells. It was also suggested that 
that treatment would downregulate a Th2 response, possibly via the induction of 
Tregs. In the case of prostate cancer, 10 patients were treated with heat-killed M. 
vaccae intradermally at regular intervals, using the prostate specific Ag (PSA) as a 
marker of cancer advancement. The levels of PSA in the serum rise as the cancer 
progresses. In half the patients, the rate at which PSA increased slowed down 
significantly after treatment with M. vaccae. Although treatment with M. vaccae 
was successful in slowing the rate of PSA in half the patients, this study showed no 
induction of IFN-y, and only in three responding patients was a reduction in PBMC 
secretion of IL-4 observed [Hrouda eta! 1998]. The improvements of PSA levels, 
however, lead to more trials using M. vaccae as an adjuvant in combination with 
chemotherapy.
It is hypothesized that chemotherapy treatment induces release of tumour-specific
Ags or tumour-associated Ags from the treated tumour, and that a non-specific
immunostimulator, such as M. vaccae, could enhance recognition of tumour-
specific or tumour-associated Ag in patients, who may be suffering from
immunosuppression. The encouraging results from the prostate cancer Phase I/ll
trial [Hrouda et al 1998] suggested that M. vaccae was a potential
immunostimulator. Trials were carried out on patients with inoperable small-cell
lung cancer (SCLC) non-small-cell lung cancer (NSCLC) and mesothelioma (a less
common cancer arising from the serosa of the lung and closely associated with
asbestos exposure), using M. vaccae as an adjuvant in combination with
chemotherapy [O’Brien et al 2000, Assersohn et al 2002, Mendes et al 2002].
Promising results were observed in all these trials. In the case of SCLC, mean
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survival time increased from 8.6 months to 12.9 months, for patients treated with 
chemotherapy alone versus patients treated with a combination of chemotherapy 
and M. vaccae respectively [Assersohn et al 2002]. A trend towards improved 
mean survival and improved 1-year survival was observed when M. vaccae was 
given in combination with chemotherapy in with NSCLC and mesothelioma. Sleep 
and appetite also were noted to improve, after treatment with M. vaccae. In 
addition, an increase in the activation of NK cells, and a decrease in the 
percentage of IL-4 producing T cells were observed in the peripheral blood after 
treatment with M. vaccae [O’Brien et a /2000].
Unfortunately, results from a Phase III clinical trial into NSCLC failed to confirm 
significant beneficial results (www.srpharma.com/documents/SRL172_ 
updated_050617.pdf). Little work has hence been carried out using M. vaccae as 
a treatment for cancer. Interestingly, it has been suggested that naturally occurring 
Tregs play a major role in the development of cancer. Indeed, increased numbers 
of CD4+CD25+ T cells have been observed in the peripheral blood of patients 
suffering from epithelial malignancies [Wolf et al 2003]. It would have been 
interesting to observe whether M. vaccae treatment had any effect on the numbers 
of CD4+CD25+ Tregs circulating in the peripheral blood or tumour tissue of cancer 
patients.
1.4.2 Immunoreguiation
The treatment of allergic mice with M. vaccae induces immunoreguiation via IL-10 
production. The actual source of the IL-10 remains, however, unclear. Treatment 
with M. vaccae has shown to induce the development of Tregs, which secrete IL- 
10. Transfer of these M. vaccae-induced CD4+CD45RBLow Tregs i.v. to recipient 
allergic mice significantly reduced the number if eosinophils in the BAL fluid 
[Zuany-Amorim et al 2002b]. The importance of these Tregs in reducing 
pulmonary inflammation, suggests that these cells may be the source of IL-10. 
However, in this thesis pulmonary CD11c+ APCs were isolated from mice treated 
with M. vaccae, which also secrete enhanced levels of IL-10.
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When these IL-10-producing CD11c+ APCs were incubated with naive CD4+ T 
cells, an increased amount of IL-10 was produced. From the experiments carried 
out, it is unclear whether the IL-10 is produced by the CD4+ T cells, or by CD11c+ 
APCs. Colleagues from the same laboratory have observed similar data. Murine 
pDCs were generated by incubating bone-marrow derived DCs with flt3-ligand, as 
previously described [Bjorck et al 2001]. These pDCs were the incubated 
overnight with either M. vaccae or Propionibacterium acnes. When co-cutured with 
naive CD4+ T cells, significantly elevated levels of IL-10 were observed in the 
supernatants from the cultures containing pDCs treated with M. vaccae. The 
cultures containing pDCs treated with P. acnes did not have elevated IL-10 
production [Martinelli et al unpublished observations]. It is still unclear whether the 
pDCs or the naive T cells are secreting the IL-10. To determine this, the pDCs 
could be isolated from the bone marrow of IL-10'7" mice. If, once treated with M. 
vaccae, and cultured with wild type naive T cells they still produce IL-10, then it 
can be concluded the T cells are producing the IL-10. If no IL-10 is produced, then 
it is the M. vaccae treated pDCs are the source of IL-10.
These data correlate with the data observed in this thesis. Furthermore, these 
data suggest that the IL-10-producing CD11c+ APCs described in this thesis may 
be pDCs. The fact that these CD11c+ APCs also expressed elevated levels of 
IFN-a supports this hypothesis. However, the limited FACS staining that was 
carried out suggests that they are not pDCs, since they are CD8a- and B220-. 
However, not all groups have observed pDCs as being B220+, so analysis of more 
pDC associated markers, such as Gr-1 and CD11b, may be necessary. In 
addition, problems were encounter when analysising the pulmonary CD11c+ 
APCs FACS staining, which was discussed in detail in Chapter 4. Briefly, 
excessive autofluorescence of cells stained with the isotype control made staining 
difficult to detect. B220 staining may have been present, but not detected using 
FACS analysis.
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1.4.3 Role of APCs in immunoreguiation
Although it is known that M. vaccae promotes the development of Tregs, the 
mechanism by which they are induced is unclear. APCs are likely to play a major 
role, as they not only are involved in the initiation of inflammation but also in the 
initiation of mucosal tolerance [Holt et al 2000]. Microorganisms associated with 
the hygiene hypothesis have been observed to induce Tregs via APC stimulation. 
For example, human DCs incubated with Schistosoma-derived 
lysophosphatidylserine are characterised by decreased IL-12 production and 
increased IL-10 production. They are also observed to drive the generation of IL- 
10 secreting Tregs in vitro [van der Kleij et a /2002].
In this thesis, pulmonary CD11c+ APCs from mice treated with M. vaccae 
expressed elevated levels of IL-10, TGF-p and IFN-a mRNA (Chapter 4). M. 
vaccae may possibly influence “regulatory” APCs to induce Tregs. The way in 
which M. vaccae actually interacts with the APCs remains unclear, and should be 
further investigated. For example, additional FACS analysis is required to 
establish which cell surface receptors upregulate after treatment with M. vaccae. 
Although it appeared that M. vaccae did not upregulate expression of MHC II, 
CD80 or CD86, many other co-stimulatory pathways exist through which M. vaccae 
may signal (examples discussed in detail below). In addition to identifying through 
which pathway M. vaccae signals, the relevant M. vaccae-derived Ag responsible 
for inducing tolerance could also be identified. If the actual component that is 
responsible for inducing Tregs can be isolated, this could have positive implications 
for treatment. Once the active component has been identified, being that a protein, 
carbohydrate or a lipid, a synthetic mimic can be synthesised. Already, one 
component of M. vaccae has been synthesised (termed SRP312™), and patent 
applications for SRP312™ have been submitted. Pre-clinical data suggest that, 
like heat-killed M. vaccae, treatment with SRP312™ significantly reduces allergic 
pulmonary inflammation. It is however likely, that a number of individual 
components from M. vaccae may act in concert and induce immunoreguiation, or 
that a number of them may have similar ability and act in synergy.
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1.5 “Regulatory” DCs
DCs are believed to play an important role in the initiation on any immune 
response. The three main types of DC, “lymphoid” DCs, “myeloid” DCs (mDCs) 
and “plasmocytoid” DCs (pDCs), were described and discussed in Chapter 4. 
Most of the work in regard to regulation has been done on mDCs and pDCs, but all 
have been observed to have some regulatory properties [Dhadopkar et al 2001, 
Gasche et al 2000, Kobayashi et al 2004]. ’’Regulatory” DCs can influence T cell 
activation and development through two main mechanisms; expression of co­
stimulatory markers and cytokine production. For example, immature APCs with 
low levels of CD80 and CD86 are less effective at activating T cells, since these 
ligands will preferentially bind CTLA-4 on T cells, which has a negative regulatory 
effect, rather than CD28 which activates T cell proliferation [Jonuleit e ta !2000]. In 
addition, through the secretion of cytokines such as IL-10, APCs can regulate the 
induction of Tregs [Jump et al 2002, de Heer et al 2004]. It is probable that M. 
vaccae influences “regulatory” APCs through more than one receptor or pathway.
1.5.1 APC receptors
An important feature of the innate immune system is that it can recognize and 
target microbial components. The innate immune system has evolved receptors 
that can recognize these pathogen-associated molecular patterns (PAMPs). 
PAMPs on the surface of M. vaccae and other “Old Friends” may interact with 
pattern recognition receptors on host APCs. This interaction may influence APCs 
maturation, and induce specific cytokine secretion [Rook eta l 2004, Christensen et 
al 2002, Akbari et al 2003]. It is likely that the unusual fatty acid with its double 
bond at position 10-11 (SRP312) that has been isolated from M. vaccae and 
synthesised, is able to interact with pattern recognition receptors (PRR) of APCs, 
though the nature of this interaction has not yet been defined and is an important 
target of future research.
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1.5.2 Toll-like receptors
The Toll-like receptors (TLRs) are a family of pattern recognition receptors that 
recognize a broad range of microbial products. TLRs are expressed by APCs and 
are involved in the recognition of foreign and sometimes self-Ag [Takeda et al
2003]. Stimulation of the TLRs activates nuclear factor kappa B (NF-kB), a 
transcription factor that plays a major role in initiating the production of pro- 
inflammatory cytokines. Eleven TLRs are known to date, and some form 
heterodimers with other TLRs. A wide variety of microbial components are known 
to stimulate the TLRs, including LPS (TLR4), bacterial flagellin (TLR5), double 
stranded RNA (TLR3), bacterial DNA (TLR9) and single stranded viral RNA (TLR7) 
[Underhill 2005].
Studies using mouse models deficient in TLRs have demonstrated the importance 
of TLR signaling in host defense against microbes. For example, TLR4'A mice are 
more prone to infection with Gram-negative bacteria [Hagberg et al 1984]. 
Interestingly, TLR2'/_ mice are more susceptible to mycobacteria [Heldwein et al 
2002, Seya et al 2002] and Gram-positive bacteria [Takeuchi et al 2000, 
Echchannaoui et al 2002]. A lack in TLRs means that the host cannot recognize 
PAMPS from the particular microorganism, and cannot mount an effective immune 
response.
TLR4 appears to be essential in the detection of LPS and in the defense against
Gram-negative bacteria. LPS is used as a marker for bacterial contamination. Its
has been observed that children in German farming communities who have high
levels of LPS in their bedding are less likely to develop allergies, than those
children whose bedding contains little LPS [Braun-Fahrlander et al 2002]. This
study supports the hygiene hypothesis, which suggests that exposure to a variety
of microbes should educate the immune system, so it will not respond
inappropriately to harmless Ag. If LPS is a marker of bacterial presence, and high
levels of LPS correlates with low incidence of allergy, it might be expected that
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TLR4 expression is also associated with allergy. One study of children in Sweden 
has established a link between a polymorphism in the TLR4 gene and asthma. 
Children with this polymorphism (Asp299Gly) had decreased levels of LPS-induced 
IL-12 secreted by PBMCs. This suggests that in children with an altered TLR4 
receptor, LPS may not be signaling through TLR4 adequately. These same 
children also had a four-fold higher probability of developing asthma [Fageras 
Bottcher et al 2004]. This suggests signaling through TLR4 may prevent the 
development of asthma. However, other studies have shown no evidence that a 
variety of polymorphisms, and hence genetic variation, in the TLR4 gene 
contributed to asthma susceptibility [Raby et a /2002].
Infection with mycobacteria tends to trigger APC through TLR2. For example, the 
cell wall of BCG and liporabinomannan from saprophytic mycobacteria species is 
recognized by TLR2 [Heldwein et al 2002]. Indeed, deficiencies in the TLR2 gene 
result in increased susceptibility to Mycobacterium leprae and Mycobacterium 
tuberculosis [Kang et al 2002, Bochud et al 2003, Reiling et al 2002]. In addition, 
TLR2 has been associated with allergy and the hygiene hypothesis. A study 
conducted in Germany and Austria compared TLR2 expression in children living in 
rural farming communities. Children carrying a particular polymorphism in the 
TLR2 gene were significantly more likely to be diagnosed with allergic asthma and 
hay fever compared to those children without this particular TLR2 allele [Eder et al
2004]. This suggests that genetic variation in TLR2 is a major determinant of the 
susceptibility to asthma and allergies in the children of farmers. A negative 
association between children from farming communities and the incidence of 
allergy has already been discussed in Chapter 1, so taken together with the study 
of TLR2 on children from farming communities it would be interesting to see if 
treatment with M. vaccae has any effect on TLR2 signaling.
A simple experiment to determine whether treatment of M. vaccae alleviates 
inflammation by activating TLR2 signaling would be to set up a pulmonary 
inflammation model using TLR2'7' transgenic mice. If treatment no longer 
decreases pulmonary inflammation, it can be concluded that TLR2 is essential for 
M. vaccae recognition and induction of regulatory mechanisms. Alternatively, an in
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vitro experiment could be set up to determine the effect of blocking TLR2. For 
example, the in vitro assay described in Chapter 5 (and Chapter 2 section 7.3) 
could be modified, with the addition of an anti-TLR2 neutralising Ab. The effect of 
TLR2 blockade on naive T cell proliferation could be determined, along with the 
effects it has on cytokine secretion and Foxp3 expression. Experiments such as 
these could determine whether M. vaccae binds the TLR2 receptor, and whether 
this has an effect on the induction of Tregs. It would also be interesting to know if 
SRP312 interacts with TLR2. TLR2 forms heterodimers with TLR1 or TLR6, and 
these alternative dimers recognize subtly different lipid structures.
1.5.3 CD14
Another receptor that has been linked to asthma susceptibility is CD14. CD14 is 
expressed and secreted by myeloid cells. It plays a crucial role in binding many 
microbial components, in particular LPS, and facilitating their interaction with cell 
membrane associated signaling molecules, such as TLRs. In some studies, a 
specific polymorphism in the 5’ promoter region of CD14 is associated with high 
levels of IgE in the peripheral blood. Children who were homozygous for the base 
T at -159 had less serum IgE and more serum sCD14 compared to children who 
were homozygous C or heterozygous, suggesting that the increase in sCD14 and 
decrease in serum IgE may be the result of a recessive allele [Baldini et al 1999]. 
This suggests that CD14 may play a role in asthma susceptibility. Indeed, studies 
in farming communities have shown that the PBMCs cells from children of farmers, 
who have a lower risk of developing allergies, expressed higher levels of CD 14 
mRNA [Lauener et al 2002].
Mycobacteria do not contain LPS in their thick outer wall, but do have other lipids
and glycolipids. CD14 expression on APCs may be involved in binding such lipids,
and activating pattern recognition receptors, such as TLRs. For example, infection
of mycobacteria through TLR2 signaling has been shown to be enhanced by CD14
activation [Bochud et a /2003]. As with TLR2, the effect of M. vaccae treatment on
CD14 expression would be an interesting observation. To determine if M. vaccae
influences CD14 expression, an in vitro experiment can be set up using an APC
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cell line, such as Thp1. Thp1 is a human monocyte/macrophage cell line. Thp1 
cells could be treated with either M. vaccae or saline, and the expression of CD14 
analysed either by FACS or RT-PCR. If M. vaccae does activate APCs via CD 14, 
it would be expected that CD14 expression in Thp1 cells would be enhanced by 
treatment with M. vaccae.
1.5.4 Co-stimulatory pathways
In this thesis, FACS analysis of M. vaccae-induced pulmonary CD11c+ cells 
showed no difference in staining for co-stimulatory markers MHC II, CD80 and 
CD86 (Chapter 4). This is an unexpected finding as others have shown that an 
elevation of IL-10 decreases MHC Class II and CD80 expression [Koppelman et al 
1997]. Surprisingly, expression of CD40 was not detected on the CD11c+ cells. 
This was unexpected, since CD40 has been shown to be upregulated after 
allergen challenge [Vermaelen et al 2003]. Interestingly, CD40 has also been 
shown to be upregulated upon infection with Mycobacterium tuberculosis 
[Gonzalez-Juarrero et al 2001]. One explanation for this puzzling result is that a 
technical fault has occurred. The CD11c+ APCs autofluorescence was very high, 
so that fluorescence from fluorochrome-conjugated Abs was masked. This 
possibility was discussed in detail in Chapter 4. An alternative explanation is that 
other co-stimulatory pathways are involved in the Ag presentation of M. vaccae. 
CD40 signaling leads to increased signaling through the B7 pathway. This in turn 
leads to increased cytokine release, especially IL-4 from naive T cells, via the 
OX40-OX40-L pathway [Flynn et al 1998]. However, since IL-4 is decreased in the 
lungs of mice treated with M. vaccae (Chapter 3), it may be that the CD40 pathway 
is not involved, and that another co-stimulatory pathway is activated.
One possible co-stimulatory pathway, the ICOS-ICOS-L pathway, has been shown 
to be essential for Treg induction by DCs [Akbari e ta !2002, Akbari e ta !2003]. In 
addition, it also to plays an essential role in the development of AHR and airway 
inflammation [Gonzalo et al 2001, Tesciuba et al 2001, Akbari et al 2002]. Since 
ICOS-ICOS-L engagement superinduces IL-10, the involvement of the ICOS 
pathway in M. vaccae induction of Tregs warrants further investigation.
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Unfortunately, in this thesis, no difference in ICOS-L expression by CD11c+ cells 
could be detected between OVA-sensitized and challenged mice treated with either 
saline or M. vaccae (Chapter 4). This may be due to limitations of the experimental 
design. CD11c+ cells were isolated from murine lungs 24 hours after the OVA- 
challenge. A longer period between challenge and sacrifice may be needed, since 
ICOS doesn’t reach maximum upregulation till 48 hours after activation [Hutloff et 
al 1999]. Although this does not rule out the possibility that ICOS is affected by M. 
vaccae, no evidence was found during the course of this thesis to suggest so.
Another possible co-stimulatory pathway through which M. vaccae may signal is 
the 4-1BB (CD137) pathway. Like ICOS and OX-40, the 4-1BB receptor [Kwon et 
al 1989] is not expressed on naive T cells, but is upregulated about 24 hours after 
T cell activation on both CD4+ and CD8+ T cells [Pollok et al 1993, Schwarz et al 
1996, Croft et al 2003]. However, 4-1 BB expression is not exclusive to T cells, 
and is present on B cells, M4>s and DCs. Its ligand, 4-1BB-L, is found on B cells, 
DCs and M<E>s, and can be regulated by LPS [Futagawa et al 2002, Goodwin et al 
1993, Pollock et al 1994]. 4-1 BB has the ability to promote CD8+ cell survival, and 
most work regarding 4-1 BB has been done using CD8+ T cells [Cooper et a /2002]. 
More recently, 4-1 BB has been shown to induce proliferation of CD4+CD25+ 
Tregs, both in vitro and in vivo, without IL-2 production. Murine CD4+CD25+ cells 
isolated from the spleen were stimulated with anti-CD3 and soluble 4-1BB-Fc. No 
proliferation was detected and no IL-2 protein was detected in the supernatants 
from the culture [Zheng et al 2004, Lee et al 2005]. 4-1 BB may therefore be
important for the expansion of Tregs. M. vaccae may have the ability to signal 
through the 4-1 BB pathway, enabling Treg expansion. Analysis of 4-1BB-L 
expression on the M. vaccae-induced CD11c+ cells, both of RT-PCR and FACS, 
may be an interesting observation and could be included in any future work.
1.6 Real-time RT-PCR
In this thesis, the real-time RT-PCR method was adopted and optimised, giving 
very consistent results. Real-time RT-PCR has advantages over end point PCR,
218
mainly in terms of sensitivity and accuracy. It does however, have some 
disadvantages associated with its use when quantifying RNA levels. These 
problems, which extend to basic end point PCR also, include the variability of the 
RNA extracted, along with the efficiencies of the reverse transcription and PCR 
reactions. Consequently, for accurate quantification of RNA levels, a precise 
method of normalisation is necessary to take into account all these possible 
variables. Several strategies have been put forward for normalising real time RT 
PCR data, but unfortunately all these have their limitations.
1.6.1 Normalization of real-time RT-PCR
In this thesis, all RT-PCR data from genes of interest are normalised to the 
housekeeping gene, GAPDH. This method of normalisation estimates the amount 
of mRNA extracted from each individual sample. A housekeeping gene is a gene 
that encodes an enzyme, which is essential for the upkeep and survival of the cell 
(hence known as a housekeeping gene). By using the mRNA transcribed from a 
housekeeping gene, the efficiencies of the RNA extraction, the cDNA conversion 
and the PCR reaction are all taken into account for each sample. A housekeeping 
gene is used to make an estimate of the amount of mRNA present.
In the laboratory, the most commonly used housekeeping genes are GAPDH, p-
actin, HPRT and 18S rRNA. All these genes messages are expressed at relatively
high levels in all cells, so detection of a housekeeping gene can also act as a
positive control. If a specific gene, for example IL-10, is not expressed in a tissue,
successful detection of the housekeeping gene by PCR serves to confirm the
presence of cDNA. If the gene of interest in not detected by PCR, but the
housekeeping gene is, then the gene of interest must be either very weakly
expressed, or not expressed at all, in that particular tissue or sample. Expression
levels of some of these housekeeping genes do, however, vary between tissues or
may be altered under certain conditions. For example, HPRT is more highly
expressed in parts of the CNS compared to the rest of the human body [Stout et al
1985]. Hence, if comparing gene expression between different tissues, an
increased expression of the housekeeping gene in one tissue could alter the
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results significantly. If the housekeeping gene is expressed at a higher level in the 
CNS compared to spleen tissue, but expression of IL-10 remains unchanged, it 
would appear that IL-10 expression was downregulated in the CNS. HPRT would 
not be an appropriate housekeeping gene to use if comparing expression of genes 
in different tissue types. The expression of a housekeeping gene can also vary 
between individual patients. For example, p-actin has been observed to be 
expressed at different levels in different leukaemia patient tumour samples 
[Blomberg et al 1987], probably due to the varying numbers of infiltrating cells into 
the tumour. Depending on the stage and size of the tumour, the number of cells 
infiltrating it will vary. A similar sized biopsy may contain different numbers of cells, 
depending on the individuals’ stage of cancer. It is therefore important to select the 
most appropriate housekeeping gene, and to realise that any results obtained 
using this method are only an estimation and not absolute values.
In this thesis, the housekeeping gene used was GAPDH. In humans, variations in 
GAPDH expression probably exist between individuals, because of genetic 
diversity. However, all the experiments were carried out using BALB/c mice. 
These mice are highly inbred, and hence are genetically similar. This should 
minimise the differences in GAPDH expression between individual mice. However, 
GAPDH was not validated against any other housekeeping genes, and no attempt 
was made to ensure that expression of GAPDH relative to total RNA is not altered 
by the conditions of the experiments, for instance, by Th2 cytokines. Future work 
could use a housekeeping gene that has been validated in the experiments 
performed, and shown not to change in expression level. An alternative approach 
is the use of several different housekeeping genes to establish whether the use of 
one has advantages or disadvantages over another [Dheda et al 2004]. RNA 
should be extracted from all different tissues that are being analysed in a particular 
study, such as lung and spleen, from all treatment and control groups. A selection 
of common housekeeping genes, such as GAPDH, HPRT, p-Actin, and 18S rRNA, 
should be amplified by RT-PCR, and normalised to total RNA. Each copy number 
obtained from each sample should be averaged, and the SEM calculated to 
establish how variable a particular housekeeping gene is between tissue types,
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and between treatment groups. The housekeeping gene with the least variability 
should then be chosen and used in each subsequent experiment [Dheda et al
2004]. This experiment should ideally be carried out for every study where a 
housekeeping gene is being used to normalise PCR data.
1.6.2 Other normalisation methods
Alternative methods of normalisation have been suggested, but all appear to 
present different limitations. The simplest method of normalisation is to ensure the 
sample volume or sample weight is always the same, for example the same 
volume of blood or weight of tissue. The problem with using this method alone is 
the fact that often, similar weights or volumes do not represent the same number of 
cells. Blood or tumour tissue, for example, will have varying numbers of cells in a 
given volume or weight, depending upon the hosts state of immunocompetence or 
immunosuppression [Alexander et al 2003]. For example, if comparing blood 
obtained from a healthy volunteer with blood from an HIV patient, the number of 
cells present in the same volume of blood is likely to vary significantly between the 
individuals. With in vitro cultures, cell may have proliferated, differentiated or 
clumped, leading to inaccurate estimates. This method of normalisation is hence 
rarely used.
A commonly used method for mRNA normalisation is normalising to total RNA.
There are several methods for measuring RNA quantity, one of which is LabChip
(Agilent 2100) [Dheda et al 2004]. Labchip is a kit that estimates the total RNA
concentration. Normalisation to total RNA is advantageous, since it takes into
account the efficiency of the RNA extraction process. Each RNA sample has been
through the identical processes and has been exposed to the same conditions.
Unfortunately, normalising to total RNA does not control the variation that can
occur during the reverse transcription process or the PCR reaction. For example,
individual RNA extractions may be converted into cDNA at different rates, resulting
in some samples having more cDNA in than others. Normalising to total RNA
measured before the cDNA transcription would not detect these differences.
Another disadvantage is that measuring total RNA extraction will include
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measuring rRNA, which makes up approximately 80% of all RNA. RT-PCR is the 
measurement of gene expression, meaning quantifying the amount of mRNA. 
mRNA only comprises approximately 5% of total RNA, with tRNA making up the 
last 15%. To use total RNA as a normalisation method, it must be assumed that 
the mRNA:rRNA ratio is unchanged between control and treatment groups, which 
is not always the case [Spanakis et al 1993].
Since normalising to total RNA does not take into account the efficiencies of the 
reverse transcription, genes can be normalised to the amount of cDNA obtained 
[Whelan et al 2003]. This has the advantage of quantifying the actual amount of 
mRNA present in the sample. A double stranded fluorescent dye, such as 
picogreen, can be used as long as the cDNA remains double stranded after 
reverse transcription. This can be achieved by using a reverse transcriptase with a 
limited RNase H activity. RNase H is an enzyme that degrades the RNA template 
strand of the double stranded cDNA. Most reverse transcriptase enzymes have a 
natural RNase H activity, so cDNA is usually single stranded. Some reverse 
transcriptases have been developed without RNase H activity, so the cDNA 
remains double stranded. As long as the second strand remains intact, cDNA 
quantification can be carried out, eliminating any RNA left over [Whelan et a /2003]. 
The disadvantage with this is that it does not control the differences in the 
efficiencies of the PCR reactions. Also, picogreen will bind non-specifically to 
double stranded DNA or RNA, meaning any hairpin loops in the total RNA will be 
erroneously included in the calculations.
Normalisation to genomic DNA has also been suggested [Talaat et al 2002]. As 
cells proliferate, their genomic DNA doubles at an exponential rate so that it will 
contain exponentially more copies of genomic genes than non-proliferating cells. A 
major problem with this normalization technique is that RNA extraction procedures 
are not usually designed to purify DNA and RNA from the same sample. This 
would mean that a sample would have to be split, and RNA extracted from one and 
DNA from the other. This would mean the extraction rate of genomic DNA might 
vary from that of RNA extraction, leading to variation. This method is therefore 
rarely used.
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1.7 Clinical implications of work so far
1.7.1 Clinical trials involving M. vaccae
Heat-killed M. vaccae has been tested in clinical trials with patients suffering with 
atopic dermatitis and atopic asthma [Arkwright et al 2001, Camporota et al 2003]. 
In an atopic dermatitis, double-blinded placebo controlled clinical trial, 41 children 
aged 5 to 18 years old with moderate to severe eczema were enrolled. Split 
randomly into two groups, one group was given an intradermal injection of heat- 
killed M. vaccae and the other groups a buffer solution as a placebo. Children 
treated with M. vaccae showed a mean 48% reduction in surface area of skin 
affected by dermatitis, compared to a mean of 4% in the group treated with the 
placebo. The group treated with M. vaccae also saw a significant reduction in the 
severity of their dermatitis [Arkwright et al 2001]. This double-blinded placebo 
study suggested that treatment with heat-killed M. vaccae did have a positive effect 
on the symptoms of moderate to severe atopic dermatitis in children. Further work 
failed to show a difference in the levels of IFN-y, IL-2 or IL-5 protein obtained from 
the supernatants of cultured PBMCs from children with atopic dermatitis, either 
treated with M. vaccae or with placebo. No change was observed in IL-4, IL-2 or 
TGF-p mRNA from the same cells either [Hadley et a /2005]. Although these trials 
resulted in improvement of atopic symptoms, no changes in immune responses 
were observed between the group treated with M. vaccae and those treated with 
the placebo.
A clinical study was carried out on patients suffering from atopic asthma. 24 males 
aged 12-53 years of age were enrolled for a placebo controlled clinical trial. All 
patients demonstrated both an early and a late airway response, and either 
suffered from mild or moderate asthmatic symptoms. Patients were injected 
intradermally with either 0.1 mg of heat-killed M. vaccae or the placebo buffer. 
Serum IgE levels were measured 18 days later, and 21 days later patients were 
challenged with histamine, and their PBMCs cultured. Patients were challenged 
again with histamine on day 22 and PBMCs cultured later, at day 42. The group
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treated with M. vaccae showed a significant improvement in the forced expiratory 
volume per second (FEVi -  a frequently used index to measure lung capacity) 
before and after treatment. This improvement was not observed in the group 
treated with the placebo. When the PBMC cultures were investigated, although 7 
out of 10 patients treated with M. vaccae showed a gradual decrease in IL-5 
protein secreted by the cultured PBMCs, no significant difference was observed 
between the PBMC cultures from the group treated with M. vaccae and those 
obtained from the group treated with the placebo. No difference was observed in 
the serum IgE from the group treated with M. vaccae compared to the group 
treated with the placebo [Camporota et al 2003]. This clinical trial showed a trend 
towards an improvement in asthmatic symptoms following treatment with M. 
vaccae, albeit not significant. It may be that optimizing the dose and timing of 
administration of M. vaccae will give significant results.
Results from these published human clinical trials were encouraging, and 
additional phase II trials have now been completed. One trial has been performed 
on children suffering from atopic dermatitis. Children with moderate to severe 
atopic dermatitis were treated with either heat-killed M. vaccae or a placebo, and 
symptoms monitored using the six-area six-sign atopic dermatitis score (SASSAD). 
This score is obtained by grading six signs (erythema, exudation, excoriation, 
dryness, cracking and lichenification), each on a scale of 0 (absent), 1 (mild), 2 
(moderate), or 3 (severe), at each of six sites; arms, hands, legs, feet, head and 
neck, trunk [Berth-Jones et al 1996]. 12 weeks after administration, no clinical 
difference was observed between the group treated with M. vaccae and the 
placebo group. It is not clear whether this is a meaningful result or not because 
there was a 30% improvement in the placebo group.
A second phase II trial was randomized, multicentered placebo controlled study
conducted in Europe. Adults with mild to moderate persistent asthma were
recruited and treated intradermally with either M. vaccae or placebo. Treatment
with M. vaccae failed to significantly improve asthmatic symptoms. Upon
reanalysis, however, it was observed that patients who received two high dose of
heat-killed M. vaccae did show significant benefits. Patients had a reduction in
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asthmatic symptoms score and asthma exacerbations, compared to patients 
treated with the placebo (http://www.srpharma.com/documents/ 
S R P299_U pdated_050617.pdf).
It still remains to be determined whether the effects of M. vaccae in human patients 
also depend on APCs cytokine secretion and Treg induction, and this needs to be 
addressed in any future work. Proving Treg and APC function in humans would be 
difficult, since BAL fluid and tissue samples are not readily available. Work would 
have to be done on the peripheral blood. PBMCs could be isolated from the blood, 
and FACS staining done for CD4+CD25+ T cells. These cells could then be sorted 
and analysed using RT-PCR for Treg markers. However, the number of Tregs 
circulating in the periphery is very small in healthy individuals (approximately 10% 
of all CD4+ T cells). This number would theoretically be much less in patients with 
atopic allergy. Obtaining enough Tregs to carry out any functional assays may be 
difficult. However, one study has isolated CD4+CD25+ from the peripheral blood 
of allergic and non-allergic donors. Allergen peptide immunotherapy was used to 
treat allergic patients with cat allergies in a double-blinded placebo study. 
CD4+CD25+ cells were isolated from peripheral blood and cultured with cat 
allergen in vitro. There was a significant reduction in both proliferation and IL-13 
production by allergen-stimulated CD4+ T cells after therapy, compared to pre­
therapy, whereas no change was seen after treatment with a placebo. 
CD4+CD25+ T cells suppressed proliferation by CD4+CD25- T cells before and 
after therapy. These data suggests that isolation of CD4+CD25+ Tregs from the 
peripheral blood of allergic patients is possible, and that this method should be 
considered in future M. vaccae related clinical trials.
1.7.2 Alternative delivery routes
Additional work is required on the immunotherapeutic use of M. vaccae. So far, all 
treatment with M. vaccae in human trials has been administered intradermally. 
However, the presence of M. vaccae in mud and untreated water suggests that the 
most likely route of M. vaccae exposure would have been orally. This would be a 
more practical route of delivery for treatment with M. vaccae, since injection causes
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inflammation and scarring in some patient.
Oral administration of BCG to mice has been shown to protect against infection 
with Mycobacterium tuberculosis [Lagranderie et ai 2000]. The size, charge and 
hydrophobicity of mycobacteria means that they are rapidly taken up by the PPs 
[Fujimura et ai 1986, Lagranderie et al 2000]. This would suggest that oral 
administration of M. vaccae may be an efficient route of delivery, and it is possible 
that exposure to the gut mucosa may facilitate the induction of Tregs, since this 
site is considered an ideal environment for Treg development and maintenance 
[Chen efa/1994, Maloy efa/2001].
Preclinical investigations into the efficiency of oral delivery have already been 
undertaken. Stimulation of cells isolated from the MLNs of naive mice treated by 
gavage with M. vaccae resulted in enhanced IL-10 production. The MLNs drain 
the small intestine, so cells would have been exposed to Ags present in the gut. In 
addition, oral treatment of M. vaccae is as effective at ameliorating inflammatory 
symptoms in a murine model as treatment of M. vaccae s.c. A single 
administration of heat-killed M. vaccae by gavage before sensitisation to OVA 
prevented the development of severe pulmonary inflammation upon OVA 
challenge [Hunt et al 2005]. The oral effectiveness of M. vaccae has not yet been 
investigated in human clinical trials.
1.7.3 M. vaccae in conjunction with probiotics
Delivering M. vaccae by the oral route would mean that it would be absorbed 
through the gut mucosa into the Peyer’s Patches. The gut, along with its intestinal 
flora, has been deemed the most important site and source of microbial stimulation 
of the immune system [Salminen et al 1998]. Indeed, studies linking the 
composition of the intestinal flora and atopy in children have been carried out 
[Bjorksten ef a/2004]. Disruption of the natural bacteria in the gut by antibiotic use 
in infant mice leads to impaired Th1 immune responses and Th2 dominant 
immunity with elevated serum IgE levels. Subsequent administration of 
Enterococcus faecalis or Lactobacillius acidophilus after antibiotic treatment
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reversed this rise in IgE [Oyama et a /2001, Sudo et a /2002].
Several epidemiological studies have shown that antibiotic use in young children 
can affect susceptibility to allergy in later life [Droste et al 2000, Johnson et al
2005]. For example, a cohort study in the USA found that children who had 
received antibiotics within the first six months of life had an increased chance of 
developing allergy by the age of 7 years. Children who were treated with 
antibiotics were more likely to have a positive skin-prick test, and raised serum IgE 
levels, than children who did not receive antibiotic treatment. Interestingly, this 
incidence of allergy was higher in the group of children who had less than two pets 
at home [Johnson e ta !2005].
There is evidence that probiotic use can reduce the risk of developing allergies. In 
a randomized-placebo study of infants from families with a history of atopic 
disease, children were treated with either Lactobacillus rhamnosus or a placebo. 
This was begun prenatally, by giving the mother an oral capsule and was 
continued after birth for 6 months. After 4 years, children who had been treated 
with Lactobacillus rhamnosus had a reduced risk of atopic eczema compared to 
children treated with the placebo [Kalliomaki et al 2003]. A more recent study 
treated children with atopic dermatitis with Lactobacillus rhamnosus for 4 weeks 
(twice daily mixed with their food). A significant decrease was observed in the 
groups SCORAD index by the end of 4 weeks [Viljanen e ta !2005].
Although M vaccae is not naturally part of the commensal intestinal flora, it is likely 
that the humans have been exposed to M. vaccae via the oral route throughout 
human evolution. Abundantly found in mud and untreated water, the presence of 
mycobacteria during human evolution can be seen by the existence of a subset of 
CD 1-restricted T cells which appear to only recognize mycobacterial glycolipids 
[Dutronc 2002]. The hypothesis that exposure to M. vaccae is effective when 
administered orally is supported by the decrease in type-2 responses observed 
when allergic mice were treated orally with M. vaccae [Hunt e ta !2005].
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1.8 Conclusions
Published data suggest the possibility treatment with M. vaccae might alleviate 
symptoms of allergic asthma and the data presented in this thesis concurs. The 
mechanism by which this alleviation occurs is still unclear. This thesis implies that 
treatment with M. vaccae influences APCs at the site of inflammation. This thesis 
explicitly demonstrates that M. vaccae induces CD11c+ APCs in the lungs to 
secrete IL-10, TGF-p and IFN-a. In addition this thesis demonstrates that co­
culture of these CD11c+ APCs with naive CD4+ T cells results in increased 
release of IL-10 and TGF-p in the supernatant. It also demonstrates an increased 
expression of Foxp3 in the cells, compared to those cells in the cultures containing 
CD11c+ APCs from saline treated mice. Taken together these increases suggest 
that these “regulatory” APCs may have the ability to induce Tregs.
The attitude to hygiene in the developed world means that exposure to M. vaccae, 
and other “Old Friends” is extremely limited. Evidence suggests that exposure to 
“Old Friends” at an early age induces mechanisms of immunoregulation and 
prevents the development of inappropriate immune responses to allergen. 
Consequently reintroduction of non-pathogenic microorganisms orally may help 
reduce the incidence of allergic disease. Although not naturally part of the 
intestinal flora, M. vaccae is effectively absorbed through the gut mucosa. M. 
vaccae is clearly an effective immunotherapy preclinically, and this thesis provides 
further evidence that supports this statement. Furthermore this thesis suggests one 
mode of action triggered by M vaccae. Given the potential, it is therefore of the 
highest importance that further work be undertaken to prove the mechanisms 
suggested by this thesis.
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